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Chapter 1 
Introduction 
B rains of patients with Alzheimer's disease are characterized by the presence of betaMaroyloid containing plaques and neurofibrillary tangles. In addition, signs of inflammation and oxidative stress 
have been found, including activated microglia and inflammatory proteinsl 
as well as lesions that are typically associated with oxidative stress.2. 3 
Several findings suggest that inflammation may play an important role in 
the pathogenesis of Alzheimer's disease. First, use of antiMinflammatory 
medication, such as NSAIDs, has been associated with reduced risk of 
dementia.4·6 Second, some inflammatory proteins including alphal-
antichymotrypsin are known to reinforce the formation of beta-amyloid 
deposits, 7 which is thought to be crucial in Alzheimer pathogenesis.s 
Peripheral inflammation may also contribute to Alzheimer pathogenesis, 
because inflammatory proteins from the blood may pass the blood-brain 
barrier.9 However, the relation between inflammatory proteins in plasma 
and risk of dementia has not yet been studied. 
Oxidative stress may also contribute to Alzheimer pathogenesis as 
suggested by a previous randomized controlled trial. That study found that 
Alzheimer patients taking supplements of the antioxidant vitamin E had a 
slower progression of the disease than patients taking placebo.10 However, 
results from studies that assessed antioxidant plasma levels in patients 
with Alzheimer's disease and healthy controls have been inconsistent. 
Furthermore, it is not known whether high dietary intake of antioxidants 
from food is associated with reduced risk of Alzheimer's disease. 
In addition to inflammation and oxidative stress, lipids may be involved 
in Alzheimer pathogenesis. This view is supported by animal studies 
showing that higher dietary intake of cholesterol is associated with 
increased beta-amyloid deposits in the brain.ll Moreover, use of lipid-
lowering statins has been suggested to possibly reduce risk of Alzheimer's 
disease.l2·14 Other lipids including cis n-3 polyunsaturated fatty acids (n-3 
PUFA) may affect inflammatory processes because of their anti-
inflammatory properties.I5 In humans the association between dietary 
intake of cholesterol and risk of dementia has not been extensively studied. 
In addition, no definite conclusions can be drawn from the previous studies 
on the relation between statin use and risk of dementia, because they were 
cross-sectional12. IS or based on medical records from general practitioners.14 
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Furthermore, very few studies investigated the association between n-3 
PUFA and dementia. 
The relation between inflammation, oxidative stress, lipids and 
Alzheimer's disease may be through atherosclerosis that has been 
associated with dementia.16 Inflammation may contribute to atherogenesis, 
because some inflammatory proteins, such as C-reactive protein, activate 
the complement system, which is an important step in the development of 
atherosclerosis.1' Oxidative stress may increase atherosclerosis through the 
oxidation of LDL-cholesteroJ1S Lipids may be involved in atherogenesis, 
because high levels of cholesterol, saturated fatty acids and cis 
monosaturated fatty acids and low levels of PUFA are associated with more 
atherosclerosis.19, 20 
The aim of the research described in this thesis was to further investigate 
the relation between inflammation, oxidative stress and lipids and dementia 
and to examine whether these associations could be explained by 
atherosclerosis. 
I investigated whether levels of inflammatory factors in plasma were 
associated with increased risk of dementia or its subtypes (chapter 2.1 and 
2.2). Because inflammation may induce oxidative stress that may in turn 
activate inflammatory processes,l I examined whether the relation between 
inflammatory cells, such as leucocytes, and Alzheimer's disease was 
modified by intake of antioxidants that reduce oxidative stress (chapter 2.2). 
In chapter 3.1.1 I reported on plasma levels of antioxidants in Alzheimer 
patients, subjects with cognitive decline and healthy controls. Furthermore, 
I examined the relation between dietary intake of antioxidants and risk of 
Alzheimer's disease (chapter 3.1.2). Finally, I further explored the relation 
between lipids and dementia and cognitive function. I investigated the effect 
of levels of fatty acids in plasma phospholipids (chapter 3.2.1), dietary fat 
intake (chapter 3.2.2), and use of lipid-lowering medication (chapter 3.2.3) 
on risk and presence of dementia. In chapter 4, I review the main results of 
this thesis in the light of current insights with respect to dementia 
pathogenesis, I comment on methodological issues and clinical relevance 
and I conclude with recommendations for future research. 
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Chapter 2.1 
Inflammatory proteins in plasma 
and risk of dementia 
Peripheral inflammation may occur in patients with Alzheimer's disease, 
possibly even prior to clinical onset of dementia. We investigated whether 
high plasma levels of inflammatory proteins are associated with an increased 
risk of dementia. 
We performed a case-cohort study within the Rotterdam Study. The source 
population consisted of 6713 subjects who, at baseline (1990-1993), were free 
of dementia and underwent venipuncture. From these, we selected both a 
random subcohort of 727 subjects and 188 cases who had developed 
dementia at follow-up. The associations between plasma levels of alphal-
antichymotrypsin (ACT), C-reactive protein (CRP), interleukin-6 (IL6), 
soluble intercellular adhesion molecule-] (siCAM-1) and soluble vascular 
cell adhesion molecule-1 (sVCAM-1) and risk of dementia were examined 
using Cox proportional hazards models. 
High levels of ACT, IL6 and to a lesser extent CRP were associated with 
an increased risk of dementia; rate ratios per standard deviation increase 
were 1.49 (95% confidence interval (CI) 1.23-1.81), 1.28 (95% CI 1.06-1.55) 
and 1.12 (95% CI 0.99-1.25), respectively. Similar associations were observed 
for Alzheimer's disease, whereas rate ratios of vascular dementia were higher 
for ACT and CRP. Levels of siCAM-1 and sVCAM-1 were not associated with 
risk of dementia or its subtypes. 
Our findings suggest that high plasma levels of inflammatory proteins are 
associated with an increased risk of dementia, Alzheimer's disease and 
vascular dementia. 
N euritic plaques and neurofibrillary tangles are the classical neuropathological features in brains of patients with Alzheimer's disease. Furthermore, inflammation has been demonstrated in 
Alzheimer brains as is indicated by the presence of activated microglia and 
inflammatory proteins.l In addition to an immunological response within 
the brain, the peripheral immune system of dementia patients may be 
activated as well. This is suggested by cross-sectional studies that reported 
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elevated blood levels of the acute phase proteins alphal-antichymotrypsin 
(ACT),2-9 C-reactive protein (CRP)lO and their regulator, the cytokine 
interleukin-6 (IL6)6, 11-14 in Alzheimer patients as compared to controls. 
Whether ACT, CRP and IL6 are increased before clinical onset of dementia 
is not yet known as the relation between inflammatory proteins and risk of 
dementia has not been studied in a prospective way. As a result, it is 
unknown whether peripheral inflammation is a cause or a consequence of 
the pathogenetic process of dementia. Furthermore, no studies examined 
the association between ACT, CRP and IL6 and dementia in a population-
based setting, nor has the association been studied between other 
inflammatory proteins, such as cell adhesion molecules (CAMs), and 
dementia. We investigated the relation between plasma levels of ACT, CRP, 
IL6, soluble intercellular adhesion molecule-1 (siCAM-1) and soluble 
vascular cell adhesion molecule-1 (sVCAM-1) and the risk of dementia in a 
large population-based prospective study. 
Methods and materials 
Source population 
The Rotterdam Study is a population-based prospective cohort study among 
persons living in Ommoord, a suburb of the city of Rotterdam, the 
Netherlands.15 The study was approved by the medical ethics committee of 
the Erasmus University Rotterdam. The objective was to investigate 
determinants of chronic and disabling cardiovascular, neurodegenerative, 
locomotor and ophthalmologic diseases in the elderly IS 
All 10 275 residents of Ommoord who were aged 55 years and over in 
1990, were invited to participate. Of these, 7983 (78%) gave their written 
informed consent and took part in the baseline examination. The baseline 
examination took place between 1990 and 1993 and consisted of a home 
interview and 2 clinical examinations at the research center. At the clinical 
examination blood samples were drawn from 7050 subjects (88% of total 
cohort), of whom cognitive status was assessed in 7047 subjects. Dementia 
was diagnosed in 334 participants resulting in a source population of 6713 
subjects who both were at risk for dementia and had venipuncture at 
baseline. Follow-up examinations took place in 1993-1994 and 1997-1999. In 
addition, the total cohort was continuously monitored for major disease 
outcomes. 
Study design 
We used a case-cohort design I6, 17 in order to use the data from the source 
population most efficiently. In this design, a random sample, or a 
'subcohort', is drawn from the source population that has been followed up 
for disease outcome. In addition, subjects from the source population, who 
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had developed the disease outside the subcohort, are selected as cases.16. 11 
Baseline exposure is measured in all members of the subcohort and all 
incident cases outside the subcohort. The statistical analyses that can be 
applied in a case-cohort study are similar to that of a cohort study after 
modification of standard errors. 
Study population 
The study population for the present study consisted of a subcohort of 727 
subjects who were randomly drawn in July 1998 from all 6713 subjects who 
were dementia-free and had venipuncture at baseline. At that time, we 
additionally selected all 146 incident dementia cases that had occurred 
outside the subcohort. We followed the subcohort until December 31, 1999. 
By then, 42 subjects of the subcohort had developed dementia. The 
extension of follow-up period within the subcohort is valid, because it is 
independent of the occurrence of dementia as the subcohort is randomly 
drawn and only the subcohort contributes to follow-up time. Cases of the 
present study comprised 188 (42+146) incident dementia cases, of whom 
140 were diagnosed with Alzheimer's disease (119 without cerebrovascular 
disease, 21 with cerebrovascular disease), 23 subjects with vascular 
dementia and 25 had other dementias. 
Diagnosis of dementia 
During baseline and follow-up examinations the diagnosis of dementia 
followed a similar 3-step protocol, which has been described in detail 
elsewhere.lS In short, 2 brief tests of cognition (Mini-Mental State 
Examination (N[MSE)19 and the Geriatric Mental State schedule (GMS) 
organic leveJ2D) were used to screen all subjects. Screen positives (N[MSE 
score < 26 or GMS organic level > 0) underwent further cognitive testing 
using the Cambridge examination for mental disorders of the elderly 
(CAMDEX).21 The CAMDEX also included an informant interview.21 
Subjects who were suspected of having dementia were examined by a 
neurologist, a neuropsychologist and, if possible, had a brain scan made by 
magnetic resonance imaging. In addition, the total cohort was continuously 
monitored for incident dementia cases through computerized linkage 
between the study database and digitalized medical records from general 
practitioners and the Regional Institute for Outpatient Mental Health 
Care.ls Dementia diagnoses were made by a panel of a neurologist, 
neuropsychologist and research physicianlS 1n accordance with 
internationally accepted criteria for dementia (DSM-III-R),22 Alzheimer's 
disease (NINCDS-ADRDA)23 and vascular dementia (NINDS-AIREN)24 By 
use of these criteria, subjects were classified as having Alzheimer's disease 
in case they had a gradually progressive global decline of cognitive functions 
for which no other medical cause was found. If the ongoing gradual 
progressive decline had abruptly been worsened by the occurrence of an 
incident stroke, we subclassified Alzheimer's disease as Alzheimer's disease 
with cerebrovascular disease. Subjects with onset of dementia within 3 
months following a recognized incident stroke, a history of abrupt 
deterioration in cognitive functions, or stepwise progression of cognitive 
deficits were classified as vascular dementia. 
Assessment of plasma level of ACT, CRP, IL6, siCAM-1 and sVCAM-1 
Levels of inflammatory proteins were assessed in baseline plasma from the 
subcohort and the cases. At the research center a venipuncture was 
performed with minimal stasis and a 21 gauge Butterfly needle with tube 
(Terumo Surflo® winged infusion set). Blood was collected in tubes 
containing 0.5 ml sodium citrate solution. All tubes were stored on ice before 
and after blood sampling. Platelet-free plasma was obtained by 2-stage 
centrifugation at 4 °C, firstly for 10 minutes at 1,600 g and subsequently for 
30 minutes at 7,000 g. Platelet-free plasma was immediately frozen in liquid 
nitrogen, transferred to the laboratory and stored at -80 °C. Median storage 
time was 6.5 years (interquartile range 4. 7-7.6 years). 
Measurements of plasma levels of inflammatory proteins were performed 
without knowledge of the dementia diagnosis. Plasma levels of ACT and 
CRP were measured by kinetic nephelometry (Behring Nephelometer 
BN200®) after a 5 times dilution by use of Behrings N-dilutent®. Levels of 
IL6, siCAM-1 and sVCAM-1 were determined by means of commercially 
available ELISA (IL6: Quantikine HS®; siCAM-1 and sVCAM-1: 
Parameter®). Interassay coefficients of variations for ACT, CRP, IL6, 
siCAM-1 and sVCAM-1 were 2.8%, 4.4%, 8. 7%, 6.9% and 5.0%, respectively. 
Due to insufficient plasma ACT, CRP, IL6, siCAM-1 and sVCAM-1 could not 
be determined in 17, 17, 6, 3 and 3 subjects, respectively. 
Covariates 
During the baseline home interview information on level of education and 
smoking habits was obtained. Data on medication use at time of 
venipuncture were obtained from the baseline interview if venipuncture had 
taken place before December 31, 1990 (n=226, 25.9%). After this date, data 
on medication use were obtained directly from a pharmacy database that 
was linked to the study database.2' At the research center height and 
weight were measured and blood samples were drawn. Systolic blood 
pressure at the ankle and the arm was measured by means of a random zero 
sphygmomanometer.26 Also, ultrasonography of both carotid arteries was 
performed.27 
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Highest level of education was categorized in 4 groups: completed 
primary education, lower vocational training or general education, 
intermediate vocational training or intermediate and higher general 
education, and higher vocational training, college or university. Smoking 
habits were dichotomized in current versus former or never smoking. All 
drugs were classified according to their corresponding Anatomical-
Therapeutical-Chemical-code (ATC-code).28 Participants who used systemic 
non-steroidal anti-inflammatory drugs (NSAID) (ATC-code m01a), systemic 
corticosteroids (ATC-codes h02a or h02b), or inhalation corticosteroids 
(ATC-code r03ba) were classified as users of systemic NSAID or users of 
systemic, or inhalation corticosteroids, respectively. Body mass index was 
calculated in kilograms per meter squared. Diabetes was considered present 
if the subject was taking oral diabetics or insulin (ATC-code a10) or if the 
random or post-load serum glucose level was equal to or higher than 11.1 
mmolfl (WHO-criteria for epidemiological studies of diabetes).29 
As indicators of atherosclerosis, we used 3 measures. First, peripheral 
arterial disease was used, which was defined by the ankle-to-brachial ratio 
of the systolic blood pressure. This ratio was computed using the average 
systolic blood pressure of 2 measurements at the arm and the lowest value of 
2 legs. Peripheral arterial disease was considered present if the ankle-to-
brachial ratio was below 0.9 and absent if the ratio was equal to or above 0.9. 
Second, atherosclerotic carotid plaques were determined at 6 different 
locations in the carotid arteries: common carotid artery, carotid bifurcation, 
and internal carotid artery at both left and right side.27 Four categories were 
made according to number of locations with plaques: 0, 1-2, 3-4 and 5-6 
locations. Third, the intima media thickness was defined as the average of 
near-wall and far-wall measurements of the common carotid artery.27 For 
the analyses, we computed the average of left and right common carotid 
intima media thickness. 
Apolipoprotein E (APOE) genotype was assessed on coded DNA samples 
using polymerase chain reaction without knowledge of the dementia 
diagnosis.30 The APOE genotype was dichotomized in presence or absence of 
the apolipoprotein E* 4 (APO E* 4) allele. 
Data analysis 
Differences between incident dementia cases within the subcohort (n=42) 
and incident cases outside the subcohort (n=146) were tested by means of 
Mann-Whitney test for baseline age, MMSE-score, ACT, CRP, IL6, siCAM-1 
and sVCAM-1. Differences between gender and educational level were 
tested using the Chi-square test. 
The association between plasma levels of inflammatory proteins (ACT, 
CRP, IL6, siCAM-1 and sVCAM-1, respectively) and incident dementia and 
Chapter 2.1 
its subtypes was evaluated in a case-cohort design by use of standard Cox 
proportional hazards models with modification of standard errors based on 
robust variance estimates.l6, 17 We used the method according to Barlow in 
which the subcohort is weighted by the inverse of the sampling fraction from 
the source population.16 In a case~cohort analysis only subjects from the 
subcohort contribute to follow-up time. 
Analyses were based on subjects with complete data on inflammatory 
protein. Plasma levels of inflammatory proteins were first entered into the 
model as quintiles in order to explore any deviations from linearity in the 
relation between inflammatory proteins and risk of dementia. In case of a 
non~linear association or a threshold~effect all analyses were performed 
using quintiles of inflammatory proteins. Otherwise, plasma levels of 
inflammatory proteins were entered into the model through a linear term, 
in which the regression coefficient was expressed per standard deviation 
increase. Quintiles and standard deviations of the respective inflammatory 
proteins were based on the distribution of the subcohort. We additionally 
performed analyses in which level of inflammatory proteins were 
logtransformed in order to check whether associations were driven by 
extreme values. In all analyses adjustments were made for age, gender and 
education. To adjust most efficiently for age, we used age as timescale in the 
model. Entry time was defined as age at study entry. Participants from the 
subcohort were followed until the age of onset of dementia, death or end of 
study, whichever came first. The proportional hazard assumption was 
checked for each inflammatory protein and each covariate by adding the 
time-dependent interaction of the variable with age to all models. 
We first analyzed the relation between inflammatory proteins and risk of 
dementia, Alzheimer's disease and vascular dementia. Subsequently, in 
order to investigate the relation between inflammatory proteins and 
Alzheimer's disease without cerebrovascular disease, we excluded subjects 
with the diagnosis 'Alzheimer's disease with cerebrovascular disease' (n=21). 
To examine whether current smoking, body mass index, diabetes and the 
use of anti-inflammatory medication confounded the association between 
inflammatory proteins and dementia, we additionally entered these 
variables into the model. Missing values on categorical variables, such as 
education (n=24) and smoking habits (n=23),were replaced by a missing 
indicator. No missing values were present for age, gender, body mass index, 
diabetes and use of anti~inflammatory medication. Because dementia is 
associated both with cardiovascular risk factors31 and with atherosclerosis,26 
and because atherogenesis includes inflammatory mechanisms,32 the 
following indicators of atherosclerosis were additionally added to the model: 
peripheral arterial disease, carotid plaques and intima media thickness, 
respectively. Missing values on peripheral arterial disease (n=Sl) and 
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carotid plaques (n=53) were replaced by a missing indicator; missing values 
on intima media thickness (n=69) were replaced by the mean of either cases 
or subcohort, depending on subject status. 
Furthermore, we performed the analyses of Alzheimer's disease within 
strata of APOE*4 allele. In this latter analysis, 20 subjects, of whom no 
APOE genotype was available, were excluded. Statistical interactions were 
tested by adding a product term to the unstratified model. 
In addition, the analyses were repeated after exclusion of all subjects 
with anti-inflammatory medication (n=93, 10.7%). Finally, the analyses for 
dementia were performed after exclusion of subjects with possible acute 
inflammation as is indicated by CRP levels over 15 mg/1 (n=53, 6.1 %). All 
data analyses were performed using SAS statistical software. 
Results 
Table 1 presents the baseline characteristics of the subcohort. The mean age 
was 71.7 years (SD 9.0), a small majority were women, one-third had 
Table 1 Baseline characteristics of the subcohort 
Mean age (y) (SD)' 
Women(%) 
Primary education only(%) 
Current smoking(%) 
Mean body mass index (kg/m2) (SD)* 
Diabetes(%) 
Systemic use of NSAID (%) 
Systemic use of corticosteroids(%) 
Inhalation use of corticosteroids(%) 
Presence of peripheral arterial disease(%) 
5-6 Locations with carotid plaques(%) 
Median intima media thickness (mm) (range)t 
Carrier of APOE*4 allele(%) 
Median ACT (mg/dl) (range)t 
Median CRP (mg/1) (range)t 
Median IL6 (pg/ml) (range)t 
Median siCAM-1 (nglml) (range)t 
Median sVCAM-1 (ng/ml) (range)t 
*standard deviation 
t interquartile range 
Subcohort (n=727) 
71.7 (9.0) 
52.9 
37.7 
22.4 
26.4 (3.5) 
9.0 
2.9 
2.5 
2.2 
9.8 
6.5 
0.77 (0.68-0.85) 
28.6 
45.0 (38.3-55.8) 
1.72 (0.80-3.68) 
1.95 (1.27-3.14) 
210.5 (179.0-250.0) 
502.5 (424.6-624.9) 
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Figure 1 Adjusted• rate ratios of dementia across quintiles of inflammatory proteinst 
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primary education only and 28.6% carried at least one APOE*4 allele. 
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As expected, we found no statistical differences between incident 
dementia cases within the subcohort and incident dementia cases outside 
the subcohort in terms of baseline age, MMSE-score, ACT, CRP, IL6, 
siCAM-1 and sVCAM-1 (p-values were all above 0.10). Also, gender and 
educational level were similar between the 2 groups (p-values above 0.20). 
The proportional hazards assumption was not violated for any of the 
inflammatory proteins or covariates in the subsequent analyses. In Figure 1 
the median level of the respective inflammatory proteins within the 
quintiles was plotted against the rate ratios of dementia on a logscale. From 
this figure, we saw no reason to assume that the associations could not be 
described by a linear term, in particular given the wide and overlapping 
Table 2 Adjusted• rate ratios of dementia and its subtypes per standard deviation (SO) 
increase in plasma level of inflammatory protein 
so Dementia Alzheimer's disease Vascular dementia 
n=188 n=140 n=23 
RR (95% Cl)t RR (95% Cl)t RR (95% Cl)t 
ACT 16.2 mg/dl 1.49 (1.23-1.81) 1.35 (1.09-1.67) 2.48 (1.67 -3.67) 
CRP 5.87 mg/1 1.12 (0.99-1.25) 1.10 (0.96-1.26) 1.31 (1.06-1.61) 
IL6 4.93 pg/ml 1.28 (1.06-1.55) 1.30 (1.05-1.61) 1.26 (0.97-1.65) 
siCAM-1 68.3 ng/ml 0.97 (0.74-1.27) 0.87 (0.63-1.21) 1.46 (0.82-2.60) 
sVCAM-1 189.9 ng/ml 0.98 (0.75-1.28) 1.02 (0.75-1.38) 0.66 (0.32-1.38) 
*adjusted for age, gender and education 
t rate ratio (95% confidence interval) 
20 Chapter 2.1 
95% confidence intervals of the point estimates within quintiles. Therefore, 
we further analyzed the data entering inflammatory protein as a linear 
term in our models. 
Table 2 presents the rate ratios of dementia and its subtypes per 
standard deviation increase in level of inflammatory protein, adjusted for 
age, gender and education. Higher levels of ACT, CRP and IL6 were 
associated with an increased risk of dementia. With every increase of 16.2 
mg/dl (standard deviation) in ACT level, the risk of dementia increased with 
49% (rate ratio (RR) 1.49 (95% CI 1.23-1.81)). The rate ratio for IL6 per 
standard deviation increase in plasma level was 1.28 (95% CI 1.06-1.55). 
The relation between CRP and dementia was borderline significant (RR 1.12 
(95% CI 0.99-1.25). The associations were not clearly driven by extreme 
values as shown by the analyses of logtransformed levels of inflammatory 
proteins: the association of logtransformed ACT with dementia was 
strongest (RR 3.40 (95% 1.61-7.19) p=0.001), the association of 
logtransformed IL6 was of intermediate strength (RR 1.36 (95% CI 0.98-
1.88) p=0.06) and was weakest for logtransformed CRP (RR 1.12 (95% CI 
0.91-1.37) p=0.29). Higher levels of ACT, CRP and IL6 were also associated 
with an increased risk of Alzheimer's disease, although high levels of ACT 
and CRP were most strongly associated with an increased risk of vascular 
dementia. IL6 was similarly associated with Alzheimer's disease and 
vascular dementia. Plasma levels of siCAM-1 and sVCAM-1 were not 
associated with risk of dementia and its subtypes. Rate ratios of dementia 
for logtransformed siCAM-1 and sVCAM-1 were 0.78 (95% CI 0.32-1.93) 
(p=0.60) and 0.78 (95% CI 0.35-1.75) (p=0.55), respectively. When Alzheimer 
cases with cerebrovascular disease were excluded the relations between the 
respective inflammatory proteins and Alzheimer's disease were very similar. 
Table 3 shows the relation between inflammatory proteins and risk of 
dementia with additional adjustments for potential confounders. 
Adjustments for current smoking, body mass index, diabetes and use of anti-
inflammatory medication did not change the results substantially. Also, 
similar results were observed when adjustments were made for measures of 
atherosclerosis. 
Table 4 presents the association between inflammatory proteins and risk 
of Alzheimer's disease across strata of APOE genotype. For all inflammatory 
proteins the association with dementia was similar for subjects with or 
without at least one APOE*4 allele. None of the statistical interactions were 
statistically significant 
When the analyses of the relation between inflammatory proteins and 
risk of dementia were performed after exclusion of subjects who used anti-
inflammatory medication, the results remained similar. Finally, separate 
Table 3 Adjusted* rate ratios of dementia per standard deviation increase in plasma level of inflammatory protein 
Model 1* Adjusted for peripheral Adjusted for carotid Adjusted for intima 
arterial disease+ plaques+ media thickness+ 
Standard deviation RR (95% Cl)t RR (95% Cl)t RR (95% Cl)t RR (95% Cl)t 
ACT 16.2 mg/dl 1.52 (1.25-1.84) 1.47 (1.19-1.82) 1.67 (1.36-2.05) 1.49 (1.36-2.05) 
CRP 5.87 mg/1 1.11 (0.99-1.26) 1.05 (0.92-1.21) 1.16 (1.03-1.31) 1.10 (0.98-1.25) 
IL6 4.93 pg/ml 1.27 (1.06-1.54) 1.25 (1.01-1.55) 1.31 (1.05-1.63) 1.27 (1.05-1.55) 
siCAM-1 68.3 ng/ml 0.88 (0.64-1.21) 0.86 (0.62-1.19) 0.80 (0.54-1.20) 0.89 (0.66-1.21) 
sVCAM-1 189.9 ng/ml 0.96 (0.71-1.29) 0.94 (0.70-1.27) 0.89 (0.62-1.26) 0.97 (0.72-1.31) 
*adjusted for age, gender, education, current smoking, body mass index, diabetes, use of anti~inflammatory medication 
:j: additional to model 1 
t rate ratio {95% confidence interval) 
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analyses after exclusion of subjects with CRP levels over 15 mg/1 also did not 
change the results substantially. 
Discussion 
We observed that elevated plasma levels of ACT and IL6 were associated 
with an increased risk of dementia and its subtypes Alzheimer's disease and 
vascular dementia. This association was less clear for CRP and was absent 
for siCAM-1 and sVCAM-1. The associations were not confounded or 
modified by atherosclerosis and APOE genotype, respectively. 
The present study has several advantages. First, our study is the first to 
prospectively examine the relation between inflammatory proteins and risk 
of dementia in a population-based study with a large number of subjects. 
Second, complete followfiup with respect to dementia diagnosis was 
obtained. As a result, selection bias as a consequence of loss to follow-up 
could not have occurred. Third, differential misclassification of level of 
inflammatory proteins was eliminated by assessing the levels blinded for 
dementia status. Finally, in contrast to most cross-sectional studies on 
inflammatory proteins and dementia, adjustments were made for an 
extensive number of potential confounders. 
A limitation of the present study is that regression dilution may have 
occurred due to measurement error and within-person variability in plasma 
level of inflammatory protein.33 Unfortunately, we did not have repeated 
measurements of plasma levels of inflammatory proteins. Therefore, we may 
have underestimated the strength of the true association between 
inflammatory proteins and risk of dementia. Another limitation may be that 
Table 4 Adjusted' rate ratios of Alzheimer's disease per standard deviation (SO) 
increase in plasma level of inftammatory protein across strata of APOE'4 allele 
SD No APOE*4 allele At least one APOE*4 allele 
cases n=80 cases n=56 
RR (95% Cl)t RR (95% Cl)t p-value:j: 
ACT 16.2 mg/dl 1.35 (1.02-1.80) 1.36 (0.95-1.96) 0.31 
CRP 5.87 mg/1 1.13 (0.98-1.32) 1.02 (0.77-1.35) 0.84 
IL6 4.93 pg/ml 1.27 (0.98-1.64) 1.45 (1.08-1.94) 0.52 
siCAM-1 68.3 ng/ml 0.94 (0.68-1.30) 0.67 (0.30-1.51) 0.25 
sVCAM-1 189.9 ng/ml 1.00 (0.68-1.46) 0.94 (0.62-1.43) 0.22 
~adjusted for age, gender and education 
t rate ratios (95% confidence interval) 
t statistical interaction of plasma level of inflammatory protein with APOE genotype 
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none of the subjects who were screen negative (MMSE score>= 26 and GMS 
organic level = 0) were further examined. As a result, we may have missed 
some mild dementia cases. However, because this will only be a very small 
percentage of all cases and because we used identical procedures at baseline 
and follow-up, it is unlikely that our results have been affected by 
misclassification of cases. 
Our findings are in line with many cross·sectional studies showing that 
plasma or serum levels of ACT and IL6 are higher in dementia patients 
compared to control subjects,2·9, 11·14 although some studies did not observe 
this association.34·40 Furthermore, our findings are in accordance with 
studies in molecular-biological research that showed presence of ACT and 
IL6 in early and late stages of neuritic plaque formation' Although the 
relation between CRP and dementia has been examined in previous 
studies,6, 10, 37, 41 only one study observed similar results as we did, showing 
that CRP levels in dementia patients were higher compared to controls.lD 
Blood levels of CAMs in relation to dementia have not been studied before. 
Our observations on siCAM-1 and s VCAM-1 and risk of dementia are in line 
with neuropathological findings showing no expression of these adhesion 
molecules on endothelial cells of capillaries in Alzheimer brains.42 
The observed elevations in plasma levels of inflammatory proteins prior 
to dementia diagnosis may either be derived from increased production in 
cerebra or by cells from the peripheral immune system. However, because 
levels of acute phase proteins (ACT, CRP) in brains are generally more than 
100 times lower than in plasma,s, 37 plasma elevations of acute phase 
proteins more likely originate from an increased production in the 
peripheral immune system. In contrast, levels of cytokines, such as IL6, are 
similar in brain and plasma."· 37 thus plasma elevations may either be 
derived from increased production in the brain or the periphery. 
Elevated plasma levels of inflammatory proteins prior to clinical onset of 
dementia may support the view that inflammation is involved in the 
pathogenetic process that leads to dementia. This view is supported by 
several observations. First, anti.inflammatory medication use, such as 
NSAID use, is associated with a decreased risk of dementia25, 43-45 Although 
NSAIDs can have effects within the brain, the effect of NSAIDs on dementia 
risk may also act by means of suppressing the peripheral immune system. 
Second, acute phase proteins, such as ACT, are known to reinforce the 
formation of beta-amyloid deposits,46 which is thought to be crucial in the 
pathogenesis of Alzheimer's disease.47 Because peripheral proteins are able 
to cross the blood-brain barrier4S and because the permeability of the blood-
brain barrier may increase with rising plasma levels of inflammatory 
proteins such as IL6,49 peripherally produced inflammatory proteins might 
also amplify formation of cerebral beta-amyloid deposits. Third, interleukin-
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1 (ILl) has already been found elevated in brains of newborns with Down 
syndrome,so a disease that is associated with beta-amyloid deposition and 
dementia from the age of 40 years.51 Finally, atherosclerosis, which is an 
inflammatory process,sz may be associated with increased risk of 
dementia.26, 31 The idea of atherosclerosis being a link between 
inflammation and dementia is supported by our observation of relatively 
strong associations of ACT and CRP with vascular dementia. However, 
several other observations in our study suggest that atherosclerosis does not 
fully explain the relation between inflammatory proteins and risk of 
dementia. First, when we adjusted for measures of atherosclerosis the 
relation between inflammatory proteins and dementia did not change. Also, 
because atherosclerosis may be associated with increased plasma levels of 
CAMs, 52, 53 one would also have expected an association between siCAJ\1-1, 
sVCM::I-1 and risk of dementia if atherosclerosis was to contribute to the 
pathogenesis of dementia. Finally, the risk associated with IL6 was similar 
for Alzheimer's disease and vascular dementia. 
On the other hand it can be hypothesized that elevation in plasma levels 
of inflammatory proteins is a consequence of the pathophysiological process 
of dementia. Elevated peripheral inflammatory proteins may be the result of 
the cerebral beta-amyloid deposition that induces the local production of 
inflammatory proteins, such as interleukin-1 (ILl) and IL6 1 These 
cerebrally produced cytokines may increase peripheral levels of 
inflammatory proteins, either because they pass the blood-brain barrier48 or 
through stimulation of peripheral production of inflammatory proteins as 
shown in animal models.54 If the activation of the peripheral immune 
system is both a cause and a consequence of the pathogenetic process of 
dementia, a self-enhancing cascade will take place. This cascade includes 
beta-amyloid deposit formation that leads to local inflammation within the 
brain resulting in the activation of the peripheral immune system that leads 
to increased beta-amyloid deposit formation. 
In summary, we observed that high plasma levels of ACT and IL6 were 
associated with an increased risk of dementia, Alzheimer's disease and 
vascular dementia. Higher levels of CRP were less strongly associated with 
risk of dementia and Alzheimer's disease. These results suggest that a 
peripheral immunological response occurs prior to clinical expression of 
dementia. Whether peripheral inflammation contributes to the pathogenesis 
of dementia remains to be elucidated. 
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Chapter 2.2 
The association between leucocyte 
count and risk of Alzheimer's disease 
is modified by intake of antioxidants 
Background Inflammation may induce oxidative stress that possibly leads 
to increased inflammation. The relation between inflammation and 
Alzheimer's disease may therefore be modified by oxidative stress and 
antioxidants that counteract oxidative stress. 
Objective To examine whether the relation between plasma leucocyte count 
as indicator of inflammation, and risk of Alzheimer's disease is modified by 
intake of antioxidants. 
Methods We used data from the Rotterdam Study, a prospective cohort 
study among elderly. At baseline (1990-1993), plasma leucocyte count and 
dietary intake were both assessed in 5093 dementia-free subjects. The cohort 
was reexamined in 1993-1994 and 1997-1999 and in addition continuously 
monitored for incident dementia. The association between leucocyte count 
and incident Alzheimer's disease was examined by Cox proportional hazards 
models, both unstratified and across strata of intake of the antioxidants beta 
carotene, flavonoids, vitamin C and vitamin E. 
Results After a mean follow-up of 6.0 years, 183 subjects developed 
dementia, of whom 136 had Alzheimer's disease. High leucocyte count was 
associated with increased risk of Alzheimer's disease (rate ratio per standard 
deviation increase was 1.10 (95% confidence interval 1.02-1.19)). This 
relation was significantly modified by intake of antioxidants and was 
particularly present in subjects with low intake. The interaction between 
leucocyte count and antioxidant intake was most pronounced in current 
smokers. 
Conclusion Our findings suggest that the association between high 
leucocyte count and increased risk of Alzheimer's disease is amplified by low 
intake of antioxidants. 
I nflammation and oxidative stress may both contribute to the etiology of Alzheimer's disease.'-3 This is supported by studies showing that plasma levels of inflammatory proteins are elevated prior to clinical 
onset of dementia4 and by studies reporting lower risk of Alzheimer's 
disease with higher dietary intake of antioxidants.s. ' 
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Inflammation and oxidative stress are related phenomena that may 
enhance each other in Alzheimer pathogenesis. On the one hand, 
inflammation may induce oxidative stress by the activation of microglia that 
generate free radicals and thus oxidative stress. On the other hand, 
inflammation may be amplified by free radicals, because free radicals may 
activate pro-inflammatory genes.' We hypothesized that the relation 
between inflammation and dementia is modified by antioxidants that 
counteract oxidative stress. 
We examined whether the association between activation of the 
peripheral inflammation system and risk of Alzheimer's disease is modified 
by dietary intake of antioxidants in the Rotterdam Study. 
Methods and materials 
The Rotterdam Study 
The Rotterdam Study is a population-based prospective cohort study that 
investigates determinants of chronic and disabling diseases in the elderly. 
The study was approved by the medical ethics committee of the Erasmus 
University Rotterdam. In total, 7983 subjects (response rate 78%) who were 
55 years and above and lived in Ommoord, a suburb of Rotterdam, the 
Netherlands, agreed to participate and gave their written informed consent.7 
The baseline examination took place between 1990 and 1993 and follow-
up examinations were in 1993-1994 and in 1997-1999. In addition, the total 
cohort was continuously monitored for major disease outcomes. 
Diagnosis of dementia 
During baseline and follow-up examinations the diagnosis of dementia 
followed a similar 3-step protocol, which has been described in detail 
elsewhere.s In brief, participants were first cognitively screened. Screen-
positives underwent further cognitive testing. Subjects who were suspected 
of having dementia were subsequently examined by a neurologist, a 
neuropsychologist and, if possible, had a brain scan made by magnetic 
resonance imaging. In addition, the total cohort was continuously monitored 
for incident dementia through computerized linkage between the study 
database and digitalized medical records from general practitioners and the 
Regional Institute for Outpatient Mental Health Care.s The diagnoses of 
dementia and Alzheimer's disease were made in accordance with 
internationally accepted criteria for dementia (DSM-III-R)' and Alzheimer's 
disease (NINCDS-ADRDA)w by a panel of a neurologist, neuropsychologist 
and research physician that reviewed all existing information.s 
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Assessment of peripheral inflammation 
As an indicator of activation of the peripheral immune system we used 
leucocyte count in plasma, which is commonly used in clinical practice to 
detect inflammation. Leucocyte count was available at baseline for a large 
number of participants of the Rotterdam Study. A venipuncture was 
performed with minimal stasis and a 21 gauge Butterfly needle with tube 
(Terumo Surflo® winged infusion set). Immediately after blood sampling, 
leucocyte count was assessed in citrate plasma using a Coulter Counter 
T540® (Coulter electronics, Luton, England), which has a coefficient of 
variation of less than 2.0%. Quality of assessments was continuously 
monitored by Instruchemie® (Hilversum, the Netherlands). 
Dietary assessment 
Dietary intake of the participants was assessed at baseline in 2 stages. First, 
the participants indicated on a checklist all foods and drinks they had 
consumed at least twice a month during the preceding year. The checklist 
also contained questions on use of supplements. Second, on the basis of the 
completed checklist the participants were interviewed by a trained dietician, 
who used an extensive, validated semiquantitative food-frequency 
questionnaire.n, 12 The food-frequency data were converted to energy intake 
and nutrient intake using the computerized Dutch Food Composition 
TableJ3. 14 For the present study we used data on intake of the antioxidants 
beta carotene, flavonoids, vitamin C, and vitamin E. Daily dietary intake of 
antioxidants from food was calculated in milligrams. 4 
Covariates 
During the baseline home interview information on level of education and 
smoking habits was obtained. Data on medication use at time of 
venipuncture were obtained from the baseline interview and from a 
pharmacy database that was linked to the study database." Participants 
who used systemic non-steroidal anti-inflammatory drugs (NSAID), 
systemic corticosteroids, inhalation corticosteroids, nasal corticosteroids or 
ophthalmologic corticosteroids were classified as users of anti-inflammatory 
medication. 
At the baseline visit to the research center, height and weight were 
measured, and intake of total energy, alcohol and antioxidative supplements 
were indicated on the semiquantitative food-frequency questionnaire. 
Subjects who used supplement preparations that contained at least 1 of the 
antioxidants beta carotene, flavonoids, vitamin C or vitamin E, were 
classified as users of antioxidative supplements. Furthermore, 
ultrasonography of both carotid arteries was performed.l6 We used presence 
of carotid plaques as indicator of atherosclerosis. Carotid plaques were 
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determined at 6 different locations in the carotid arteries: common carotid 
artery, carotid bifurcation, and internal carotid artery at both left and right 
side.ts Four categories were made according to number of locations with 
plaques: 0, 1-2, 3-4 and 5-6 locations. 
Study population 
At baseline, 7 525 participants of the Rotterdam Study underwent extensive 
screening for dementia. Dementia was diagnosed in 482 subjects resulting 
in 7043 subjects who were free of dementia at baseline. Of these, dietary 
intake was assessed in 5395 subjects who had normal cognition, lived 
independently, and had reliable dietary assessment at baseline.5 Of the 
subjects with dietary data, 5093 subjects had also baseline assessment of 
leucocyte count. In 302 subjects with dietary data leucocyte count was not 
assessed because of failed venipuncture (n=l6), missing citrate plasma 
(n=20), missing Coulter Counte!® assessment (n=l02) or unknown reasons 
(n=96). Thus, the study population of the present study consisted of 5093 
subjects who were at risk for dementia and had baseline assessment of both 
dietary intake and leucocyte count in blood. 
Data analysis 
The association between leucocyte count and risk of Alzheimer's disease was 
evaluated using Cox proportional hazards models. Leucocyte count was 
represented in the model either categorized in quartiles or by a linear term 
(per standard deviation). In all analyses adjustments were made for age, 
gender and education. 
To assess whether smoking habits, packyears of smoking, body mass 
index and use of anti-inflammatory medication confounded the relation 
between leucocyte count and risk of Alzheimer's disease, these variables 
were simultaneously added to the model. Furthermore, because dementia 
may be associated with atherosclerosis,l7 which is an inflammatory 
process,1s we separately adjusted for carotid plaques as a measure of 
atherosclerosis. In this analysis a missing indicator was used for all subjects 
with missing data on carotid plaques (n=766). 
To examine whether intake of antioxidants modified the relation between 
leucocyte count and Alzheimer's disease, we performed the analyses within 
strata of intake of beta carotene, flavonoids, vitamin C, and vitamin E, 
respectively. In these analyses rate ratios were expressed per standard 
deviation increase in leucocyte count. For each antioxidant, we made 2 
strata by dichotomizing at the median intake of the study population. 
Statistical interactions were tested by adding a product term of the linear 
terms leucocyte count and antioxidant intake to the unstratified model. 
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Furthermore, we examined the interaction between leucocyte count and 
antioxidant intake across strata of smoking habits. 
To investigate the combined effect of leucocyte count and antioxidant 
intake on risk of Alzheimer's disease, we created 4 new categorical 
variables. We first dichotomized leucocyte count and antioxidant intake into 
high and low level according to the median of the study population. 
Subsequently, for each variable 4 categories were made: low leucocyte 
count/high antioxidant intake (reference category), low leucocyte count/low 
antioxidant intake, high leucocyte count/high antioxidant intake and high 
leucocyte count/low antioxidant intake. Rate ratios of Alzheimer's disease 
were calculated for each of the categories adjusting for age, gender, and 
education. In additional analyses, we also corrected for smoking habits, 
packyears of smoking, body mass index, use of anti-inflammatory 
medication, total energy intake, alcohol intake, and use of antioxidative 
supplements. Separately, we additionally adjusted for presence of carotid 
plaques. Finally, the analyses were repeated after exclusion of all subjects 
using anti-inflammatory medication (n=736, 14%) or supplements (n=479, 
9%). 
Table 1 Baseline characteristics of the study population (n=5093)' 
Characteristic 
Age (y) 
Smoking 
Current 
Former 
Never 
Packyears of smoking 
Current smokerst 
Former smokerst 
Body mass index (kg/m2) 
Use of anti-inflammatory medication 
Total energy intake (kJ/d) 
Use of antioxidative supplements 
Beta carotene (mg/d) 
Flavonoids (mg/d) 
Vitamin C (mgld) 
Vitamin E (mg/d) 
Leucocyte count (109/L)t 
"values represent means (standard deviation) or percentages(%) 
t median (interquartile range) 
67.7 (7.8) 
23% 
43% 
34% 
27.9 (13.6-42.4) 
17.5 (5.3-35.0) 
26.3 (3.7) 
14% 
3272 (2115) 
12% 
1.53 (0.76) 
28.4 (12.2) 
121 (54.1) 
13.8 (6.2) 
6.44 (5.44-7.67) 
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All data analyses were performed using SPSS statistical software, version 
10 (SPSS Inc., Chicago, Illinois, USA). 
Results 
Table 1 shows the baseline characteristics of the study population. The 
mean age was 67.7 years (SD 7.8), 59% were women and one-third had 
primary education only. The median leucocyte count of the study population 
was 6.44*109/L. 
During a mean follow-up of 6.0 years (SD 1.3) 183 subjects developed 
dementia, of whom 136 had Alzheimer's disease. 
Table 2 presents the relation between leucocyte count and risk of 
Alzheimer's disease. Across quartiles, risk of Alzheimer's disease gradually 
increased with higher leucocyte count. When adjustments were made for 
age, gender, and education, the rate ratio of the highest quartile compared 
to the lowest quartile was 1.66 (95% CI 1.02-2.69)). Results were very 
similar after additional adjustments for smoking habits, packyears of 
smoking, body mass index and, use of anti-inflammatory medication, or 
presence of carotid plaques. Because the analyses across quartiles did not 
show deviations from linearity for the association between leucocyte count 
and risk of Alzheimer's disease, leucocyte count was added as a linear term 
per standard deviation (SD). With every increase of 2.1 *10'/L (SD) m 
leucocyte count, the risk of Alzheimer's disease increased with 11% after 
Table 2 Adjusted rete ratios of Alzheimer's disease per standard deviation (SD) 
increase in leucocyte count and across quartiles (n=5093, 136 cases) 
Model 1* Model 2t Model 3:j: 
Leucocyte count RR (95% ctm RR (95% ctm RR (95% ctm 
(109/L) 
Quartiles < 5.4 1 (reference) 
5.4- 6.4 0.99 (0.58-1.71) 0.99 (0.58-1.70) 0.99 (0.58-1.70) 
6.4- 7.7 1.31 (0.78-2.19) 1.27 (0.75-2.15) 1.30 (0.78-2.18) 
> 7.7 1.66 (1.02-2.69) 1.71 (1.04-2.81) 1.63 (1.00-2.65) 
Per SO 2.1 1.10 (1.02-1.19) 1.10 (1.02-1.19) 1.11 (1.02-1.19) 
*adjusted for age, gender and education 
t adjusted for age, gender, education, smoking habits, packyears of smoking, body mass index and use 
of anti-inflammatol)l medication 
:j: adjusted for age, gender, education and carotid plaques 
'If rate ratio {95% confidence interval) 
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Table 3 Adjusted* rate ratios of Alzheimer's disease per standard deviation increase in 
leucocyte count across strata of antioxidant intake (n=5093, 136 cases of Alzheimer's 
disease) 
Low intaket 
RR (95% Cl)§ 
Stratified by 
Beta carotene (1.43 mg/d)# 1.32 (1.11-1.58) 
F!avonoids (27.4 mg/d)# 1.43 (1.16·1.77) 
Vitamin C (113 mg/d)# 1.12 (0.96-1.31) 
Vitamin E (12.9 mg/d)# 1.27 (1.09-1.49) 
*adjusted for age, gender and education 
t defined as lower than the median intake 
:j: defined as equal to or higher than median intake 
§ rate ratio (95% confidence interval) 
High intake:j: 
RR (95% Cl)§ 
1.05 (0.90-1.21) 
1.05 (0.91-1.21) 
1.10 (1.00-1.20) 
1.05 (0.92-1.21) 
11 statistical interaction of the continuous variables leucocyte count and antioxidant intake 
#median intake 
extensive adjustments (rate ratio 1.10 (95% CI 1.02-1.19)). 
p~valuelfj 
0.10 
0.01 
0.15 
0.05 
Table 3 shows the association of leucocyte count with risk of Alzheimer's 
disease across strata of intake of antioxidants. The risk of Alzheimer's 
disease associated with higher leucocyte count was higher in subjects with 
low intake of any of the antioxidants compared to high intake. This was 
most striking across strata of flavonoids; the rate ratio of Alzheimer's 
disease was 1.43 (95% CI 1.16-1.77) for subjects with low intake of 
flavonoids and 1.05 (95% CI 0.91-1.21) for subjects with high intake. The 
statistical interaction between leucocyte count and antioxidant intake was 
significant for flavonoids and vitamin E. The interaction between leucocyte 
count and antioxidant intakes was most pronounced within current 
smokers; for beta carotene, flavonoids, vitamin C, and vitamin E the p~ 
values of the statistical interactions were 0.02, 0.18, 0.28, and 0.003, 
respectively, for current smokers, whereas the p~values for never smokers 
were 0.63, 0.4 7, 0.15, and 0.30. 
Figure 1 presents the relation of the combined effect of leucocyte count 
and antioxidant intake on risk of Alzheimer's disease when adjusted for age, 
gender, and education. Risk of Alzheimer's disease increased with higher 
leucocyte count and lower antioxidant intake and was thus highest for 
subjects with high leucocyte count and low intake of any of the antioxidants. 
For vitamin C, and vitamin E, rate ratios were significantly higher in the 
high count/low intake group when compared to the reference group (low 
count/high intake): rate ratios were 1.87 (95% CI 1.14-3.10) for vitamin C 
and 1.98 (95% CI 1.21-3.26) for vitamin E. When additional adjustments 
were made for smoking habits, packyears of smoking, body mass index, use 
Figure 1 Adjusted* rate ratios (RR) of Alzheimer's disease for categories based on 
leucocyte count and antioxidant intaket 
beta carotene 
3 
RR 2 
reference 
0 D 
low count/high low count/low high count/high high count/low 
intake intake intake intake 
flavonoids 
3 
RR 2 
reference 
0 D 
low count/high low count/low high count/high high count/low 
intake intake intake intake 
vitamin C 
3 
RR 2 
reference 
0 D 
low count/high low count/low high count/high high count/low 
intake intake intake intake 
vitamin E 
3 
RR 2 
reference 
0 D 
low count/high low count/low high count/high high count/low 
intake intake intake intake 
*adjusted for age, gender and education 
t we made 4 categories on the basis of the median of leucocyte count and the median of the respective 
antioxidant intakes: low count/high intake (reference category), low count/low intake, high count/high 
intake and high count/low intake 
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of anti-inflammatory medication, total energy intake, alcohol intake, and 
use of antioxidative supplements, the results were very similar. Also, 
adjustment for presence of carotid plaques as a measure of atherosclerosis 
did not change the results, nor did exclusion of users of anti-inflammatory 
medication or antioxidative supplements. 
Discussion 
We observed that high leucocyte count was associated with increased risk of 
Alzheimer's disease, in particular in persons with low dietary intake of 
antioxidants. Within current smokers the interaction between leucocyte 
count and antioxidant intake was most pronounced. 
Before interpreting the results some methodological issues need to be 
discussed. First, leucocyte count is a rather aspecific indicator of 
inflammation, and it correlates with other inflammatory factors such as 
levels of inflammatory proteins. We are unable to conclude from our data 
whether the association of increased risk of Alzheimer's disease with 
increased leucocyte count reflects a relation with increased inflammation in 
general or is due to specific inflammatory factors. Second, the interaction 
between leucocyte count and antioxidant intake may be confounded by 
smoking. Smoking is related to both inflammationl9 and to intake of 
antioxidants. Although additional adjustment for smoking habits or 
packyears smoked did not change the results, confounding by smoking may 
still have occurred since the interaction between leucocyte count and 
antioxidants was particularly present within current smokers. 
The strengths of this study are its prospective design, its size and its 
population-based setting. Furthermore, we achieved complete follow-up with 
regard to dementia status. As a result, selection bias as a consequence of 
loss to follow-up could not have occurred. 
Several biological mechanisms may explain the observed modifying effect 
of dietary antioxidants on the relation between peripheral inflammation as 
indicated by leucocyte count and risk of Alzheimer's disease. First, the 
interaction between dietary antioxidants and peripheral leucocyte count 
may be a reflection of an interaction between antioxidants and 
inflammation in the brain. This is suggested by animal studies showing that 
elevated inflammatory proteins in the brain may result in activation of the 
peripheral immune systemzo and that antioxidant levels within the brain 
may be related to peripheral levels of antioxidants.Zl-2-3 Dietary antioxidants 
may thus block the interaction between inflammation and oxidative stress 
that may occur in Alzheimer brains. This interaction includes activation of 
microglia that leads to neuronal cell damage through the generation of free 
radicals,l which in turn may amplify inflammation by the activation of pro-
inflammatory genes.l Second, the interaction between peripheral 
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inflammation and antioxidants in Alzheimer's disease may be explained by 
atherosclerosis. In atherogenesis, inflammation is also suggested to interact 
with oxidative stress and thus antioxidants, because oxidative stress leads 
to LDL-oxidation, subsequent inflammation and atherosclerotic plaques24 
and because inflammation is accompanied by increased count of leucocytes 
that produce free radicals in itself. However, because additional adjustment 
for carotid plaques as a measure of atherosclerosis did not change our 
results, we think that the interaction between leucocyte count and 
antioxidants in relation to risk of Alzheimer's disease will not entirely be 
explained by atherosclerosis. 
In summary, we observed that the relation between leucocyte count and 
risk of Alzheimer's disease was modified by intake of antioxidants: higher 
leucocyte count was particularly associated with increased risk of 
Alzheimer's disease in subjects with low antioxidant intake. 
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Plasma levels of antioxidants are 
not associated with Alzheimer's 
disease or cognitive decline 
Antioxidants prevent oxidative stress that possibly causes neuronal loss in 
Alzheimer's disease. We examined whether high plasma levels of the 
antioxidant vitamins A and E were associated with lower prevalence of 
Alzheimer's disease or cognitive decline. 
We performed a cross-sectional study based on 3717 participants from the 
Rotterdam Study who had blood samples drawn at second follow-up 
examinations. From these, we included 65 patients with Alzheimer's disease 
and 293 dementia-free persons with cognitive decline. Controls were 437 
randomly drawn subjects without dementia or cognitive decline. The 
association between vitamin A and E and Alzheimer's disease and cognitive 
decline was examined by logistic regression. 
In an univariate model higher levels of vitamin A and E were significantly 
associated with lower prevalence of Alzheimer's disease. However, when 
additional adjustments were made for important confounders, such as age, 
gender and total cholesterol, the relation substantially weakened (odds ratios 
per standard deviation increase were for vitamin A 0.87 (95% confidence 
interval (95% CI) 0.64-1.19) and for vitamin E 0.94 (95% CI 0.60-1.48). 
Antioxidants were not related to cognitive decline. 
Our findings suggest no association between plasma levels of vitamin A 
and E and Alzheimer's disease or cognitive decline. 
S igns of oxidative stress have been observed in brains of patients with Alzheimer's disease.l For instance, it has been found that DNA and membrane lipids are damaged by oxidation. This oxidation leads to 
neuronal cell loss, an important feature in Alzheimer brains. Because 
antioxidants can counteract oxidation and thus prevent neuronal cell death, 
high levels may lower risk of Alzheimer's disease. 
Recently, we and others reported that high dietary intake of vitamins C 
and E was associated with lower risk of Alzheimer's disease.2· 3 The relation 
between plasma levels of antioxidants. particularly vitamin A and E, and 
Alzheimer's disease has been examined in many cross-sectional studies, of 
which some observed an inverse relation4-s whereas others did not find any 
association.9-14 However, all these studies were performed in hospital-based 
populations. Furthermore, many studies did not adjust for confounders,'· 6, 9. 
12, 14 whereas those that did make adjustments4• 7, s, 10, 11, 1.'3 only corrected for 
either age, gender or cholesterol. However, these covariates as well as 
education and smoking may be important confounders. We examined 
whether high plasma levels of vitamin A and E were associated with lower 
prevalence of Alzheimer's disease within a population-based study, 
adjusting for important confounders. In addition, we investigated whether 
high levels of antioxidants were related to an increased prevalence of 
cognitive decline, which may indicate imminent dementia. 
Subjects and methods 
Eligible population 
We performed a cross-sectional study within the Rotterdam Study, a large 
population-based prospective cohort study that was designed to investigate 
determinants of chronic disabling diseases in the elderly.l5 The Rotterdam 
Study was performed among inhabitants of a district of Rotterdam, the 
Netherlands, who were 55 years and over. The medical ethics committee of 
the Erasmus University Rotterdam approved the study and written 
informed consent was obtained from all 7983 participants. 
The baseline, first follow-up and second follow-up examinations took 
place in 1990-1993, 1993-1994 and 1997-1999, respectively. In addition, the 
total cohort was continuously monitored for mortality and major morbidity. 
At baseline, 7525 subjects were cognitively screened, of whom 5757 
subjects were still alive at second follow-up. The 3717 participants (64.6% of 
the living) who had fasting blood samples drawn at second follow-up were 
eligible for the present study. 
Diagnosis of dementia 
Cognitive screening was performed by use of a 3-step protocol at both 
baseline and follow-up examinations_16 First, subjects underwent 2 brief 
tests of cognition, namely the Mini Mental State Examination (MMSE)17 
and the Geriatric Mental State schedule (GMS) organic level.IB Screen 
positives (MMSE score < 26 or GMS organic level > 0) were further 
cognitively tested using the Cambridge examination for mental disorders of 
the elderly (CAMDEX) 1 9 If a participant was suspected of having dementia, 
he or she was subsequently examined by a neurologist and a 
neuropsychologist and a magnetic resonance imaging scan of the brain was 
made. Diagnoses of dementia and Alzheimer's disease were made according 
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to criteria of DSM-III-R2D and NINCDS-ADRDA,21 respectively, by a panel of 
a neurologist, neuropsychologist and research physician.l6 
Definition of cognitive decline 
The definition of cognitive decline was based on MMSE-scores at baseline, 
first follow-up and second follow-up from all dementia-free participants in 
the eligible population (n=3633). For each participant the yearly decline in 
MMSE-score over a mean period of 6.5 years (SD 0.3) was calculated by 
means of a random effects model using SAS statistical software (SAS 
Institute Inc., Cary, NC, USA). We defined subjects as having cognitive 
decline in case their decline in MMSE-score fell within the highest 8th 
percentile of the distribution of MMSE-decline. This cut-off point 
corresponded to a decline in MMSE~score of 0.11 points per year or more. 
Cases and controls 
Cases and controls were selected from the eligible population (n=3717). Of 
the 84 dementia patients within this population, 65 subjects suffered from 
Alzheimer's disease and served as Alzheimer cases in the present study. 
Cases of cognitive decline were all 293 dementia-free subjects from the 
eligible population, who had cognitive decline according to the definition 
given before. As controls we used 437 subjects who were randomly drawn 
from that part of the eligible population that was free of dementia and 
cognitive decline (n=3340). 
Assessments of plasma levels of vitamin A and E 
At the second follow-up examination blood samples were drawn from 
subjects who had fasted overnight. Obtained citrate plasma was 
immediately frozen in liquid nitrogen, transferred to the laboratory and 
stored at -80°C. 
Measurements of vitamins were performed blindly for case/control status. 
We determined plasma levels of total vitamin A (retinol) and total vitamin E 
(alpha-tocopherol) using methods described elsewhere.22, 23 In brief, 
reversed-phase HPLC with UV detection was applied using a RP C18 
column 100 mm x 4.6 mm (Merck Lichrospher 100 RP-18e ®). Vitamin A 
was detected at 324 nanometer (nm) and vitamin E at 288 nm. The 
interassay coefficient of variation was 4.0 % for vitamin A and 3.2 % for 
vitamin E. 
Covariates 
We assessed level of education and smoking habits. In addition, blood 
samples were drawn and weight and height were measured. For the present 
study, we categorized highest attained level of education in 2 groups: low 
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education versus high education. Low education was defined as completed 
primary education, lower vocational training or lower general education. 
High education was defined as intermediate or higher vocational training or 
education, college or university. Smoking habits were dichotomized into 
yes/no current smoking. Total cholesterol was determined in serum with an 
automated enzymatic procedure24 and body mass index was calculated by 
dividing the weight by the squared height. 
Data analysis 
The relation between plasma levels of vitamin A and E and Alzheimer's 
disease and cognitive decline was assessed using logistic regression 
analyses. Plasma levels of antioxidants were first entered into the model as 
a linear term. In this model, the regression coefficient was expressed per 
standard deviation increase in plasma level. In addition, we performed 
analyses using tertiles of antioxidant levels. Standard deviations and 
tertiles were based on the distribution of the controls (n=437). The analyses 
were firstly performed without adjustments for any covariate. Subsequently, 
adjustments were made for age and gender. In addition, total cholesterol 
was added to the model as well as education, current smoking and body 
mass index. Finally, we excluded current smokers from the fully adjusted 
model. 
We used a significance level of 5% based on 2 sided testing. All data 
analyses were performed using SPSS statistical software, version 10 (SPSS 
Inc., Chicago, Illinois, USA). 
Table 1 Characteristics of the study population* 
Cases of Alzheimer's Cases of Controls 
disease cognitive decline (no437) 
(no65) (no293) 
Age (y) 83.7 (7.1) 75.5 (8.1) 71.9 (6.7) 
Women 60% 64% 59% 
Total cholesterol (mmoi/L) 5.5 (1.1) 5.8 (1.0) 5.9 (0.9) 
Low educationt 65% 26% 29% 
Current smoking 8% 16% 16% 
Body mass index (kg/m2 ) 25.5 (2.9) 26.9 (3.8) 26.9 (4.1) 
Vitamin A ~moi!L) 1.48 (0.41) 1.59 (0.40) 1.59 (0.37) 
Vitamin E ()..lmoi/L) 25.0 (5.6) 27.4 (6.6) 27.9 (6.4) 
*values represent means (SO) or percentages(%) 
t low education was defined as completed primary education, lower vocational training or lower general 
education 
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Results 
Table 1 presents the characteristics of the study population. Cases of 
Alzheimer's disease and cognitive decline were older compared to control 
subjects and were more often women. Educational level was clearly lowest 
in cases with Alzheimer's disease compared to cases with cognitive decline 
and controls. Unadjusted plasma levels of vitamin A were lower for 
Alzheimer cases, whereas levels of vitamin E were lower for both cases of 
Alzheimer's disease and cognitive decline compared with controls. 
Table 2 presents the odds ratios of Alzheimer's disease per standard 
deviation increase in plasma level of vitamin A and vitamin E. Unadjusted, 
the prevalence of Alzheimer's disease significantly decreased with 28% with 
every 0.40 ~mol/L (SD) increase in vitamin A level (odds ratio (OR) 0. 72 
(95% confidence interval (95% CI) 0.55-0.96)). In addition, high level of 
vitamin E was associated with lower prevalence of Alzheimer's disease: the 
odds ratio per standard deviation increase was 0.58 (95% CI 0.43-0.80). 
However, when we entered age and gender into the models the relation 
substantially weakened both for vitamins A and E. The strength of the 
association further decreased after additional adjustment for total 
cholesterol as well as education, current smoking and body mass index; in 
the fully adjusted models the odds ratios were for vitamin A 0.98 (95% CI 
0. 71-1.37) and for vitamin E 0.86 (95% CI 0.53-1.40). The results were 
similar after exclusion of current smokers. 
Table 3 shows the association between plasma levels of vitamins A and E 
and cognitive decline. Both antioxidants were not associated with presence 
of cognitive decline either in the univariate or in the multivariate model; 
when fully adjusted, odds ratios were 1.05 (95% CI 0.89-1.24) for vitamin A 
Table 2 Adjusted odds ratios of Alzheimer's disease per standard deviation increase in 
plasma levels of vitamin A and E• 
Unadjusted Adjusted for age Adjusted for Fully adjustedt 
and gender age, gender and 
total cholesterol 
SDt OR (95% Cl)~ OR (95% Cl)~ OR (95% Cl)~ oR (95% c1m 
Vitamin A 0.40 0.72 (0.55-0.96) 0.84 (0.62-1.13) 0.87 (0.64-1.19) 0.98 (0.71-1.37) 
Vitamin E 6.6 0.58 (0.43-0.80) 0.82 (0.57-1.18) 0.94 (0.60-1.48) 0.86 (0.53-1.40) 
* 65 cases of Alzheimer's disease, 437 controls 
t adjusted for age, gender, total cholesterol, education, current smoking and body mass index 
+standard deviation (f.UTloi/L) 
'11 odds ratio (95% confidence interval) 
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Table 3 Adjusted odds ratios of cognitive decline per standard deviation increase in 
plasma levels of vitamins A and E* 
Unadjusted Adjusted for age Adjusted for Fully adjustedt 
and gender age, gender and 
total cholesterol 
SOt OR (95% el)~ OR (95% el)~ oR (95% e1m oR (95% e1m 
Vitamin A 0.40 1.00 (0.86-1.16) 1.02 (0.87-1.18) 1.04 (0.89-1.22) 1.05 (0.89-1.24) 
Vitamin E 6.6 0.93 (0.80-1.07) 0.98 (0.84-1.15) 1.04 (0.85-1.28) 1.03 (0.84-1.27) 
"293 cases with cognitive decline, 437 controls 
t adjusted for age, gender, total cholesterol, education, current smoking and body mass index 
:j: standard deviation (IJ.ITloi/L) 
11 odds ratio (95% confidence interval) 
and 1.03 (95% CI 0.84-1.27) for vitamin E. Exclusion of current smokers did 
not change the results. 
Figure 1 presents the relation between tertiles of antioxidants and 
Alzheimer's disease with adjustments for age, gender, total cholesterol, 
education, current smoking and body mass index. Also across tertiles, levels 
of vitamins A and E were not associated with Alzheimer's disease. 
Figure 2 shows that tertiles of vitamins A and E were not related to 
cognitive decline. 
Discussion 
After adequate adjustment for confounding, we observed no association 
between plasma levels of the antioxidant vitamins A and E and presence of 
Alzheimer's disease. Furthermore, no relation was found between 
antioxidants and cognitive decline in dementia-free subjects. 
The present study has several advantages. First, our study examined the 
relation between antioxidant levels and Alzheimer's disease and cognitive 
decline in a population-based study. Second, antioxidant assessments were 
performed blinded for case/control status. As a result, differential 
misclassification could not have occurred. Finally, adjustments were made 
not only for age and gender, but also for important other confounders such 
as total cholesterol, education, current smoking and body mass index. 
A limitation of the study is the cross-sectional design that makes it 
impossible to determine whether antioxidants are etiologically involved in 
Alzheimer pathogenesis. Levels of antioxidants may have altered due to 
changing dietary intake as a result of cognitive dysfunction. Another 
limitation may be our definition of cognitive decline as a proxy for 
preclinical stages of Alzheimer's disease. This definition was based on the 
Figure 1 Adjusted odds ratios (OR) of Alzheimer's disease plotted on a logarithmic 
sca!e against median level of vitamins A and E within terti!es* 
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indicate 95% Cl 
Figure 2 Adjusted odds ratios (OR) of cognitive decline plotted on a log-scale against 
median level of vitamins A and E within tertiles* 
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MMSE that may have been too crude to accurately classify dementia-free 
subjects in terms of cognitive decline. This random misclassification may 
have resulted in an underestimation of the true association of antioxidants 
with cognitive decline. 
Numerous hospital-based studies examined the relation between blood 
levels of antioxidants and the prevalence of Alzheimer's disease.4-l4 For 
vitamin E, the results were conflicting: 5 studies observed higher prevalence 
of Alzheimer's disease with lower levels of vitamin E,4·S whereas 5 other 
studies did not find any association.9·13 For vitamin A, 54-s out of 64-S, 14 
previous studies showed significantly higher prevalence of Alzheimer's 
disease with lower levels. However, the studies on vitamin A and E and 
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Alzheimer's disease either did not adjust for confounders5, 6, 9, 12, 14 or only 
adjusted for age and gender•· 7, s, lO, 11 or lipid levels.13 Therefore, results of 
these studies are difficult to interpret since we showed that the association 
between vitamin A and E and prevalence of Alzheimer's disease disappeared 
when adjustments were made for age, gender, total cholesterol, education, 
current smoking and body mass index. Our results on cognitive decline are 
in accordance with the findings of a previous population-based study that 
adequately adjusted for confounding25 This French study also observed no 
association of vitamin E with cognitive decline 4 years later. 
The absent association between plasma level of vitamin E and 
Alzheimer's disease in the present study is in contrast with previous 
findings of lower risk of Alzheimer's disease with higher vitamin E intake.2• 
3 This discrepancy may be explained in 2 ways. First, the present study on 
plasma levels was cross-sectional, whereas the intake study was 
longitudinal. In cross-sectional studies rather than in longitudinal studies 
(absence of) associations may be due to changing antioxidant status as a 
result of cognitive dysfunction. Second, studies on plasma levels and intake 
may not be comparable because plasma levels are not only determined by 
intake, but also by absorption, usage and storage. As a result, the 
correlation between plasma levels of vitamin E and dietary intake is not 
very high (r=0.34)26 
In summary, this population-based study showed that the cross-sectional 
association between plasma levels of vitamin A and E and Alzheimer's 
disease was largely due to confounding factors. Vitamin A and E were not 
related to cognitive decline either. Prospective studies are needed to 
elucidate whether plasma levels of antioxidants are reduced prior to clinical 
onset of dementia. 
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Chapter 3.1.2 
Dietary intake of antioxidants and 
risk of Alzheimer's disease 
Context Laboratory findings have suggested that oxidative stress may 
contribute to the pathogenesis of Alzheimer's disease. Therefore, the risk of 
Alzheimer's disease might be reduced by intake of antioxidants that 
counteract the detrimental effects of oxidative stress. 
Objective To determine whether dietary intake of antioxidants is related to 
risk of Alzheimer's disease. 
Design and Setting The Rotterdam Study, a population-based, prospective 
cohort study conducted in the Netherlands. 
Participants A total of 5395 participants who, at baseline (1990-1993), 
were aged at least 55 years, free of dementia, and noninstitutionalized and 
had reliable dietary assessment. Participants were reexamined in 1993-1994 
and 1997-1999 and were continuously monitored for incident dementia. 
Main Outcome Measures Incidence of Alzheimer's disease, based on 
Diagnostic and Statistical Manual of Mental Disorders, Revised Third 
Edition (DSM-111-R) criteria and National Institute of Neurological and 
Communicative Disorders and Stroke and Alzheimer's Disease and Related 
Disorders Association (NINCDS-ADRDA) criteria, associated with dietary 
intake of beta carotene, flavonoids, vitamin C, and vitamin E. 
Results After a mean follow-up of 6 years, 197 participants developed 
dementia, of whom 146 had Alzheimer's disease. When adjustments were 
made for age, sex, baseline Mini-Mental State Examination score, alcohol 
intake, education, smoking habits, packyears of smoking, body mass index, 
total energy intake, presence of carotid plaques, and use of antioxidative 
supplements, high intake of vitamin C and vitamin E was associated with 
lower risk of Alzheimer's disease (rate ratios (RRs) per standard deviation 
increase in intake were 0.82 (95% confidence interval (CI) 0.68-0.99) and 0.82 
(95% CI 0.66-1.00), respectively. Among current smokers, this relationship 
was most pronounced (RRs 0.65 (95% CI 0.37-1.14) and 0.58 (95% CI 0.30-
1.12), respectively) and also was present for intake of beta carotene (RR 0.49 
(95% CI 0.27-0.92) and flavonoids (RR 0.54 (95% CI 0.31-0.96)). The 
associations did not vary by education or apolipoprotein E genotype. 
Conclusion High dietary intahe of vitamin C and vitamin E may lower the 
risk of Alzheimer's disease. 
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S everal findings suggest that oxidative stress may play an important role in the pathogenesis of Alzheimer's disease. First, the brains of patients with Alzheimer's disease contain lesions that are typically 
associated with exposure to free radicals_1,2 In addition, oxidative stress in 
brains of Alzheimer patients is indicated by elevated cerebral levels of 
endogenous antioxidants that scavenge free radicals.s Moreover, in vitro 
studies suggest that exogenous antioxidants reduce the toxicity of beta-
amyloid in brains of Alzheimer patients,1,2 Based on these findings, it has 
been hypothesized that antioxidants from food may reduce the risk of 
Alzheimer's disease. 
A previous randomized controlled trial4 found that patients taking 
vitamin E supplement had a slower progression of the disease than patients 
taking placebo. It is thus possible that high intake of antioxidants may also 
prevent the onset of dementia, because antioxidants may reduce neuronal 
loss due to oxidative damage.1,2 
Two studies examined the longitudinal relationship between antioxidants 
from supplements and risk of Alzheimer's disease. 5·6 These studies found 
conflicting results: vitamin C supplement use was related to lower risk of 
Alzheimer's disease in 1 study,5 whereas the other found no association for 
combined use of vitamin C and vitamin E supplements.6 However, studies 
on supplement use are prone to bias, because people who use supplements 
may also have more health problems' and more health-seeking behavior8 In 
addition, use of supplements is generally of short duration. 
To date, only 1 study has prospectively examined the association between 
dietary antioxidants and risk of dementia,' and found a reduced risk of 
dementia associated with increased intake of flavonoids. We investigated 
whether intake of a range of antioxidants from food, namely beta carotene, 
flavonoids, vitamin C, and vitamin E, was associated with the risk of 
Alzheimer's disease, using data from a population-based cohort study. 
Methods 
The Rotterdam Study 
The Rotterdam Study is a population-based, prospective cohort study of the 
frequency and determinants of neurological, cardiovascular, locomotor, and 
ophthalmologic diseases in elderly persons. The medical ethics committee of 
the Erasmus University Rotterdam approved the study. The eligible 
population comprised all inhabitants of a suburb in Rotterdam, the 
Netherlands, who were aged at least 55 years (n=10 275). Of these, 7983 
subjects (response rate 78%) gave their written informed consent and 
participated in the studyJO 
During the baseline examination (1990-1993), a research assistant 
interviewed participants in their homes and obtained information on 
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current and past health, medication, lifestyle, and risk factors for chronic 
diseases. In addition, participants visited the research center twice for 
baseline clinical examinations. Follow-up examinations took place in 1993-
1994 and 1997-1999. The total cohort was continuously monitored for 
mortality and major morbidity. 
Diagnosis of dementia and Alzheimer's disease 
Case-finding and diagnostic procedures for dementia and Alzheimer's 
disease have been described in detail.U At baseline visit and both follow-up 
examinations, a 3-stage protocol was used. Participants were cognitively 
screened with the Mini-Mental State Examination (MMSE)12 and the 
Geriatric Mental State schedule (GMS) organic level. 13 If subjects scored 
lower than 26 on the MMSE or higher than 0 on the GMS organic level, the 
Cambridge Examination of Mental Disorders in the Elderly (CAMDEX)14 
was administered. The CAl\llDEX also included an informant interview. 
Finally, participants in whom dementia was suspected were examined by a 
neurologist and neuropsychologist and, if possible, had magnetic resonance 
imaging of the brain. In addition, the total cohort was continuously 
monitored for incident dementia cases through computerized linkage 
between the study database and computerized medical records from general 
practitioners and the Regional Institute for Outpatient Mental Health 
Care.n The diagnoses of dementia and Alzheimer's disease were based on 
Diagnostic and Statistical Manual of Mental Disorders, Revised Third 
Edition (DSM-III-R)'' criteria and the National Institute of Neurological 
and Communicative Disorders and Stroke and Alzheimer's Disease and 
Related Disorders Association (NINCDS-ADRDA) criteria,16 respectively, 
and were made by a panel of a neurologist, neuropsychologist, and research 
physician that reviewed all existing information.l 1 Follow-up with respect to 
dementia was virtually complete (99.9%). 
Dietary assessment 
Dietary intake was assessed at· baseline by means of a 2-stage protocol. 
Participants first indicated on a checklist all foods and drinks they had 
consumed at least twice a month during the preceding year. The checklist 
also contained questions on dietary habits, use of supplements, and 
prescribed diets. At the second baseline visit to the research center, the 
participants were interviewed on the basis of the completed checklist. This 
interview was performed by a dietician, who used an extensive, validated 
semiquantitative food-frequency questionnaire (SFFQ)17·1s The SFFQ data 
were converted to energy intake and nutrient intake using the computerized 
Dutch Food Composition Table.19,20 We used data on intake of the 
antioxidants beta carotene, flavonoids, vitamin C, and vitamin E. Important 
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sources of beta carotene are kale, carrots, broccoli, and spinach. Flavonoids 
are found in cranberries, green and black tea, and pulses. Vitamin C is 
mainly found in citrus fruits, kiwi, sprouts, broccoli, and cabbage. Important 
sources of vitamin E are grain, nuts, milk, and egg yolk. Daily dietary 
intake of the antioxidants from food was calculated in milligrams. 
Other variables 
During the baseline home interview, participants were asked about their 
highest attained level of education and their smoking habits. At the visits to 
the research center, which were part of the baseline clinical examination, 
the MMSE was performed, height and weight were measured, and intake of 
alcohol, total energy, antioxidative supplements, total fat, and saturated fat 
were indicated on the SFFQ. Furthermore, ultrasonography of the carotid 
arteries was performed21 and blood samples were drawn. 
Level of education was categorized in 3 groups: low (primary education 
only); intermediate (lower vocational or general education); and high 
(intermediate or higher vocational or general education, college, or 
university). Smoking habits were categorized as never, former, and current 
smoking. For former and current smokers, the number of packyears was 
defined as the number of years of smoking times the number of cigarettes 
smoked daily divided by 20. Alcohol intake was categorized in 5 groups: no 
alcohol intake, less than 1 drink per week, between 1 drink per week and 1 
drink per day, between 1 and 4 drinks per day, and 4 drinks per day or 
more. Subjects who used beta carotene supplement, flavonoid supplement, 
vitamin C supplement, vitamin E supplement, or multivitamin supplement 
were classified as users of antioxidative supplements; all others were 
classified as nonusers. Intake of total and saturated fat was expressed in 
grams per day. Artherosclerotic plaques in the carotid arteries were defined 
as a focal widening relative to adjacent segments, with the protrusion into 
the lumen composed of either only calcified deposits or a combination of 
calcification and noncalcified material.21 The presence of carotid plaques 
was assessed at 6 different locations: the common carotid artery, carotid 
bifurcation, and internal carotid artery at both left and right side.21 
Subsequently, according to the number of locations with plaques, 4 
categories were made: plaques at 0, 1 to 2, 3 to 4, and 5 to 6 locations. 
Apolipoprotein E (APOE) genotype was assessed on coded DNA samples 
using polymerase chain reaction without knowledge of the dementia 
diagnosis. 22 We dichotomized APOE genotype into presence or absence of 
the apolipoprotein E*4 (APOE*4) allele. 
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Study sample 
At the baseline clinical examination, 7525 participants of the Rotterdam 
Study were screened for dementia. Dementia was diagnosed in 482 
participants, resulting in 7043 participants who were free of dementia at 
baseline. Of these, we excluded 602 participants from dietary assessment for 
2 reasons. First, dietary intake was not assessed in 125 participants who 
had questionable cognitive status (<80 CAMDEX score), because the 
participants might provide um·eliable answers regarding their food 
patterns. Second, we excluded nursing home residents (n=4 77), because 
their current diet may not reflect dietary habits in the past. Thus, 6441 
participants were eligible for dietary assessment. Of these, reliable dietary 
data were missing in 1046 participants (16%) for several reasons. First, due 
to logical inconsistencies in dietary interviews, 212 participants were 
excluded. Second, because the SFFQ was administered at the second 
baseline visit to the research center, participants who did not complete the 
second visit did not have dietary assessment (n=192). Finally, 642 
participants did not have dietary data due to logistic reasons. Thus, the 
sample comprised 5395 participants who had normal cognition, lived 
independently, and had reliable dietary assessment at baseline. 
Eligible participants without dietary data were somewhat older (2.6 
years) compared with participants from the study population, a somewhat 
lower percentage (4%) were women and a higher percentage had only 
primary education (7%). Smoking habits and body mass index were similar 
across the 2 groups. 
Data analysis 
To assess the relationship between intake of antioxidants from food and 
cognitive function at baseline, we performed linear regression analysis with 
antioxidant intake as the dependent variable and baseline MMSE score as 
independent variable. We adjusted for age, sex, alcohol intake, education, 
smoking habits, packyears of smoking, body mass index, total energy intake, 
presence of carotid plaques, and use of antioxidative supplements. 
To determine whether the incidences of Alzheimer's disease differed 
between the sample and the eligible population with missing dietary data, 
we performed a Cox proportional hazards regression analysis with 
adjustment for age, sex, and education. 
We evaluated the associations of daily dietary intake of antioxidants with 
risk of Alzheimer's disease using Cox proportional hazards regression 
analysis. Intake of antioxidant was represented in the model either by a 
linear term or by 2 dummy variables representing the 2 highest tertiles. In 
the first case, the regression coefficient was expressed per SD increase. 
Standard deviations and tertiles of the respective intake of antioxidants 
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were based on the distribution of the complete sample (n=5395). All 
analyses were initially adjusted for age and sex. Subsequently, additional 
adjustments were made for baseline MMSE score and alcohol intake, 
respectively. In another model, adjustments were simultaneously made for 
the following confounders: age, sex, baseline MMSE score, alcohol intake, 
education, smoking habits, packyears of smoking, body mass index, total 
energy intake, presence of carotid plaques, and use of antioxidative 
supplements. Missing values were indicated by a missing indicator for 
categorical variables. For continuous variables, we replaced missing values 
by the mean or median of the study population, depending on the 
distribution. Age was used as the timescale in the model. Entry time was 
defined as age at study entry. Participants were followed until onset of 
Alzheimer's disease, onset of other types of dementia, death, or end of study, 
whichever came first. Age at onset of Alzheimer's disease and other types of 
dementia was determined as the midpoint between the age of participant 
last known to be at risk of dementia and age at diagnosis of dementia. 
To avoid confounding by supplement use, we also performed the analyses 
excluding users of antioxidative supplements (n=639). We investigated the 
combined effect of antioxidant intake from food and from supplements in an 
analysis in which users of an antioxidative supplement were added to the 
highest tertile of the corresponding antioxidant intake from food. For 
instance, users of beta carotene supplements were added to the highest 
tertile of beta carotene intake from food. Users of multivitamins were added 
to the highest tertile of each of the 4 antioxidant intakes from food, because 
multivitamins can contain more than 1 antioxidant and because 
multivitamins generally contain higher amounts of antioxidants than 
antioxidant intake from food. 
All rate ratios in the subsequent analyses were calculated per standard 
deviation increase in intake of antioxidants after adjustment for age, sex, 
baseline MMSE score, alcohol intake, education, smoking habits, packyears 
of smoking, body mass index, total energy intake, presence of carotid 
plaques, and use of antioxidative supplements. Because low intake of total 
fat and saturated fat is related to both high intake of antioxidants23 and risk 
of dementia,24 the analyses were repeated with additional adjustments for 
total fat intake and saturated fat intake. 
To examine possible effect modification by education, we performed 
stratified analysis by educational level. Furthermore, because smoking 
increases the load of free radicals and thus the extent of oxidative stress,25 
we also performed the analyses within strata of smoking habits. Because 
the APOE*4 allele is an important risk factor for Alzheimer's disease26 and 
is related to oxidative stress,2 we also performed the analyses within strata 
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Table 1 Baseline characteristics of the study population (n=5395)' 
Characteristic No.(%) 
Age, mean (SO), (y) 67.7 (7.8) 
Women 3183 (59) 
Baseline MMSE secret 28 (27-29) 
Alcohol intake 
None 1113 (21) 
< 1 drinklw 1156(21) 
1 drink/w-1 drink/d 1518 (28) 
1-4 drinks/d 1443 (27) 
;:: 4 drinks/d 165 (3) 
Educationallevelrff 
Low education 1854 (35) 
Intermediate education 1538 (28) 
High education 2003 (37) 
Smoking 
Current 1257 (23) 
Fonner 2305 (43) 
Never 1808 (34) 
Packyears of smoking 
Current smokerst 28 (14-42) 
Former smokerst 18 (5-35) 
Body mass index, mean (kg/m2) 26.3 (3.7) 
Total energy intake (kJ/d) 8264 (2105) 
Use of antioxidative supplements 639 (12) 
Total fat intake (g/d) 80.7 (26.5) 
Saturated fat intake (g/d) 34.4 (12.1) 
Number of locations of carotid plaques 
0 1930 (43) 
1-2 1551 (34) 
3-4 782 (17) 
5-6 284 (6) 
Carrier of at least 1 APOE*4 allele,-r 1426 (28) 
Beta carotene (mg/d) 1.53 (0.75) 
Flavonoids (mg/d) 28.5 (12.2) 
Vitamin C (mg/d) 121 (54) 
Vitamin E (mg/d) 13.8 (6.2) 
*values represent means (standard deviation) or percentages(%) 
t median (interquartile range) 
t low education represents primary education only; intermediate education represents lower vocational or 
general education; high education represents intermediate or higher vocational or general education, 
college or university 
11 proportion is based on the actual number of individuals with data on this variable 
Table 2 Adjusted rate ratios of Alzheimer's disease per standard deviation increase in dietary antioxidant intake from food 
Adjusted for age Adjusted for age, Adjusted for age, Fully adjusted Supplement users 
and gender gender and baseline gender and mode!* exc!uded1'f 
MMSE score alcohol intake n=4756 
SDt RR (95% Cl)t RR (95% Cl)t RR (95% Cl)t RR (95% Cl)t RR (95% Cl)t 
Beta carotene 0.75 0.88 (0.72-1.08) 0.88 (0.71-1.08) 0.88 (0.71-1.08) 0.87 (0. 70-1.09) 0.81 (0.63-1.03) 
Flavonoids 12.2 0.98 (0.83-1.16) 0.99 (0.83-1.17) 0.98 (0.82-1.15) 0.99 (0.83-1.18) 0.98 (0.81-1.19) 
Vitamin C 54 0.85 (0.71-1.01) 0.83 (0.69-1.00) 0.85 (0.71-1.01) 0.82 (0.68-0.99) 0.83 (0.68-1.01) 
Vitamin E 6.2 0.90 (0.76-1.08) 0.90 (0.75-1.07) 0.91 (0.76-1.08) 0.82 (0.66-1.00) 0.84 (0.68-1.05) 
*adjusted for age, gender, baseline MMSE score, alcohol intake, education, smoking habits, packyears of smoking, body mass index, total energy intake, 
presence of carotid plaques, and use of antioxidative supplements 
~adjusted for age, gender, baseline MMSE score, alcohol intake, education, smoking habits, packyears of smoking, body mass index, total energy intake, and 
presence of carotid plaques 
t standard deviation {mg/d) 
:j: rate ratio (95% confidence interval) 
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of APOE*4 allele. In this latter analysis, 226 subjects, of whom no APOE 
genotype was available, were excluded. 
Finally, to ensure that observed associations were not the result of 
changing dietary habits due to subclinical dementia, we excluded all 
subjects with less than 2 years of follow-up (n=212). Statistical interactions 
were tested by adding a product term to the unstratified model. Because the 
antioxidative effects of vitamin C and vitamin E might be synergistic, 27 
statistical interaction was also tested between vitamin C and vitamin E 
intake. 
All data analyses were performed using SAS statistical software version 
6.12 (SAS Institute Inc, Cary, NC). We used a significance level of 0.05 
based on 2 sided test. 
Results 
Table 1 presents the baseline characteristics of the sample. At baseline, the 
mean age was 67.7 years, the majority (59%) were women (n=3183), 23% 
(n=1257) were current smokers, 12% (n=639) used antioxidative 
supplements, and 28%(n=1426) carried at least 1 APOE*4 allele. 
Intake of flavonoids was significantly greater with a higher baseline 
MMSE score; with every point increase on the MMSE score intake of 
flavonoids increase with 0.24 mg/d (regression coefficient 0.24 (95% 
confidence interval (CI) 0.031-0.45). Intake of beta carotene, vitamin C, and 
vitamin E were not associated with baseline MMSE score (regression 
coefficient 0.009 (95% CI -0.004 to 0.022) for beta carotene; -0.19 (95% CI . 
1.12 to 0.75) for vitamin C; and 0.059 (95% CI -0.034 to 0.15) for vitamin E). 
After baseline dietary assessment, participants were followed up for an 
average of 6 years (32 341 person-years of follow-up). During this period, 
197 participants developed dementia, of whom 146 had Alzheimer's disease 
(134 without and 12 with cerebrovascular disease). The incidence of 
Alzheimer's disease did not differ between the sample and the eligible 
population with missing data on dietary intake; when adjustments were 
made for age, sex, and education, the rate ratio for subjects with dietary 
data compared with subjects without dietary data was 0. 75 (95% CI 0.54-
1.05). 
Table 2 shows the rate ratios of Alzheimer's disease associated with 
intake of antioxidants per SD increase. When adjustments were made for 
age and sex; age, sex, and baseline MMSE score; or age, sex, and alcohol 
intake, intake of beta carotene, flavonoids, or vitamin E was not related to 
risk of Alzheimer's disease. High intake of vitamin C had a borderline 
significant association with risk of Alzheimer's disease in all models. When 
additional adjustments were made for education, smoking habits, packyears 
of smoking, body mass index, total energy intake, presence of carotid 
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plaques, and use of antioxidative supplements, high intake of vitamin C was 
significantly related to reduced risk of Alzheimer's disease: the rate ratio 
(RR) per standard deviation increase was 0.82 (95% CI 0.68-0.99). For 
vitamin E, the inverse relationship was of borderline significance (RR 0.82 
(95% CI 0.66-1.00)). The results for beta carotene and flavonoids did not 
change after extensive adjustment. Exclusion of supplement users did not 
substantially alter the results (Table 2). 
Table 3 presents rate ratios of Alzheimer's disease across tertiles of 
antioxidant intake. When adjustments were made for age and sex only, 
antioxidant intake was not related to Alzheimer's disease. However, in the 
fully adjusted model, higher intake of vitamin E was significantly associated 
with lower risk of Alzheimer's disease, and higher intake of vitamin Chad a 
borderline significant association with lower risk of Alzheimer's disease. For 
vitamin C, the rate ratio of highest compared with lowest tertile was 0.66 
(95% CI 0.44-1.00) and for vitamin E, it was 0.57 (95% CI 0.35-0.91). Beta 
carotene and flavonoids were not associated with Alzheimer's disease across 
tertiles of intake. Adding supplement users to the highest tertile of dietary 
intake did not change the results for any of the 4 antioxidants. When we 
performed the analyses with additional adjustments for total fat intake or 
saturated fat intake, respectively, the results were similar. 
Table 3 Adjusted rate ratios of Alzheimer's disease across tertiles of antioxidant intake 
Model 1* Model2t 
Mg/d Cases RR (95% Cl):j: RR (95% Cl):j: 
Beta carotene < 1.22 62 1 (reference) 
1.22-1.67 49 0.95 (0.66-1.39) 0.94 (0.64-1.38) 
> 1.67 35 0.85 (0.56-1.30) 0.85 (0.55-1.30) 
Flavonoids < 22.6 47 
22.6- 32.7 44 0.83 (0.55-1.26) 0.84 (0.55-1.28) 
> 32.7 55 1.00 (0.68-1.49) 1.03 (0.68-1.55) 
Vitamin C <95 57 
95-133 48 0.78 (0.53-1.15) 0.75 (0.51-1.11) 
> 133 41 0.76 (0.51-1.12) 0.66 (0.44-1.00) 
Vitamin E < 10.5 56 
10.5- 15.5 55 1.15 (0.79-1.67) 1.03 (0.70-1.51) 
>15.5 35 0.70 (0.46-1.08) 0.57 (0.35-0.91) 
*adjusted for age and gender 
t adjusted for age, gender, baseline MMSE score, alcohol intake, education, smoking habits, packyears of 
smoking, body mass index, total energy intake, presence of carotid plaques, and use of antioxidative 
supplements 
:j: rate ratio (95% confidence interval) 
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Table 4 Adjusted* rate ratios of Alzheimer's disease per standard deviation increase in 
dietary antioxidant intake from food across strata of education 
Low educationt Intermediate High educationt 
n=1854 educationt n=2003 
(82 cases) n=1538 (38 cases) 
(26 cases) 
SDt RR (95% Cl)§ RR (95% Cl)§ RR (95% Cl)§ p-value1J 
Beta carotene 0.75 0.89 (0.66-1.19) 0.98 (0.66-1.44) 0.70 (0.44-1.13) 0.69 
Flavonoids 12.2 1.07 (0.85-1.36) 0.91 (0.58-1.43) 0.91 (0.65-1.28) 0.34 
Vitamin C 54 0.92 (0.73-1.16) 0.50 (0.30-0.85) 0.80 (0.55-1.16) 0.44 
Vitamin E 6.2 0.81 (0.61-1.09) 0.86 (0.52-1.42) 0.76 (0.51-1.14) 0.62 
*adjusted for age, gender, baseline MMSE-score, alcohol intake, smoking habits, packyears of smoking, 
body mass index, total energy intake, presence of carotid plaques, and use of antioxidative supplements 
t low education represents primary education only; intermediate education represents lower vocational or 
general education; high education represents intermediate or higher vocational or general education, 
college or university 
:t: standard deviation (mg/d) 
§ rate ratio (95% confidence interval) 
11 statistical interaction of intake with education 
Table 4 shows the relationship between antioxidant intake and risk of 
Alzheimer's disease across strata of education. The risk of Alzheimer's 
disease for beta carotene, flavonoids, and vitamin E did not significantly 
differ across strata of education and none of the statistical interaction terms 
was significant. High vitamin C intake was related to a lower risk of 
Alzheimer's disease within intermediate level of education. However, the 
statistical interaction was not significant. 
Table 5 presents associations of antioxidants with risk of Alzheimer's 
disease across strata of smoking habits. The risk of Alzheimer's disease 
associated with higher intake of vitamin C and vitamin E was lower in 
current smokers compared with former and never smokers, but the 
respective statistical interaction terms were not significant. For beta 
carotene, statistical interaction with smoking habits was significant and of 
borderline significance for flavonoids: high intake of beta carotene and 
flavonoids was associated with reduced risk of Alzheimer's disease in 
current smokers. 
Table 6 shows the relationship between intake of antioxidants and risk of 
Alzheimer's disease across strata of APOE*4 allele. In participants with at 
least 1 APOE*4 allele, higher intake of 3 of the 4 antioxidants (except for 
flavonoids) was associated with somewhat lower risk of Alzheimer's disease 
compared with the risk of Alzheimer's disease in participants without an 
APOE*4 allele. However, statistical interactions of intake with APOE 
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Table 5 Adjusted* rate ratios of Alzheimer's disease per standard deviation increase in 
dietary antioxidant intake from food across strata of smoking habits 
Never smokers Former smokers Current smokers 
n=1808 (64 cases) n=2305 (58 cases) n=1257 (22 cases) 
SOt RR (95% Cl)t RR (95% Cl)t RR (95% Cl)t p-value§ 
Beta carotene 0.75 0.77 (0.53-1.11) 1.09 (0.87-1.38) 0.49 (0.27-0.92) 0.03 
Flavonoids 12.2 1.04 (0.80-1.36) 1.07 (0.81-1.42) 0.54 (0.31-0.96) 0.05 
Vitamin C 54.1 0.83 (0.62-1.10) 0.91 (0.69-1.19) 0.65 (0.37-1.14) 0.35 
Vitamin E 6.2 0.98 (0.71-1.35) 0.77 (0.56-1.06) 0.58 (0.30-1.12) 0.21 
*adjusted for age, sex, baseline MMSE score, alcohol intake, education, smoking habits, packyears of 
smoking, body mass index, total energy intake, presence of carotid plaques, and use of anti oxidative 
supplements 
t standard deviation (mg/d) 
+rate ratio (95% confidence interval) 
§statistical interaction of intake with smoking habits 
genotype were not significant. 
We observed no statistical interaction between vitamin C intake and 
vitamin E intake with Alzheimer's disease. Finally, restriction of the 
analyses to participants with at least 2 years of follow-up did not 
substantially change the results: rate ratios per standard deviation increase 
in intake were 0.80 (95% CI 0.61-1.06) for beta carotene, 0.95 (95% CI 0.77-
1.18) for flavonoids, 0.82 (95% CI 0.66-1.03) for vitamin C, and 0.85 (95% CI 
0.66-1.08) for vitamin E. 
Discussion 
We found that high intake of vitamin C and vitamin E from food may be 
associated with a lower incidence of Alzheimer's disease after a mean follow-
up period of 6 years. The risk reduction associated with intake of all 4 
antioxidants was consistently largest for current smokers, although the 
differences in rate ratios for beta carotene and flavonoids between smokers 
and nonsmokers were of marginal statistical significance, while those for 
vitamin C and vitamin E were not significant. Nonetheless, these 
associations persisted after controlling for a number of potentially 
confounding variables, such as use of vitamin supplements, education, and 
alcohol use. 
Before interpreting the results, some methodological issues should be 
considered. First, although we adjusted for a large number of potential 
confounding factors such as age, sex, alcohol intake, education, smoking 
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habits, and use of supplements, the possibility of residual confounding can 
never be completely excluded from an observational study. Second, we 
cannot completely exclude the possibility of subclinical dementia at time of 
dietary assessment, which may have led to changes in dietary reporting or 
dietary habits. To minimize this potential source of confounding, we 
excluded cognitively impaired subjects and adjusted for baseline MMSE 
score. In addition, we also recomputed the results after excluding the first 2 
years of follow-up, which did not alter the results. Thus, we do not think 
that our results were affected by the presence by subclinical dementia. 
Third, because dietary assessment was performed only once, it may not have 
precisely reflected the participants' long-term dietary habits, which are 
more likely to influence disease risk. However, this may have led to dilution 
and thus an underestimation of the associations of antioxidants with risk of 
Alzheimer's disease. Finally, we cannot completely rule out the possibility of 
confounding by use of dietary supplements. Although only a small number 
of participants reported supplement use, we do not have data on duration of 
use and dosage of the antioxidative supplements. Nonetheless, our results 
were unchanged after either excluding supplement users from the analysis 
or after controlling for supplement use, suggesting that our results are not 
confounded by supplement use. 
The strengths of our study are its prospective design and the population-
based setting. Another important feature is that follow-up with respect to 
dementia diagnosis was virtually complete, and thus there was no resulting 
selection bias. 
Table 6 Adjusted* rate ratios of Alzheimer's disease per standard deviation increase in 
dietary antioxidant intake from food according to APOE genotype 
No APOE*4 allele At least one APOE*4 allele 
n=3743 (75 cases) n=1426 (68 cases) 
SOt RR (95% Cl)t RR (95% Cl)t p-value§ 
Beta carotene 0.75 0.95 (0.72-1.25) 0.73 (0.49-1.09) 0.62 
Flavonoids 12.2 0.95 (0. 73-1.23) 1.04 (0.81-1.34) 0.61 
Vitamin C 54.1 0.89 (0.69-1.15) 0.74 (0.55-1.00) 0.90 
Vitamin E 6.2 0.82 (0.61-1.09) 0.74 (0.54-1.02) 0.82 
*adjusted for age, sex, baseline MMSE score, alcohol intake, education, smoking habits, packyears of 
smoking, body mass index, total energy intake, presence of carotid plaques, and use of antioxidative 
supplements 
t standard deviation (mg/d) 
:j: rate ratio (95% confidence interval) 
§statistical interaction of intake with APOE genotype 
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Several studies have examined the relationship between Alzheimer's 
disease and intake of vitamin C and vitamin E from supplements. 4·6•28,29 A 
case-control study of Broe et al2B and a prospective study in men6 showed no 
association between supplement intake and Alzheimer's disease. Another 
prospective study found that use of supplements, in particular of vitamin C 
but not vitamin E, was associated with a lower risk of Alzheimer's disease.5 
The only controlled trial of supplemented antioxidant intake and 
Alzheimer's disease was performed within patients who were already 
diagnosed with Alzheimer's disease.• This study reported that patients who 
took vitamin E supplements had a slower progression of the disease than 
patients who took placebo. 
Results on supplement use and risk of dementia, however, may not be 
comparable with results on intake from food for several reasons. First, 
supplement users are generally a selected group of persons with either 
health problems' or more health-seeking behaviors.s Therefore, associations 
between supplement use and Alzheimer's disease may be biased. Second, 
intake of antioxidants from food reflects long-term intake, whereas 
supplement intake is generally of shorter duration. If duration of 
antioxidant intake is more important than the dose, high-lifetime intake 
from food would more likely be related to Alzheimer's disease than short-
term high intake by supplements. Finally, antioxidants from food are 
always simultaneously consumed with other nutrients in a certain 
proportion, whereas antioxidants from supplements are consumed in a very 
high dose either with or without other substances. This might lead to 
differences in absorption or biological activity between antioxidants from 
food and antioxidants from supplements, though little is yet known on these 
issues.3o 
Previously, the relationship between intake of flavonoids from food and 
risk of dementia has been studied.9 This prospective study found that high 
flavonoid intake was significantly associated with a lower risk of dementia. 
However, the response rate for dietary assessment was relatively low, only a 
small part of the study population underwent a detailed dietary assessment, 
and confounding or effect modification by smoking was not examined. 
In our study, risk of Alzheimer's disease associated with vitamin C and 
vitamin E was lowest in current smokers and beta carotene, and flavonoids 
seemed inversely related to Alzheimer's disease in current smokers only. 
Because smoking itself is associated with increased risk of Alzheimer's 
disease, 31 high antioxidant intake may partly counteract the excess risk of 
Alzheimer's disease for smokers. This is supported by the finding of 
smokers' increased load of free radicals,25 which may be reduced by 
antioxidants. 
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Several biological mechanisms could explain a possible relationship 
between antioxidants from food and Alzheimer's disease. First, antioxidants 
may decrease the level of oxidative stress in the brain. Antioxidants may 
thereby reduce the amount of DNA damage, neuronal cell death, and the 
aggregation of beta -amyloid within the brainl,2 These phenomena are all 
important neuropathological features in Alzheimer's disease; by preventing 
the genesis of these features, the risk of dementia might be reduced. Second, 
because Alzheimer's disease is both associated with cardiovascular risk 
factors and atherosclerosis32,33 and oxidative processes are involved in 
atherogenesis, 34 high intake of antioxidants could also decrease the risk of 
dementia by reducing the risk of atherosclerosis. However, because 
additional adjustment for carotid plaques as a measure of atherosclerosis 
did not change our results, we doubt that atherosclerosis is an important 
intermediary in the relationship between antioxidants and risk of 
Alzheimer's disease. 
In conclusion, our results suggest that higher intake of vitamin C and 
vitamin E from food may be associated with a lower risk of Alzheimer's 
disease. Whether this reflects a causal association remains to be elucidated. 
Randomized controlled trials can help evaluate a possible causal 
relationship between antioxidant intake from supplements and risk of 
Alzheimer's disease. However, the effect of short-term supplement use in 
clinical trials may not be comparable with long-term intake from dietary 
sources. Therefore, more cohort studies are needed to further investigate the 
relationship between dietary antioxidant intake and risk of Alzheimer's 
disease. 
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Chapter 3.2.1 
Fatty acid composition in plasma 
phospholipids and cognitive 
function 
Background N-3 polyunsaturated fatty acids (n-3 PUFA) have anti-
inflammatory properties. Other fatty acids, such as saturated fatty acids, are 
associated with increased atherosclerosis. Because inflammation and 
atherosclerosis may be involved in dementia pathogenesis, fatty acids may 
also be related to dementia as well as to cognitive decline. 
Objective To examine whether fatty acids in plasma phospholipids were 
associated with cognitive decline in dementia-free subjects. 
Methods The study was performed within the Rotterdam Study, a 
population-based study among elderly. Baseline, first follow-up and second 
follow-up examinations took place in 1990-1993, 1993-1994 and 1997-1999, 
respectively, and included the Mini Mental State Examination (MMSE). The 
eligible population for the present study consisted of all 5487 subjects who 
were alive and dementia-free at second follow-up. For each subject, cognitive 
change between baseline and second follow-up was calculated on the basis of 
the subsequent MMSE-scores. Fatty acids were assessed at second follow-up 
in plasma phospholipids of 731 subjects and were expressed as percentage of 
total fatty acids. The association between fatty acids and cognitive change 
was examined by linear regression. 
Results After adjustments for age, gender and education, higher levels of 
saturated fatty acids, lower levels of PUFA and n-6 PUFA and a lower ratio 
of PUFA to saturated fatty acids were significantly associated with more 
cognitive decline. No association was found between trans fatty acids, 
monounsaturated fatty acids, n-3 PUFA, 18:2n-6, 18:3n-3, 20:4n-6, 20:5n-3, 
22:6n-3 and the ratio ofn-6 PUFA to n-3 PUFA and cognitive change. 
Conclusion Our findings suggest that saturated fatty acids are positively 
and unsaturated fatty acids are inversely related to cognitive decline. 
S everal observations suggest that fatty acids may play a role m dementia and cognitive function. First, some fatty acids, such as eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid 
(DHA, 22:6n-3), are known to inhibit inflammatory responses,' which have 
been found present in Alzheimer's disease.' Second, high levels of saturated 
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fatty acids and cis monounsaturated fatty acids (MUFA) and low levels of 
c1s polyunsaturated fatty acids (PUFA) are related to increased 
atherosclerosis,s which may be associated with dementia4 and cognitive 
decline.' Finally, the fatty acid composition of brain cell membranes differs 
between Alzheimer patients and control subjects. For instance, cell 
membranes within the (para)hippocampal region of Alzheimer brains 
contained less n-6 PUFA and less n-3 PUFA compared to membranes in the 
same region of control brains. 6, 7 
Previously, 2 cross~sectional studies examined the relation between fatty 
acids in plasma phospholipids and dementia and showed that levels of 
saturated fatty acids were highers and levels of EPA and DHA were lowers. 9 
within Alzheimer patients as compared to control subjects. Prospectively, 
DHA and EPA were studied in relation to Alzheimer's disease showing 
lower risk with higher levels of DHA onlylo Whether fatty acids are related 
to cognitive function within dementia~free subjects is not yet known. We 
examined the relation between various fatty acids in plasma phospholipids 
and change in cognitive function within dementia-free subjects over a mean 
period of 6.5 years. 
Methods 
Eligible population 
The present study was performed within the Rotterdam Study, a large 
population-based prospective cohort study designed to investigate 
determinants of chronic disabling diseases in the elderly.u Participants of 
the Rotterdam Study were 7983 inhabitants (response rate 78%) of a suburb 
of Rotterdam, the Netherlands, aged 55 years and over. The medical ethics 
committee of the Erasmus Medical Center Rotterdam approved the study 
and written informed consent was obtained from all participants. 
At present, 3 examination rounds have taken place, which all included a 
home interview and clinical examinations at the research center. The 
baseline examinations were performed in 1990-1993, first follow-up 
examinations took place in 1993-1994 and second follow-up examinations 
were in 1997-1999. 
Cognitive examinations within the Rotterdam Study included the Mini 
Mental State Examination (MMSE)12 and the Geriatric Mental State 
schedule (GMS) organic level13 at both baseline and follow-up14 In case of 
low scores on these tests (MMSE-score < 26 or GMS organic level > 0), 
additional cognitive testing was performed. If suspected of dementia, 
subjects were subsequently examined by a neurologist, a neuropsychologist 
and underwent magnetic resonance brain imaging. In addition, subjects 
were continously monitored for incident dementia.14 Diagnosis of dementia 
was based on DSM-III-R criteria." 
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The eligible population for the present study comprised 5463 persons, 
who were alive and still free of dementia at time of second follow-up 
examinations. 
Assessment of change in cognitive function 
In the eligible population, change of cognitive function over time was 
determined on the basis of subsequent MiVISE-scores at baseline, first 
follow-up and second follow-up. We used a random effects model (SAS 
statistical software, SAS Institute Inc., Cary, NC, USA) to calculate yearly 
change in MMSE-score for each participant. Subsequently, yearly MMSE-
change was multiplied by 6.5 in order to obtain change in cognitive function 
over the mean follow-up period of 6.5 years (SD 0.3). 
Study population 
The study population of the present study was selected from the eligible 
population (n=5463). For efficiency reasons, we oversampled subjects with 
severe decline in cognitive function. We therefore selected all 439 subjects 
who had a decline in MMSE-score that fell within the lowest 8% of the 
distribution of MMSE-change. This corresponded to a decline in MMSE-
score of 2.4 or more over 6.5 years (MMSE-change <= -2.4). In addition, we 
randomly selected 650 subjects from the remaining part of the eligible 
population (n=5024). Two-third of both selected groups (293 and 438, 
respectively) had blood samples drawn at second follow-up; these subjects 
were included in the study. Thus, the study population consisted of 731 
subjects who were dementia-free and underwent venipuncture at second 
follow-up. 
Assessments of fatty acids in plasma phospholipids 
At the second follow-up examination blood samples were drawn from 
subjects who had fasted overnight. Obtained citrate plasma was 
immediately frozen in liquid nitrogen, transferred to the laboratory and 
stored at -80°C. 
Measurements of fatty acids in plasma phospholipids were performed 
blinded for cognitive status. The assessments of fatty acids followed a 5-
stage protocoL First, lipids were extracted from plasma according to the 
methods used by Bligh and Dyer.l6 Second, phospholipids were separated 
from other lipids by means of solid phase extraction. Third, phospholipids 
were methylated via reaction with 14% boron trifluoride in methanol at 100 
oc for 1 hour. Fourth, butylated hydroxytoluene was added as antioxidant to 
all organic solvents. Finally, the fatty acid composition of the phospholipids 
was analysed using a gas chromatograph (Shimadzu® GC-17 A) with a FID 
detector and a CP-Sil88 column (50 m x 0.25 mm id. 0.22 11m film thickness, 
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Varian®). Fatty acids in the phospholipid fraction were quantified using 
19:0 fatty acid methyl ester as an internal standard. 
For the present study we classified fatty acids into various subgroups: 
saturated fatty acids, trans unsaturated fatty acids (trans fatty acids), cis 
monounsaturated fatty acids (MUFA), cis polyunsaturated fatty acids 
(PUFA), n-6 PUFA and n-3 PUFA. Furthermore, we examined the following 
separate fatty acids: the essential fatty acids linoleic acid (LA, 18:2n-6) and 
alpha-linolenic acid (ALA, 18:3n-3), the pro-inflammatory arachidonic acid 
(AA, 20:4n-6), and the anti-inflammatory n-3 PUFA eicosapentaenoic acid 
(EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3). All fatty acids 
were expressed as percentages of total fatty acids in plasma phospholipids. 
In addition, we calculated ratios ofPUFA to saturated fatty acids (PiS ratio) 
and n-6 PUFA to n-3 PUFA (n-6/n-3 ratio). 
Covariates 
Level of education and apolipoprotein E (APOE) genotype were assessed at 
baseline. Data on myocardial infarction was obtained at baseline and during 
follow-up. Depressive symptoms, functional status, medication use, fasting 
level of glucose and vitamin E, and presence of carotid plaques were 
assessed at the second follow-up examinations. 
Level of education was categorized in 4 groups: completed primary 
education, lower vocational training or general education, intermediate 
vocational training or intermediate and higher general education, and 
higher vocational training, college or university. APOE genotype was 
assessed on coded DNA samples using polymerase chain reaction.17 We 
dichotomized APOE genotype into presence or absence of the apolipoprotein 
E*4 (APOE*4) allele. Incident myocardial infarction was reported by the 
general practitioners by means of a computerized system. Myocardial 
infarctions reported by the participant or the general practitioner were 
verified and defined as code I21 according to the International Classification 
of Diseases, lOth edition.IS Depressive symptoms were assessed in the 
interview using the Dutch version of the original Center for Epidemiology 
Studies Depression scale (CES-D). Functional status was also determined in 
the interview by means of the Disability Index of the Stanford Health 
Assessment Questionnaire_19 Data on medication use were obtained from 
the interview and a pharmacy database that was linked to the study 
database. Subjects who used lipid-lowering medication (Anatomical-
Therapeutical-Chemical-code (ATC-code) clO) were classified accordingly. 
Diabetes was considered present if the subject was taking oral diabetics or 
insulin (ATC-code alO) or if the fasting serum glucose level was equal to or 
higher than 7.8 mmol!l (WHO-criteria for epidemiological studies of 
diabetes)20 Level of vitamin E (a-tocopherol) was determined in plasma by 
Fatty acid composition in plasma phospholipids an,j cognitive function 73 
means of reversed-phase HPLC with UV detection.21 We used 
ultrasonography of the carotid arteries to assess presence of carotid plaques 
at 6 different locations: the common carotid artery, carotid bifurcation and 
internal carotid artery at both left and right side.22 Subsequently, 4 
categories were made according to the number of locations with plaques: 
plaques at 0, 1-2, 3-4 and 5-6 locations. 
Data analysis 
The association between fatty acids, fatty acid ratios and cognitive change 
over 6.5 years (mean follow-up of the study population) was firstly assessed 
by means of linear regression analyses. In these analyses, fatty acid or fatty 
acid ratio was entered as independent variable and change in MMSE-score 
as dependent variable. Regression coefficients were expressed per standard 
deviation increase in fatty acid or fatty acid ratio. In addition, we performed 
analyses of covariance in which mean change in 1\11V[SE-score was calculated 
across tertiles of fatty acid or fatty acid ratio. Tertiles and standard 
deviations were based on the distribution of the complete study population 
(n=731). In all analyses adjustments were made for age, gender and 
education. 
Because comorbidity may be associated both with fatty acid level through 
diet and with cognitive function, we performed additional analyses in which 
we simultaneously adjusted for myocardial infarction, depressive symptoms 
and functional status. In addition, because diabetes changes fat metabolism 
and is associated with increased risk of dementia,23 we controlled for 
presence of diabetes in a separate analysis. Furthermore, in order to check 
whether atherosclerosis was an intermediate or confounder of the relation 
between fatty acids and cognitive change we adjusted for presence of carotid 
plaques. In this analysis a missing indicator was used for the 44 missing 
values on carotid plaques. 
Because the APOE*4 genotype both is an important risk factor for 
Alzheimer's disease24 and is involved in fat metabolism,25 we repeated the 
analyses within strata of APOE*4 genotype. In this latter analysis, 36 
subjects, of whom no APOE genotype was available, were excluded. 
Statistical interactions were tested by adding a product term to the 
unstratified model. Furthermore, because vitamin E may reduce 
detrimental oxidation of unsaturated fatty acids, we tested statistical 
interaction between unsaturated fatty acids and vitamin E in relation to 
MMSE-change. Finally, because the relation between fatty acid levels and 
cognitive change may be affected by use of lipid-lowering medication, we 
performed a separate analysis in which we excluded users (n=92, 12.6%). 
All data analyses were performed using SPSS statistical software, version 
10 (SPSS Inc., Chicago, Illinois, USA). 
Results 
Table 1 shows the characteristics of the study population. The mean age was 
73.3 years, 61% of the subjects was female and 29% was carrier of at least 1 
APOE*4 allele. The median change in MMSE-score over 6.5 years was -1.3 
points. Figure 1 presents the median fatty acid levels in plasma 
phospholipids in a flow chart. The majority of fatty acids from phospholipids 
were unsaturated fatty acids (53.9%), to which cis fatty acids contributed 
most. The main contributor to cis fatty acids is n-6 PUFA (35.6%). Relative 
amounts of LA and ALA in phospholipids were 21.8% and 0.2%, 
respectively. The long-chain n-3 PUFA EPA and DHA contributed for 0.8% 
and 3.5%, respectively, to fatty acids in plasma phospholipids. 
Table 2 presents the association of fatty acid composition in plasma 
phospholipids with change in MMSE-score over a period of 6.5 years. With 
Table 1 Characteristics of the study population (n=731 )' 
Characteristic 
Age (y)t 
Women(%) 
Low education (%) 
Diabetes(%) 
Carrier of APOE*4 allele(%) 
5-6 Locations with carotid plaques(%) 
Saturated fatty acids (% of total)=!: 
Trans fatty acids(% of total) 
MUFA (%of total) 
PUFA (%of total) 
N-6 PUFA (%of total) 
N-3 PUFA (%of total) 
LA (18:2n6) (%of total) 
ALA (18:3n3) (%of total) 
AA (20:4n6) (% of total) 
EPA (20:5n3) (%of total) 
DHA (22:6n3) (%of total} 
P/S ratio 
N-6/n-3 ratio 
Change in MMSE-score in 6.5 yrs~ 
*values represent medians (mterquartlle ranges) or percentages{%) 
t mean (standard deviation) 
:j: percentage of total fatty acids in plasma phospholipids 
1[6.5 years corresponds to mean follow-up in the study population 
73.3 (7.5) 
61.0 
37.9 
15.0 
28.9 
6.7 
46.0 (45.2; 46.8) 
0.9 (0.8; 1.1) 
11.6 (10.5; 12.8) 
41.3 (40.0; 42.7) 
35.4 (33.7; 37.3) 
5.46 (4.66; 6.53) 
21.8 (20.1; 23.6) 
0.2 (0.1; 0.2) 
8.9 (7.7; 10.2) 
0.8 (0.6; 1.0) 
3.5 (2.3; 4.3) 
0.9 (0.86; 0.94) 
6.5 (5.3; 7.9) 
-1.3 (-3.0; -0.3) 
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every 1.4% (standard deviation) increase in saturated fatty acids, the 
MMSE-score significantly declined with 0.14 points (regression coefficient 
(RC) -0.14 (95% confidence interval (95% CI) -0.27; -0.010)). In contrast, 
higher percentages of PUFA and n-6 PUFA and higher P/S ratio were 
significantly associated with an increase in MMSE-score (RC was 0.16 (95% 
CI 0.030; 0.29)) for PUFA, 0.13 (95% CI 0.006; 0.26) for n-6 PUFA and 2.69 
(95% CI 0.71; 4.67) for P/S ratio). Trans fatty acids, MUFA, n-3 PUFA, LA, 
ALA, AA, EPA, DHA and n-6/n-3 ratio were not associated with change in 
M.\VISE-score. 
Figure 1 Median percentages of various fatty acids in plasma phospholipids of the 
study population 
MUFA 
11.7% 
n-3 PUFA 
5.6% 
Cis fat 
53.0% 
MUFA =cis monounsaturated fatty acids 
PUFA =cis polyunsaturated fatty acids 
Total fatty acids 
100% 
Unsaturated fat 
53.9% 
PUFA 
41.3% 
n-6 PUFA 
35.6% 
Trans fat 
0.9% 
Saturated fat 
46.1% 
other PUFA 
0.1% 
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When we calculated mean changes in MMSE-score within tertiles of fatty 
acids and fatty acid ratios, we did not find any indication for non-linear 
associations. Figure 2 shows the mean change in MMSE-score according to 
tertiles of saturated fatty acids, PUFA, n-6 PUFA and PiS ratio. Increasing 
percentage of saturated fatty acids in plasma phosphoplipids across tertiles 
was associated with more decline in cognitive function: the mean change in 
MMSE-score for the highest tertile was -1.8 (95% CI -2.0; -1.6) versus -1.5 
(95% CI -1.7; -1.3) for the lowest tertile. Higher PUFA, n-6 PUFA or PiS 
ratio were associated with less decline in cognitive function. Mean MMSE-
changes in the highest versus the lowest tertile were for PUFA -1.6 (95% CI 
-1.8; -1.4) and -1.9 (95% CI -2.1; -1.7), for n-6 PUFA -1.6 (95% CI -1.8; -1.4) 
and -1.8 (95% CI -2.0; -1.6), and for the PiS ratio -1.5 (95% CI -1.7; -1.3) and 
-1.9 (95% CI -2.1; -1.7). 
When additional adjustments were simultaneously made for myocardial 
infarction, depressive symptoms and functional status, the results were very 
similar. Also, additional adjustment for diabetes and presence of carotid 
plaques, respectively, did not change the results. Furthermore, the 
associations between fatty acids and fatty acid ratios and cognitive change 
were similar across strata of APOE genotype and none of the interactions 
Table 2 Adjusted• regression coefficients describing the change in MMSE-score per 
standard deviation increase in percentage of total fatty acids or per 1 unit increase in 
fatty acid ratio 
so (%)t Regression coefficient (95% Cl):j: 
Saturated fatty acids 1.4 -0.14 (-0.27; -0.010) 
Trans fatty acids 0.3 0.032 (-0.098; 0.16) 
MUFA 1.9 -0.081 (-0.21; 0.048) 
PUFA 2.2 0.16 (0.030; 0.29) 
N-6 PUFA 2.9 0.13 (0.006; 0.26) 
N-3 PUFA 1.6 -0.027 (-0.16; 0.1 0) 
LA 2.9 0.045 (-0.084; 0.17) 
ALA O.D7 0.055 (-0.074; 0.19) 
AA 2.0 0.096 (-0.032; 0.22) 
EPA 0.6 -0.075 (-0.20; 0.053) 
DHA 1.1 -0.020 (-0.15; 0.11) 
P/S ratio 2.69 (0. 71; 4.67) 
N-6/n-3 ratio 0.0078 (-0.053; 0.069) 
*adjusted for age, gender and education 
t standard deviation of the percentage of total fatty acids 
.:t 95% confidence interval 
p-value 
O.D3 
0.63 
0.22 
0.02 
0.04 
0.63 
0.50 
0.40 
0.14 
0.25 
0.76 
0.01 
0.80 
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Figure 2 Adjusted' mean change in MMSE-score across tertiles of saturated fatty 
acids, PUFA, n-6 PUFA and P/S ratio in plasma phospholipids 
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between fatty acids and APOE genotype were statistically significant (p-
values all above 0.10). In addition, we observed no statistical interaction 
between trans fatty acids, MUFA, PUFA, n-6 PUFA, n-3 PUFA, LA, ALA, 
AA, EPA or DHA and level of vitamin E in relation to cognitive change (p-
values were all above 0.10). Finally, associations were very similar after 
exclusions of users of lipid-lowering medication. 
Discussion 
In this study we observed that high levels of saturated fatty acids in plasma 
phospholipids, low levels ofPUFA and n-6 PUFA and a low ratio ofPUFA to 
saturated fatty acids were associated with more cognitive decline. Trans 
fatty acids, MUFA, n-3 PUFA, LA, ALA, AA, EPA and DHA, and the ratio of 
n-6 PUFA to n-3 PUFA were not related to change in cognitive function, The 
associations were not confounded or modified by comorbidity and APOE 
genotype, respectively. 
Before interpreting the results, some methodological issues need to be 
discussed. First, the design of the study was cross-sectional. We therefore 
cannot exclude that fatty acid levels are the consequence rather than the 
cause of change in cognitive function. Second, no data were available on 
dietary intake of fatty acids at time of the assessment of phospholipid levels, 
As a result, we could not determine whether observed associations were the 
consequence of differences in dietary intake or differences in fatty acid 
metabolism. 
This study has several advantages. First, change in cognitive function 
was defined on the basis of several measurements over time. This will have 
reduced the disturbing effect of within-person variability and therefore 
improved the ranking of persons in terms of cognitive decline, even though 
using the MMSE to test cognitive function is rather crude. Other 
advantages of the study are its size and its population-based setting. 
Previously, fatty acids in phospholipids have been studied in relation to 
cognitive impairment showing that levels of EPA, DHA and total n-3 PUFA 
were lower and the n-6/n-3 ratio was higher in cognitively impaired subjects 
compared to control subjects,' Levels of saturated fatty acids, PUFA and n-6 
PUFA were similar in cognitively impaired subjects compared to control 
subjects.9 
Three studies examined the relation between fatty acids in plasma 
phospholipids and Alzheimer's disease.S-lO Two of these were cross-sectional 
and observed that levels of EPA and DHA were lower in Alzheimer patients 
compared to control subjects.s, 9 Also, levels of the main saturated fatty acids 
16:0 and 18:0 were higher in Alzheimer patients compared to control 
subjects in one study,s whereas the other study showed higher levels of n-6 
PUFA in Alzheimer patients-' A longitudinal study found that lower levels 
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of DHA, but not EPA, were associated with increased risk of Alzheimer's 
disease.lO A neuropathological study showed more saturated fatty acids in 
phospholipids within the hippocampus and frontal grey matter of Alzheimer 
patients when compared to control subjects.6 It has also been found that the 
(para)hippocampal region of Alzheimer brains contained less n-6 PUFA and 
less n~3 PUFA compared to membranes in the same region of control 
brains_G, 7 However, results of previous studies on the relation between fatty 
acids and cognitive impairment or Alzheimer's disease are difficult to 
compare with our findings, because most of them did not adjust for 
important confounders, such as age, gender and education. 
The relation between plasma phospholipid levels of saturated fatty acids, 
PUFA, n-6 PUFA, PIS ratio and cognitive decline may be etiological through 
several mechanisms. First, atherosclerosis may explain the observed 
relation, because increased atherosclerosis is associated both with increased 
prevalence of dementia4 and cognitive decline,5 and with high phospholipid 
levels of saturated fatty acids, low levels of PUFA and a low P/S ratio.3 
However, additional adjustment for carotid plaques as a measure of 
atherosclerosis did not change our results. Also, MUFA was not associated 
with cognitive decline, whereas increased MUFA is related to increased 
atherosclerosis.3 Therefore, we think that atherosclerosis does not fully 
explain our findings. Second, peripheral levels of fatty acids may determine 
the fatty acid composition of brain cell membranes that is involved in 
optimal cell functioning. This is suggested by findings in both animals and 
humans. In animals, fatty acid composition within the brain can be altered 
by changing dietary intake,26. 27 probably through changing blood levels of 
fatty acids. In human infants, higher DHA levels in erythrocytes were 
associated with a higher amount of DHA within the cortex.28 Thus, plasma 
levels of fatty acids may reflect fatty acid composition within the brain. 
Because fatty acid composition within the brain can affect functioning of 
neuronal cells,26.27 it might also alter cognitive function. 
In conclusion, we observed that high phospholipid levels of saturated 
fatty acids, low levels of PUFA and n-6 PUFA and a low ratio of PUFA to 
saturated fatty acids were associated with increased cognitive decline. 
\iVhether fatty acid composition in plasma changes prior to onset of cognitive 
decline remains to be elucidated. 
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Chapter 3.2.2 
Diet and risk of dementia: does fat 
matter? 
Objective To examine whether high intake of total fat, saturated fatty acids 
(saturated fat), trans fatty acids (trans fat) and cholesterol and low intake of 
monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA), 
n- 6 PUFA and n-3 PUFA are associated with increased risk of dementia and 
its subtypes. 
Methods We used data from the Rotterdam Study, a prospective cohort study 
among elderly. At baseline (1990-1993), 5395 subjects had normal cognition, 
were non-institutionalized and underwent complete dietary assessment by a 
semiquantitative food-frequency questionnaire. We continuously monitored 
the cohort for incident dementia and performed re-examinations in 1993-1994 
and 1997-1999. We examined the association between fat intake and incident 
dementia by Cox proportional hazards models. 
Results After a mean follow-up of 6.0 years 197 subjects developed dementia 
(146 Alzheimer's disease, 29 vascular dementia). High intake of total, 
saturated, trans fat and cholesterol and low intake of MUFA, PUFA, n-6 
PUFA and n-3 PUFA were not associated with increased risk of dementia or 
its subtypes. Rate ratios of dementia per SD increase in intake were for total 
fat 0.93 (95% CI 0.81-1.07), for saturated fat 0.91 (95% CI 0. 79-1.05), for 
trans fat 0.90 (95% CI 0. 77-1.06), for cholesterol 0.93 (95% CI 0.80-1.08), for 
MUFA 0.96 (95% CI 0.84-1.10), for PUFA 1.05 (95% CI 0.80-1.38), for n-6 
PUFA 1.03 (95% CI 0. 77-1.36) and for n-3 PUFA 1.07 (95% CI 0.94-1.22). 
Conclusions High intake of total, saturated and trans fat and cholesterol 
and low intake of MUFA, PUFA, n-6 PUFA and n-3 PUFA were not 
associated with increased risk of dementia or its subtypes. 
S everal findings in various research areas suggest that fat may be involved in the etiology of dementia. First, animal studies show that cerebral beta-amyloid deposition, assumed to be crucial in the 
pathogenesis of Alzheimer's disease,1 is increased by higher dietary intake of 
cholesterol.2 Second, pharmaco-epidemiological studies in humans observed 
that use of medication that lowers serum cholesterol, such as statins, may be 
related to lower prevalence of Alzheimer's disease.3·5 Third, other 
epidemiological studies found that higher serum levels of cholesterol are 
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associated with increased risk of dementia.6, 7 Finally, biochemical studies 
showed that specific fatty acids, such as cis n-3 polyunsaturated fatty acids 
(n-3 PUFA), have anti-inflammatory properties8 Because inflammation may 
be associated with increased risk of dementia,' high levels of n-3 PUFA may 
reduce dementia risk. 
Based on these observations, we hypothesize that cholesterol increases 
and n-3 PUFA reduce dementia risk. Cholesterol levels are increased by a 
diet high in total fat, saturated fatty acids (saturated fat), trans unsaturated 
fatty acids (trans fat) and cholesterol and low in cis unsaturated fatty 
acids)O, 11 Likewise, n-3 PUFA levels are increased with increasing dietary 
intake of n-3 PUFA. We examined whether high dietary intake of total fat, 
saturated fat, trans fat and cholesterol and low intake of cis 
monounsaturated fatty acids (MUFA), PUFA, n-6 PUFA and n-3 PUFA were 
associated with an increased risk of dementia and its subtypes. We 
performed the study within the Rotterdam Study, a population-based cohort 
study with a mean follow-up of 6.0 years. 
Methods 
The Rotterdam Study 
The Rotterdam Study is a large population-based prospective cohort study 
that examines risk factors for neurological, cardiovascular, locomotor and 
ophthalmologic diseases in the elderly population.12 The conduct of the study 
was approved by the medical ethics committee of the Erasmus University 
Rotterdam. All 10 275 inhabitants from Ommoord, a suburb of Rotterdam, 
the Netherlands, who were 55 years and over, were invited to participate in 
the study. Of these, 7983 subjects (response rate 78%) gave their written 
informed consent and participated in the study.l2 
The baseline examination (1990-1993) consisted of an interview at home 
and 2 visits at the research center. The interview was performed by a 
trained research assistant who obtained information on lifestyle, current 
and past health, medication and determinants for chronic diseases. Clinical 
examinations were carried out at the research center. Follow-up 
examinations took place in 1993-1994 and 1997-1999. In addition, the cohort 
was continuously monitored for major disease outcomes. 
Diagnosis of dementia 
Subjects were screened for dementia in a 3-step procedure that was similar 
at baseline and follow-up examinations.l3 In brief, participants were 
cognitively screened with the Mini Mental State Examination (MMSE)14 and 
the Geriatric Mental State schedule (GMS), organic level.l5 Subjects with a 
MMSE score below 26 or a GMS score above 0 underwent further 
neuropsychological testing by the Cambridge Examination of Mental 
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Disorders in the Elderly (CAMDEX)1 6 The CAMDEX also included an 
informant interview. Persons who were suspected of having dementia were 
examined by a neurologist and a neuropsychologist and, if possible, had a 
brain MRI. In addition, the cohort was continuously monitored by 
computerized linkage of the study database with general practitioners' 
medical records and the database of the Regional Institute for Outpatient 
Mental Health Care (RIAGG).'' Dementia diagnoses were based on DSM-III-
R critieria," diagnoses of Alzheimer's disease on NINCDS-ADRDA,1S and 
diagnoses of vascular dementia on NINDS-AIREN19 criteria. All diagnoses 
were made on the basis of all existing information by a panel that consisted 
of the neurologist, the neuropsychologist and the research physician.l3 
Dietary assessment 
Dietary assessment was performed in 2 stages at baseline. First, 
participants completed a checklist at home, on which they indicated all foods 
and drinks they had consumed at least twice a month during the preceding 
year. The checklist also contained questions on use of supplements. 
Subsequently, the participants were interviewed by a trained dietician at the 
research center. An extensive, validated semiquantitative food-frequency 
questionnaire2o. 21 was used to quantify the amounts and frequencies of food 
and drink intake that had been indicated on the checklist. The data were 
converted to energy intake and nutrient intake using the computerized 
Dutch Food Composition Table.21. 22 Intake of specific fatty acids was based 
on a food composition database derived from the TRA:-fSFAIR study.23 For 
this database, the 100 food items that contribute most to fat intake in the 
Dutch dietary pattern were sampled and analyzed as methyl esters of the 
fatty acids present in the food. For the present study we used data on intake 
of total fat, saturated fat, trans fat, cholesterol, MUFA, PUFA, n -6 PUFA 
and n-3 PUFA. Total fat intake comprises all intake of fatty acids and 
cholesterol. Important sources of saturated fat are meat, dairy and cookies. 
Trans fat is partially hydrogenated fat and can be found in margarines and 
salad and cooking oils. Cholesterol is present in animal products only. Large 
amounts of MUFA are found in olive oil. Most PUFA intake is derived from 
intake of n-6 PUFA and n-3 PUFA. N-6 PUFA is particularly found in 
vegetable oil, and n-3 PUFA is present in fatty fish, such as salmon, tuna 
and mackerel. All fat intakes were calculated in grams per day. The amount 
of energy from fat intake was expressed as a percentage of total energy 
intake. 
Other variables 
The baseline home interview contained questions on highest attained level of 
education, smoking habits and prevalent diseases, such as myocardial 
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infarction. Data on medication use at time of the baseline examination and 
second follow-up examination were obtained from both the interview and a 
pharmacy database that was linked to the study database from December 
31, 1990 onwards. At the baseline visit to the research center we assessed 
intake of total energy, vitamin E, alcohol, fruit and vegetables as well as use 
of dietary supplements on the basis of the food-frequency questionnaire. 
Also, height and weight were measured and blood samples were drawn. 
Level of education was categorized in 4 groups: completed primary 
education, lower vocational training or general education, intermediate 
vocational training or intermediate and higher general education, and 
higher vocational training, college or university. Smoking habits were 
classified as current, former and never smoking. A history of myocardial 
infarction was considered present if any event that was reported by the 
subject could be verified in medical records.24 All drugs were classified 
according to their corresponding Anatomical-Therapeutical-Chemical-code 
(ATC-code).25 Subjects who used lipid-lowering medication (ATC-code clO) 
according to the interview data or the pharmacy data were classified 
accordingly. Daily intake of total energy was expressed in kilojoules and 
intake of vitamin E in milligrams. Intake of alcohol, fruit and vegetables 
were expressed as grams per day. Subjects who reported use of supplements 
were classified accordingly. Body mass index was expressed in kilograms 
per meter squared. Diabetes was considered present if the subject was 
taking oral antidiabetics or insulin (ATC-code alO), or if the random or post-
load serum glucose level was equal to or higher than 11.1 mmol/L (WHO-
criteria for epidemiological studies of diabetes).26 
Study population 
At the baseline clinical examination 7525 participants of the Rotterdam 
Study underwent extensive screening for dementia. Dementia was diagnosed 
in 482 subjects resulting in 7043 subjects who were free of dementia at 
baseline. Of these, we excluded 602 subjects from dietary assessment for 2 
reasons. First, dietary intake was not assessed in 125 subjects who had 
questionable cognitive status (CAMDEX-score lower than 80), because they 
might provide unreliable answers regarding their food patterns. Second, we 
excluded nursing home residents (n=4 77), because their current diet will not 
reflect dietary habits in the past as food will be prepared by nursing home 
staff. Thus, 6441 subjects were eligible for dietary assessment. Of these, 
reliable dietary data were missing in 1046 subjects (16%) for several reasons. 
First, due to logical inconsistencies in dietary interviews, 212 subjects were 
excluded. Second, because the food-frequency questionnaire was 
administered at the second visit to the research center, subjects who missed 
the second visit did not have dietary assessment (n=192). Finally, 642 
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subjects did not have dietary data due to logistic reasons. Thus, the study 
population for this study comprised 5395 participants who had normal 
cognition, lived independently and had reliable dietary assessment. 
Eligible subjects without dietary data were somewhat older (2.6 years) 
compared to subjects from the study population, a somewhat lower 
percentage (4% lower) were women and a higher percentage had only 
primary education (7% higher). Smoking habits and body mass index were 
similar across the 2 groups. 
Data analysis 
Because of the high correlation between fat intake and total energy intake 
we calculated energy-adjusted intake of fat. Energy-adjusted intake was 
obtained by use of the residual method that consisted of a 3-step 
procedure. 27 First, we performed a linear regression analysis with fat intake 
as the dependent and total energy intake as the independent variable. 
Second, we used this regression equation to calculate the expected mean fat 
intake of the study population for the mean total energy intake of the study 
population. Third, the energy-adjusted intake of each individual was 
calculated by adding the expected mean fat intake of the study population to 
the individual residual that was derived from the regression analysis. These 
3 steps were repeated for each type of fat intake separately to obtain energy-
adjusted intake for all eight fat variables. Additional to the residual method, 
we also applied the standard multivariate method and the nutrient density 
method to adjust for total energy intake. 27 
To evaluate whether the incidence of dementia or its subtypes differed 
between the study population and the eligible population without dietary 
data we used a Cox proportional hazards regression model with adjustment 
for age, gender and education. 
To assess whether energy-adjusted intake of fatty acids and cholesterol 
were associated with risk of dementia, Alzheimer's disease or vascular 
dementia, we performed Cox proportional hazards regression analyses. 
Intake of fat was first expressed as categorical variable (tertiles) in order to 
check whether the relation between fat intake and risk of dementia was 
linear. Because the relations did not show large deviations from linearity, 
all associations were analyzed using a linear term for fat intake. In this 
analysis, the regression coefficient was expressed per SD increase in intake 
to allow comparison of strengths of associations across the different fat 
intakes. The SDs of the respective intake off a tty acids and cholesterol were 
based on the distribution of the study population (n=5395). All models were 
adjusted for age, gender, education and intake of vitamin E. To adjust most 
efficiently for age, age was used as the timescale in the model. Entry time 
was defined as age at study entry. Participants were followed until onset of 
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dementia, death or end of study, whichever came first. Age at onset of 
dementia was determined as the midpoint between the age of subject last 
known to be at risk of dementia and age at diagnosis of dementia. 
In additional analyses of the relation between fat intake and risk of 
dementia and Alzheimer's disease, adjustments were additionally made for 
lifestyle associated factors, such as smoking habits, intake of alcohol, fruit 
and vegetables, use of dietary supplements and body mass index. Because of 
the few cases with vascular dementia, no additional analyses were 
performed for vascular dementia. 
Because the relation between fat intake and incident dementia and 
Alzheimer's disease may be disturbed by use oflipid-lowering medication, all 
analyses were repeated after exclusion of subjects who used lipid-lowering 
medication at baseline (n=145, 2.7%) or at second follow-up (n=490, 9.1%). 
Furthermore, because myocardial infarction, as a proxy for atherosclerosis, 
and diabetes may both be related to dietary intake and risk of dementia,2S. 29 
we repeated the analyses after exclusion of subjects with one of these 
conditions (n=796, 14.8%). Finally, in order to minimize the possibility that 
the observed associations were the result of changing dietary habits due to 
subclinical dementia, we also performed the analysis after exclusion of 
subjects with less than 2 years offollow-up (n=212, 3.9%). 
All analyses were performed using SAS statistical software (SAS Institute 
Inc., Cary, NC, USA). 
Results 
At baseline, the mean age of the study population was 68 years (SD 8 years), 
most participants were women (59%) and 35% had primary education only 
(Table 1). The mean vitamin E intake of the study population exceeded the 
recommended daily amount (RDA) of 10 mg/day for men and 8 mg/day for 
women. so The rather high mean daily intake of 349 grams of vegetables can 
partly be attributed to the consumption of potatoes. One-third of the study 
population used dietary supplements, of which only 1% contained fatty acids. 
The study population consumed on average 81 grams of fat per day. 
Thirty-seven percent of all energy intake from the study population was 
provided by fat intake (Figure 1). Fatty acids are the main contributor to 
energy from fat. Most of the energy from fatty acids was derived from 
unsaturated fat to which cis fat contributed most. The most important cis 
fat in terms of energy was MUFA and the most important PUFA was n-6 
PUFA. 
During a mean follow-up of 6.0 years (SD 1.3 years), 197 (3.7%) 
participants became demented. Of these, 146 (74.1%) were diagnosed as 
having Alzheimer's disease, 29 (14. 7%) had vascular dementia and 22 
(11.2%) had other types of dementia. The incidence of dementia, Alzheimer's 
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Table 1 Baseline characteristics of the study population (n=539.5)" 
Characteristic 
Age (y) 
Women 
Primary education on!y 
Total energy intake (kJ/d) 
Vitamin E intake {mg/d) 
Smoking 
Current 
Former 
never 
Alcohol intake {g/d) 
Fruit intake {g/d) 
Vegetable intake (g/d) 
Use of supplements 
with fatty acids 
without fatty acids 
Body mass index (kg/m2) 
Energy-adjusted intake of 
total fat (g/d) 
saturated fat {gfd) 
trans fat (g/d) 
cholesterol (g/d) 
MUFA (g/d) 
PUFA (g/d) 
n-6 PUFA (g/d) 
n-3 PUFA (g/d) 
; values represent means (SO) or percentages(%) 
t median (interquartile range) 
67.7 (7.8) 
59% 
35% 
8264 (2105) 
13.8 (6.2) 
23% 
43% 
34% 
3.4 (0.2-14.9)t 
228 (132) 
349 (137) 
1% 
33% 
26.3 (3.7) 
80.7 (13.5) 
34.4 (7.2) 
2.7 (1.0) 
0.23 (0.062) 
24.3 (5.4) 
17.4 (6.7) 
16.0 (6.6) 
1.3 (0.60) 
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disease and vascular dementia did not significantly differ between the study 
population and the eligible subjects without dietary data; when adjustments 
were made for age, gender and education the rate ratio (RR) for subjects 
with dietary data compared with subjects without dietary data was 0. 76 
(95% CI 0.57-1.01) for dementia, 0.75 (95% CI 0.54-1.05) for Alzheimer's 
disease and 0. 70 (95% CI 0.33-1.48) for vascular dementia. 
When adjustments were made for age, gender, education, total energy 
intake and intake of vitamin E, intake of the various energy-adjusted fatty 
acids or cholesterol were not associated with risk of dementia or vascular 
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dementia (Table 2). Mter similar adjustments, we observed for Alzheimer's 
disease that higher intake of total fat, saturated fat, trans fat and 
cholesterol was associated with lower risk. With every increase of 13.5 g/day 
(SD) in intake of total fat, the risk of Alzheimer's disease decreased by 14% 
(RR 0.86 (95% CI 0.73-1.01)). Rate ratios per SD increase in intake were for 
saturated fat 0.83 (95% CI 0. 70-0.98), for trans fat 0.80 (95% CI 0.65-0.97) 
and for cholesterol 0.86 (95% CI 0.72-1.02). Intake of MUFA, PUFA, n-6 
PUFA and n-3 PUFA were not associated with Alzheimer's disease. The 
associations did not change when we applied the standard multivariate 
method or the nutrient density method instead of the residual method to 
Figure 1 Mean fat intake of the study population as percentage of total energy intake 
I Saturated fat 15.6% 
I 
I MUFN 11.0% 
I 
n-3 PUFA 
0.6% 
*cis monounsaturated fatty acids 
#cis polyunsaturated fatty acids 
I Total fat I 36.7% 
I Total fatty acids II Cholesterol I 36.6% 0.1% 
I I Unsaturated fat II Unidentified tat I 
20.1% 0.9% 
Cis fat I Trans fat I 18.9% 1.2% 
II PUFM I 7.9% 
II n-6 PUFA II other PUFA I 7.2% 0.1% 
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Table 2 Adjusted* rate ratios of dementia, Alzheimer's disease and vascular dementia 
per standard deviation increase in intake of energy-adjusted fat (g/d) 
Total dementia Alzheimer's disease Vascular dementia 
n=197 n=146 n=29 
so RR (95% Cl)t RR (95% Cl)t RR (95% Cl)t 
Total fat 13.5 0.93 (0.81-1.07) 0.86 (0.73-1.01) 1.06 (0.74-1.50) 
Saturated fat 7.2 0.91 (0.79-1.05) 0.83 (0.70-0.98) 1.03 (0.73-1.46) 
Trans fat 1.0 0.90 (0.77-1.06) 0.80 (0.65-0.97) 1.01 (0.71-1.44) 
Cholesterol 0.062 0.93 (0.80-1.08) 0.86 (0.72-1.02) 1.04 (0.72-1.50) 
MUFA 5.4 0.96 (0.84-1.10) 0.91 (0.77-1.07) 1.05 (0.76-1.47) 
PUFA 6.7 1.05 (0.80-1.38) 1.09 (0.79-1.50) 1.16 (0.58-2.33) 
N-6 PUFA 6.6 1.03 (0.77 -1.36) 1.07 (0.77-1.49) 1.09 (0.52-2.26) 
N-3 PUFA 0.60 1.07 (0.94-1.22) 1.07 (0.91-1.25) 1.17 (0.85-1.59) 
*adjusted for age, gender, education, total energy intake and vitamin E intake 
t rate ratio (95% confidence interval) 
adjust for total energy intake. \Vhen additional adjustments were made for 
lifestyle associated factors (i.e. smoking habits, intake of alcohol, fruit and 
vegetables, use of dietary supplements and body mass index), the results 
were very similar both for dementia and Alzheimer's disease. Furthermore, 
restriction of the analyses to subjects without lipid-lowering medication did 
not substantially change the results of dementia nor did exclusion of subjects 
with myocardial infarction or diabetes. Also, results on dementia did not 
change after exclusion of subjects with less than 2 years of follow-up. For 
Alzheimer's disease the results after the various exclusions also remained 
very similar as is shown in Table 3. 
Discussion 
In this population-based study high dietary intake of total fat, saturated fat, 
trans fat and cholesterol and low intake ofMUFA, PUFA, n-6 PUFA and n-3 
PUFA were not related to increased risk of dementia, Alzheimer's disease or 
vascular dementia. Additional adjustment for lifestyle associated 
confounders did not change the results, nor did exclusion of users of lipid-
lowering medication or subjects with a history of myocardial infarction or 
diabetes. 
Advantages of the present study are the population-based and 
longitudinal design with long duration of follow-up. Furthermore, we 
achieved complete follow-up with respect to dementia diagnosis. Also, 
Table 3 Adjusted' rate ratios of Alzheimer's disease per standard deviation (SO) increase in intake of energy-adjusted fat (g/d) in complete study 
population and in subpopulations 
Complete study population Subjects without lipid~lowering 
146 cases medication, 142 cases 
so RR (95% Cl)t RR (95% Cl)t 
Total fat 13.5 0.86 (0.73-1.01) 0.85 (0.72-1.01) 
Saturated fat 7.2 0.83 (0.70-0.98) 0.83 (0.70-0.98) 
Trans fat 1.0 0.80 (0.65-0.97) 0.79 (0.65-0.97) 
Cholesterol 0.062 0.86 (0. 72-1.02) 0.84 (0.70-1.01) 
MUFA 5.4 0.91 (0.77-1.07) 0.90 (0.76-1.07) 
PUFA 6.7 1.09 (0.79-1.50) 1.07 (0. 77-1.48) 
N-6 PUFA 6.6 1.07 (0.77-1.49) 1.06 (0.76-1.48) 
N-3 PUFA 0.60 1.07 (0.91-1.25) 1.04 (0.89-1.22) 
*adjusted for age, gender, education, total energy intake and vitamin E intake 
:j: myocardial infarction 
t rate ratio (95% confidence interval) 
Subjects without Ml:j: or diabetes Subjects with at least 2 years of 
117 CASP.S follow-up, 106 cases 
RR (95% Cl)t RR (95% Cl)t 
0.81 (0.68-0.98) 0.85 (0.66-1.08) 
0.77 (0.64-0.93) 0.81 (0.63-1.04) 
0.82 (0.65-1.02) 0.81 (0.61-1.08) 
0.84 (0.69-1.04) 0.83 (0.63-1.08) 
0.87 (0.72-1.05) 0.91 (0.71-1.16) 
1.05 (0.73-1.50) 1.07 (0.66-1.71) 
1.03 (0.71-1.49) 1.01 (0.61-1.66) 
1.07 (0.89-1.27) 1.15 (0.93-1.42) 
((.) 
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dietary data were available for specific groups of fat, such as trans fat, n-6 
PUFA and n-3 PUFA. Finally, we made adjustments for an extensive 
number of potential confounders. 
Some methodological issues of the present study have to be discussed. 
First, bias may have occurred because of conditions that are associated both 
with fat intake and with dementia. These conditions include cardiovascular 
disease indicating atherosclerosis,28 and diabetes.29 Although exclusion of 
participants with one of these conditions did not alter the results 
substantially, bias may still have occurred due to selective survival. If 
subjects with high intake of, for instance, saturated fat did not die from 
cardiovascular disease because of insensitivity to the effect of fat, these 
subjects will also less likely develop dementia. This would then lead to the 
spurious result of high intake of saturated fat being associated with reduced 
risk of dementia. Second, a single assessment of fat intake may not precisely 
reflect subjects' long-term intake, which is more likely to influence disease 
risk. According to Dutch dietary surveys, total fat intake as percentage of 
total energy intake in persons older than 65 years decreased by 3% from 
40% to 37% over the period 19987-1998.31 The percentage of saturated fat 
slightly decreased by 0.7% and the percentage of PUFA increased by 0.6%. 
The change offat intake over time may particularly have occurred in health-
minded subjects and subjects at high cardiovascular risk. Because the first 
group may be at low risk of dementia and the latter group at high risk, the 
effect of misclassification, if any, on the association between fat intake and 
risk of dementia is hard to predict. Third, bias may have occurred due to the 
presence of subclinical dementia at baseline that may have led to changes in 
dietary habits or to less reliable dietary reporting. We tried to minimize this 
bias by excluding subjects who either were cognitively impaired at baseline 
or had logical inconsistencies in the food-frequency questionnaire. Also, we 
excluded the first 2 years of follow-up in an additional analysis. Because 
this analysis did not change the results, we think that bias due to 
subclinical dementia, if any, is limited. Finally, the number of cases with 
vascular dementia was small. As a result, we cannot draw firm conclusions 
on the relation between fat intake and vascular dementia. 
Saturated fat intake as percentage of total energy intake in our study 
(15.6%) was similar to the intake reported in the Dutch Zutphen Elderly 
Study (16.3%) and 2 American studies: the Framingham Heart Study 
(15.0%) and the Nurses' Health Study (15.6%).32-34 In Finland, saturated fat 
intake was higher (19.8%), whereas in Italy it was lower (8.6%).32 MUFA 
intake was low (11.0%) in our study compared with other studies; the 
Zutphen study reported 13.8%, the American studies 15.8% and 16.0%, a 
Finnish cohort 12.3% and an Italian study 18.0%. PUFA intake was highest 
in the Netherlands (7.9% in our study and 7.0% in the Zutphen Study) 
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compared with the USA (5.4% and 4.3%), Finland (5.0%) and Italy (3.6%). 
However, intake differences in these studies are difficult to interpret due to 
large differences in subject characteristics such as age and gender. Also, 
intake may differ because of large differences in timing of dietary 
assessments that varied from 1966-1969 to 1990-1993. This may have led to 
differences in report of fat intake due to the general decrease in fat intake 
over time. 
In the present study, we could not confirm that high intake of total fat, 
saturated fat, trans fat and cholesterol and low intake ofMUFA, PUFA, n-6 
PUFA and n-3 PUFA were associated with increased risk of dementia or its 
subtypes. In the literature, several findings suggest that high levels of 
cholesterol increase risk of dementia, however, evidence IS not 
unambiguous. Some prospective studies on cholesterol levels in serum and 
risk of Alzheimer's disease show that high levels are associated with 
increased risk of dementia,6. 7 whereas others report no association35. 36 or 
even an inverse association,37 Also, increased cerebral beta-amyloid 
deposition with higher dietary intake of cholesterol has been observed in 
animals,2 but may not directly be translated to humans.38 Furthermore, 
although a relation between statin use and lower prevalence of Alzheimer's 
disease has been found,'·' this may not be through the cholesterol-lowering 
effect of statins. 
Previously, we examined the relation between fat intake and dementia 
within the Rotterdam Study after a follow-up period of 2 years on average39 
and observed that high intake of total fat, and also low intake of fish as an 
indicator of n -3 PUFA, were significantly associated with an increased risk 
of dementia. High intake of total fat as well as high intake of saturated fat 
were particularly associated with an increased risk of dementia with a 
vascular component, whereas low intake of fish was particularly associated 
with an increased risk of Alzheimer's disease without cerebrovascular 
disease. No significant relations were found between either cholesterol and 
risk of dementia or linoleic acid (n-6 PUFA) and risk of dementia.39 The 
discrepancy between the results of that study and our present findings may 
be explained by the short follow-up in the previous study and a smaller 
number of incident dementia cases. Therefore, the previous study may have 
been more prone to bias due to subclinical dementia and observed estimates 
may not have been very precise. 
Two cross-sectional studies previously reported on the association 
between intake of total fat and dementia,•o. 41 one of which found higher 
prevalence of Alzheimer's disease with higher intake,4o whereas the other 
study observed no association.41 Furthermore, a small randomized 
controlled trial found that Alzheimer patients who took PUFA supplements 
for 4 weeks improved in short-term memory compared to patients who took 
95 
placebo.42 Given the limited number of studies on fat intake and risk of 
dementia, we think it is premature to conclude from our observational study 
that cholesterol or cholesterol affecting fats are not associated with risk of 
dementia or its subtypes. More large prospective studies with long follow-up 
are needed to confirm our findings. 
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Chapter 3.2.3 
Statins and risk of dementia 
Background Previous studies reported that use of statins was associated 
with lower prevalence of dementia. However, confounding by indication and 
misclassification of drug use may have played an important role in all of 
these studies. 
Objective To examine prospectively whether statin use as reported by 
pharmacy records are associated with lower risk of dementia and 
Alzheimer's disease. 
Methods We used data from the Rotterdam Study, a prospective, 
population-based cohort study among elderly aged 55 years and above. The 
study population included 6983 subjects who were free of dementia at 
baseline (1990-1993). Information on drug use was derived from 
computerized pharmacy records. The cohort was continuously monitored for 
incident dementia and re-examined in 1993-1994 and 1997-1999. To 
examine the relation between statin use and rish of dementia and Alzheimer's 
disease we used Cox proportional hazards models, in which statin use was 
entered as a time-varying variable. 
Results During an average follow-up period of 6.8 years, 394 subjects 
became demented (293 Alzheimer's disease, and 1 OJ other types of dementia). 
Any use of statins was not associated with lower rish of dementia; when 
adjustments were made for age and gender the rate ratio was 0. 72 (95% 
confidence interval (CI) 0.34-1.35) for statin use compared to nonuse. Also, 
longer duration or higher dosage of statin use were noi~ associated with lower 
risk of dementia. Additional adjustment for level of education or vascular 
risk factors did not change the results. Results were similar for Alzheimer's 
disease. 
Conclusion The present study does not support the hypothesis that statin 
use is associated with a lower risk of dementia or Alzheimer's disease. 
T o date, 3 studies reported on the relation between statin use and dementia.l-3 These studies observed that statin use was related to a lower prevalence or risk of dementia. However, these studies were 
cross-sectionall· 3 or based on medical records of general practitioners2 and 
confounding by indication most likely influenced the results. Moreover, no 
adjustments were made for several possible confounders, such as 
educationallevell· 2 and some vascular risk factors.2·3 Finally, the relation 
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between duration and dosage of statin use and risk of dementia has not 
been studied. 
We examined whether any statin use, duration of statin use and dosage of 
statin use were associated with lower risk of dementia and Alzheimer's 
disease in a prospective, population-based cohort study. We used 
computerized pharmacy records in order to obtain complete information on 
statins that were used a few years before dementia diagnosis. We controlled 
for educational level and vascular risk factors. 
Methods 
The Rotterdam Study 
The Rotterdam Study is a large population-based prospective cohort study 
that examines risk factors for neurological, cardiovascular, locomotor and 
ophthalmologic diseases in the elderly population4 The study was approved 
by the Medical Ethics Committee of the Erasmus University. All 10 275 
inhabitants from Ommoord, a suburb of Rotterdam, the Netherlands, who 
were 55 years and over, were invited to participate in the study. Of these, 
7983 subjects (response rate 78%) gave their written informed consent and 
participated in the study.4 
The baseline examination of the Rotterdam Study was conducted in 1990-
1993. The follow-up examinations were done in 1993-1994 and 1997-1999. 
During both baseline and follow-up examinations participants were 
interviewed at home and subsequently clinically examined at the research 
center. In addition, the cohort was continuously monitored for major disease 
outcomes. 
Use of statins and other lipid-lowering drugs 
Data on medication use were derived from the pharmacies in Ommoord. 
These pharmacies were fully automated and registered all prescriptions on 
drug use from January 1, 1991 through December 31, 1998. Prescriptions 
included the product name of the drug, the generic name, the Anatomical 
Therapeutical Chemical (ATC) code,s the number of tablets, capsules or 
other vehicles in the filled prescription, the date of delivery of the product, 
the prescribed daily number of tablets to be taken, the daily drug dosage, 
and the duration of the prescription. Thus, for all statin prescriptions we 
have data on date of delivery of statins, duration and dosage of statin use as 
well as type of stalin. 
Statin use was expressed in 3 ways. First, any use of statins was defined 
as at least one prescription for statins during the study period (1991-1998). 
Second, duration of statin use was defined as the cumulative number of 
days for which statins were prescribed. Third, dosage of statins was defined 
by means of defined daily doses (DDD). The DDD is referred to as the 
Statins and risk of dementia 
average dosage of a drug used by an adult for the main indication.5 We 
calculated the average DDD for the total duration for which statins were 
used. 
Use of other lipid-lowering drugs was defined as at least one prescription 
for fibrates, colestipol, cholestyramine, acipimox or niacin/nicotinic acid 
during the study period (1991-1998). 
Other variables 
During the baseline home interview information on level of education, 
smoking and medical history was obtained. Data on co-medication at 
baseline were obtained from both the interview and the pharmacy database. 
At the research center dietary intake was assessed by means of a semi-
quantitative food frequency questionnaire.B Also, height and weight were 
measured, blood samples were drawn and blood pressure of the arm was 
measured using a random sphygmomanometer. Finally, ultrasonography of 
both carotid arteries was performed. 7 
Level of education was categorized in 4 groups: completed primary 
education, lower vocational training or general education, intermediate 
vocational training or intermediate and higher general education, and 
higher vocational training, college or university. Smoking was classified as 
current, former and never smoking. Packyears of smoking were calculated 
as the average daily number of cigarettes divided by 20 and multiplied with 
the number of years smoked. A history of myocardial infarction or stroke 
was considered present if any event that was reported by the subject could 
be verified in medical records.7 Alcohol intake was expressed in grams per 
day and body mass index in kilograms per meter squared. Diabetes was 
considered present if the subject was taking oral antidiabetics or insulin at 
baseline (ATC-code a10), or if the random or post-load serum glucose level 
was equal to or higher than 11.1 mmol/L (WHO-criteria for epidemiological 
studies of diabetes).s Total cholesterol concentrations were determined in 
serum by an automated enzymatic procedure.9 Hypercholesterolaemia was 
defined as a cholesterol level above 6.5 mmol/L. Apolipoprotein E (APOE) 
genotype was assessed on coded DNA samples using polymerase chain 
reaction without knowledge of the dementia diagnosis.'" The APOE 
genotype was dichotomized in presence or absence of at least one APOE*4 
allele. Hypertension at baseline was considered present if the systolic blood 
pressure was 160 mm Hg or above, if the diastolic blood pressure was 95 
mm Hg or above, or if a subject used antihypertensive drugs (ATC-code c02). 
As an indicator of atherosclerosis we used presence of carotid plaques. 
Carotid plaques were detected in 6 different locations: common carotid 
artery, carotid bifurcation, and internal carotid artery at both left and right 
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side.7 Four categories were made according to number of locations with 
plaques: 0, 1-2, 3-4 and 5-6 locations. 
Diagnosis of dementia 
Dementia was assessed by a 3-phase approach.n Firstly, all participants 
were screened for dementia using 2 tests: the Mini Mental State 
Examination (MMSE)z and the Geriatric Mental State schedule, organic 
level (GMS).u Secondly, participants scoring below 26 on the MMSE or more 
than 0 on the GMS were further neuropsychologically tested by a research 
physician using the Cambridge examination for mental disorders of the 
elderly (CAMDEX)." Finally, persons suspected of dementia were examined 
by a neurologist and a neuropsychologist and, if possible, had a magnetic 
resonance imaging (MRI) scan of the brain. 
In addition, the cohort was continuously monitored by means of 
computerized linkage of the study database with general practitioners' 
medical records and the database of the Regional Institute for Outpatient 
Mental Health Care (RIAGG).n Diagnoses of dementia and Alzheimer's 
disease were based on DSM-III-R" and NINCDS-ADRDAie criteria, 
respectively, using all existing information that was reviewed by a panel 
that consisted of the neurologist, the neuropsychologist and the research 
physician.11 
Study population 
At the baseline clinical examination 7525 participants of the Rotterdam 
Study underwent screening for dementia. Dementia was diagnosed in 482 
subjects resulting in 7043 subjects who were free of dementia at baseline. Of 
these, we excluded 60 subjects for whom follow-up ended before July 1, 
1991, because they had data on medication use for less than 6 months. 
Thus, the study population of the present study consisted of 6983 subjects. 
Data analysis 
The relation between statin use and dementia was assessed by means of Cox 
proportional hazards regression analyses in which statin use was added to 
the model as a time-varying variable.17 
Statin use was firstly entered into the model as any use. Secondly, to 
examine the effect of duration of statin use, we created 3 categories based on 
the median duration of use in incident dementia cases: nonuse (reference), 
use of statin for 2.8 years or less and statin use for more than 2.8 years. 
Thirdly, to examine the relation between dosage of statins and risk of 
dementia we made 3 categories on the basis of the median dosage of statin 
use in incident dementia cases: nonuse (reference), use of statins in a dosage 
of 0.66 DDD or less and statin use in a dosage of more than 0.66 DDD. 
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Table 1 Baseline characteristics of the study population• 
Characteristic Entire cohort Statin use+ No statin use 
n = 6983 n = 776 (11%) n = 6207 (89%) 
Age (y) 69.4 (9.1) 65.2 (5.9) 69.9 (9.2) 
Women 60% 58% 60% 
Primary education only 37% 33% 37% 
Smoking 
Current 22% 25% 22% 
Former 41% 47% 37% 
Never 35% 27% 36% 
History of myocardial infarction 12% 19% 11% 
History of stroke 3% 2% 3% 
Alcohol intake (g/d)t 9.0 (0.7-10.6) 7.4 (0.4-14.5) 9.0 (0.7-10.5) 
Body mass index (kg/m2 ) 26.3 (3.6) 26.6 (3.4) 26.3 (3.7) 
Diabetes 10% 11% 10% 
Total cholesterol (mmoi/L) 6.6 (1.2) 7.6(1.4) 6.5 (1.1) 
Carrier of at least 1 APOE*4 allele 26% 30% 25% 
Hypertension'TI 33% 43% 32% 
5-6 Locations with carotid plaques 5% 8% 5% 
Statin use:j: 11% 
Duration (y)t 2.1 (0.9-4.3) 
Dosage (ODD) 0.7 (0.6-1.0) 
Use of other lipid-lowering drugs+ 9% 26% 7% 
"values represent means {standard deviation) or percentages(%) 
t median (interquartile range) 
:j: any use within the study period (1991-1998) 
~defined as a systolic blood pressure of 160 and above, a diastolic blood pressure of 95 or above, or the 
use of antihypertensive drugs 
All analyses were adjusted for age and gender. To adjust most efficiently 
for age, we used age as the timescale in the model. Participants were 
followed until onset of dementia, death or end of study, whichever came 
first. Age at onset of dementia was determined as the midpoint between the 
age of subject last known to be at risk of dementia and age at diagnosis of 
dementia. Age at study end was defined as age at which second follow-up 
examination was performed unless this examination was performed after 
1998. In this case study end was defined as December 31, 1998, because it 
was the last date on which data on statin use were available. 
To examine whether level of education confounded the association 
between statins and dementia, we additionally adjusted for level of 
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education. Subsequently, we added the following possible vascular 
confounders to the model: smoking, packyears of smoking, history of 
myocardial infarction, history of stroke, alcohol intake, body mass index, 
diabetes, cholesterol, presence of APOE*4 allele, hypertension and carotid 
plaques. Missing values on continuous variables were replaced by the mean 
or the median, depending on distribution of the variable. Missing values on 
categorical variables were replaced by a missing indicator. To study the 
relationship between statin use and Alzheimer's disease we repeated all 
analyses. 
We also repeated the analyses of dementia within strata of age (younger 
than 75 years versus 75 years and above), level of education (primary 
education only versus more than primary education), hypercholesterolaemia 
(yes/no), and presence of APOE*4 allele (yes/no), respectively. Statistical 
interactions were tested by adding a product term to the unstratified model. 
In addition, we examined the relation between use of other lipid-lowering 
drugs and risk of dementia. Finally, we studied the relation between 
hypercholesterolaemia at baseline and risk of dementia within subjects who 
did not use any lipid-lowering drugs (n=5761). For all analyses we used SAS 
software package (version 6.12, SAS Institute, Cary, NC, USA). 
Results 
Table 1 presents the baseline characteristics of the study population. The 
mean age of the cohort was 69.4 years (SD 9.1), 60% of the participants were 
women and 37% had primary education only. The mean cholesterol level of 
was 6.6 mmol/L (SD 1.2). In total, 11% of the subjects had used statins 
within the study period and 9% had used other lipid-lowering drugs. Statin 
users had higher baseline prevalence of vascular risk factors, such as 
smoking, history of myocardial infarction, diabetes, hypertension and 
carotid plaques, compared with nonusers. 
During a mean follow-up time of 6.8 years, 394 subjects became 
Table 2 Use of statins by the study cohort during the study period (1991-1998) 
Type of statin use 
Simvastatin 
Pravastatin 
Atorvastatin 
Fluvastatin 
Prescriptions (n=14 038)t 
10 276 (73%) 
2420 (17%) 
566 (4%) 
483 (3%) 
t type of statin was unknown in 3% of prescriptions 
Defined daily dose (mg) 
15 
20 
10 
40 
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Table 3 Adjusted rate ratios of dementia associated with use of statins (n=6983) 
Adjusted for age Adjusted for age, Fully adjustedt 
and gender gender and level 
of education 
Cases RR (95% Cl):j: RR (95% Cl)t RR (95% Cl):j: 
Any use of statins 7 0.72 (0.34-1.35) 0.73 (0.34-1.55) 0.74 (0.34-1.61) 
Duration of use 
nonuse 387 1 (reference) 
<=2.8 y 4 0.60 (0.22-1.62) 0.61 (0.22-1.64) 0.62 (0.23-1.70) 
> 2.8 y 3 0.98 (0.31-3.08) 0.99 (0.31-3.11) 0.99 (0.31-3.16) 
Dosage 
nonuse 387 1 (reference) 
<=0.66 ODD* 4 0.88 (0.33-2.39) 0.89 (0.33-2.41) 0.95 (0.35-2.60) 
> 0.66 ODD* 3 0.57 (0.18-1.80) 0.58 (0.19-1.83) 0.57 (0.18-1.81) 
t adjusted for age, gender, level of education, smoking, packyears of smoking, history of myocardial 
infarction, history of stroke, alcohol intake, body mass index, diabetes, cholesterol, presence of APOE*4 
allele, hypertension and carotid plaques 
::1: rate ratio (95% confidence interval) 
* DOD is defined as the average dosage of a drug used by an adult for the main indication 
demented. Of these, 293 had Alzheimer's disease, and 101 other types of 
dementia. 
Table 2 presents types of statins used by the study population. 
Simvastatin was the most frequently used statin (73% of total statin 
prescriptions). Pravastatin was less often prescribed (17% of total statin 
prescriptions). Atorvastatin and fluvastatin were rarely prescribed. 
Table 3 shows the association of statin use with risk of dementia. When 
adjustments were made for age and gender, any use was associated with a 
lower risk of dementia. However, the association was not statistically 
significant; the rate ratio of any use compared with nonuse was 0. 72 (95% 
confidence interval (CI) 0.34-1.35)). Additional adjustment for level of 
education did not change the results, nor did adjustment for vascular risk 
factors in the fully adjusted modeL Also, longer duration of statin use was 
not associated with lower risk of dementia; with nonuse as the reference 
rate ratios were 0.60 (95% CI 0.22-1.62) for statin use of 2.8 years or less, 
and 0.98 (95% CI 0.31-3.08) for use of more than 2.8 years. Again, results 
were very similar after additional adjustments. Risk of dementia was lower 
with higher dosage of statins, although associations were not statistically 
significant. Compared with nonusers rate ratios were 0.88 (95% CI 0.33-
2.39) for users of a statin dosage of 0.66 DDD or less and 0.57 (95% CI 0.18-
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Table 4 Adjusted rate ratios of Alzheimer's disease associated with use of statins 
(n=6983) 
Adjusted for age Adjusted for age, Fully adjustedt 
and gender gender and level 
of education 
Cases RR (95% CII:J: RR (95% Cllt RR (95% CII:J: 
Any use of statins 6 1.28 (0.55-2.981 1.31 (0.56-3.061 0.99 (0.40-2.491 
Duration of use 
nonuse 287 1 (reference) 
<=2.8 y 4 1.18 (0.42-3.301 1.21 (0.43-3.401 1.01 (0.34-3.01 1 
> 2.8 y 2 1.53 (0.36-6.61 1 1.55 (0.36-6.751 1.01 (0.21-4.821 
Dosage 
nonuse 287 1 (reference) 
<=0.66 ooo· 4 1.03 (0.37 -2.871 1.06 (0.34-2.971 0.77 (0.26-2.271 
> o.66 ooo· 2 2.53 (0.54-11.921 2.47 (0.52-11.701 2.57 (0.45-14.731 
t adjusted for age, gender, level of education, smokmg, packyears of smoking, h1story of myocardial 
infarction, history of stroke, alcohol intake, body mass index, diabetes, cholesterol, presence of APOE~4 
allele, hypertension and carotid plaques 
:j: rate ratio (95% confidence interval) 
*ODD is defined as the average dosage of a drug used by an adult for the main indication 
1.80) for users of a dosage of more than 0.66 DDD. Similar results were 
obtained in the fully adjusted model. 
Table 4 presents the association between statin use and risk of 
Alzheimer's disease. Any use of statins was not associated with lower risk of 
Alzheimer's disease; when adjustments were made for all confounders the 
rate ratio was 0.99 (95% CI 0.40-2.49)). Also, risk of Alzheimer's disease did 
not decrease with longer duration of statin use or higher dosage. 
Table 5 presents rate ratios of dementia associated with use of statins 
across strata of age, education, cholesterol and APOE*4 allele, respectively. 
The rate ratio of dementia associated with statin use was lower for 
participants younger than 75 years compared with those aged 75 years and 
above. Also, the rate ratio was lower in subjects with high education, in 
subjects with high cholesterol (>=6.5 mmol/L) and in subjects with at least 
one APOE*4 allele compared with subjects with lower education, subjects 
with lower cholesterol levels (<6.5 mmol/L) and subjects with no APOE*4 
allele, respectively. However, none of the interactions were statistically 
significant. 
Use of other lipid-lowering drugs was also not significantly associated 
with lower risk of dementia; when adjustments were made for age and 
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gender the rate ratio was 0.63 (95% CI 0.26-1.54). Furthermore, 
hypercholesterolaemia at baseline was not associated with risk of dementia 
within nonusers of any lipid-lowering drugs; when adjustments were made 
for age and gender the rate ratio was 1.17 (95% CI 0.93-1.46). 
Discussion 
In this prospective cohort study we observed no significant association 
between any use of statins and risk of dementia or Alzheimer's disease. In 
addition, long duration of statin use or high dosage of statins were not 
related to reduced risk of dementia or Alzheimer's disease. Use of other 
lipid-lowering medication was also not related to lower dementia risk. The 
results did not change after extensive adjustment for educational level and 
vascular factors. 
Statistical power was low in our study as indicated by the broad 
confidence intervals of the rate ratios. This may have led to nonsignificant 
findings even if statin use is truly related to lower dementia risk. However, 
given our study sample we had a power of 80% to detect a true risk 
reduction associated with statin use of 50% or more and a power of 90% to 
detect a true risk reduction larger than 56%. Thus, our :findings are in 
Table 5 Adjusted* rate ratios of dementia associated with any use of statins across 
strata of age, level of education, cholesterol and APOE•4 allele, respectively 
Nt RR (95% Cl):l: 
Age <75 y 1872 0.57 (0.23-1.41) 
Age >=75 y 5111 1.01 (0.25-4.10) 
Low education# 2574 0.99 (0.36-2.72) 
High education# 4211 0.56 (0.18-1.76) 
Cholesterol < 6.5 (mmoi/L) 3102 1.03 (0.25-4.20) 
Cholesterol>= 6.5 (mmoi/L) 3881 0.62 (0.25-1.52) 
No APOE*4 allele 4657 0.75 (0.24-2.39) 
At least 1 APOE*4 allele 1792 0.51 (0.16-1.62) 
*adjusted for age and gender 
t total number of subjects; subjects with missing values were excluded 
t rate ratios for any use compared with nonuse (95% confidence interval) 
'f[ statistical interaction 
p value1f 
0.52 
0.52 
0.55 
0.08 
#low education was defined as primary education only; high education was defined as lower vocational 
training or general education, intermediate vocational training or intermediate and higher general 
education, and higher vocational training, college or university 
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contrast with results from previous studiesl-3 that reported that use of 
statins was associated with a reduction in dementia risk of 60-73%,1 71%,2 
and 74%,3 respectively. 
The discrepancy in results between our study and the 3 previous studies 
may be explained by methodological differences. First, 2 of the previous 
studies were cross-sectionaJl· 3 and the third study obtained data on 
dementia from general practitioners, 2 who generally diagnose dementia in a 
late stage. As a result, in all 3 studies statin use in dementia cases may 
have differed as a result of rather than preceding the dementia. In our 
study, we diagnosed dementia earlier in the disease course through 
repeatedly screening all subjects in the cohort for dementia. Nevertheless, 
there may still have been some residual confounding by indication in our 
study as is suggested by our observation that risk of dementia was lower for 
short~term statin users only. Another methodological difference between 
previous studies and our study is that previous studies obtained information 
on statin use from either medical records'· 2 or informants,3 which are both 
vulnerable methods for misclassification of drug use. In contrast, we used 
computerized pharmacy records that are complete sources of information on 
the delivery of prescribed drugs including statins in the Netherlands. 
Finally, the previously reported associations may be due to confounding by 
unmeasured factors, such as level of educationl, 2 or diabetes,2, 3 although 
adjustment for these factors did not change the results in our study. 
An advantage of the present study is that diagnoses of dementia were 
made by a specialized panel of a neurologist, neuropsychologist and research 
physician. As a result, classification of dementia and Alzheimer's disease 
will have been rather accurate. In addition, complete follow-up with respect 
to diagnosis of dementia was achieved and thus selection bias as a 
consequence of loss to follow-up could not have occurred. 
We could not confirm that use of statins was related to a lower risk of 
dementia or Alzheimer's disease. This is in contrast with several 
observations that indicate that statins may prevent or delay dementia 
pathogenesis. For instance, statins reduce cholesterol levels that may result 
in lower brain levels of beta-amyloid,2o which is thought to cause 
neurodegeneration in patients with Alzheimer's disease.21 Furthermore, 
statins may increase blood flow,22. 2s which is reduced in Alzheimer brains.24. 
25 Finally, statins may reduce inflammation26, 27 that may contribute to the 
pathophysiology of Alzheimer's disease.2s Other findings, however, dispute a 
possible protective effect of statins on dementia. Some studies suggest that 
statins may damage neurons, because they found that long-term statin use 
was related to an increased risk of polyneuropathy.29, 3o Statins may also 
damage neurons in the brain, because some statins, such as simvastatin, 
cross the blood-brain barrier.s1 Furthermore, results on the association 
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between cholesterol levels and risk of dementia were conflicting: some 
studies showed that high cholesterol levels are associated with increased 
risk of dementia,s2. sa whereas others demonstrated no rellations4. s5 or even an 
inverse association.se In addition, high dietary intake of fats that increase 
cholesterol levels is not associated with increased risk of Alzheimer's 
disease.11 Finally, although one study observed lower risk of dementia with 
use of non-statin lipid-lowering medication2, another studys as well as our 
study showed no association. 
In conclusion, this prospective cohort study does not support the 
hypothesis that statin use is associated with a lower risk of dementia or 
Alzheimer's disease. However, because of limited power we cannot exclude a 
beneficial effect of statins on dementia. If anything, the risk reduction 
associated with statin use is less than the 70% previously reported. Larger 
prospective cohort studies are needed in order to examine whether statin 
use is moderately associated with lower risk of dementia. 
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Chapter 4 
General discussion 
T he aim of the research described in this thesis was to further investigate the relation between inflammatory factors, antioxidants and lipids, and dementia and to examine whether these associations 
could be explained by atherosclerosis. 
All studies in this thesis were based on the Rotterdam Study, an ongoing 
prospective population-based study among 7983 subjects of 55 years and 
over, who were living in Ommoord, a suburb in Rotterdam, the Netherlands. 
At baseline (1990-1993), 7525 participants of the Rotterdam Study 
underwent extensive screening for dementia, of whom 482 were diagnosed 
as having dementia. Of these, 353 (73%) suffered from Alzheimer's disease 
and 72 from vascular dementia (15%). The 7043 subjects who were 
dementia-free at baseline were followed up for 5. 7 yea:rs on average. During 
this period, 395 participants developed dementia, of whom 293 (7 4%) had 
Alzheimer's disease and 57 (14%) vascular dementia. 
In this general discussion, I will give an overview of the main findings in 
this thesis in the light of current knowledge regarding dementia 
pathogenesis. In addition, some methodological issues will be discussed as 
well as the clinical relevance of our findings. Finally, I will give some 
recommendations for future research. 
Main findings and mechanisms 
Inflammatory factors and dementia 
To date, it is generally accepted that inflammation occurs within brains of 
patients with Alzheimer's disease. In the periphery, inflammation may also 
occur as is suggested by elevated inflammatory proteins in blood samples of 
dementia patients. 
We studied whether blood levels of inflammatory proteins were already 
elevated prior to clinical onset of dementia, Alzheimer's disease and 
vascular dementia (chapter 2.1). We showed that higher levels of alpha1· 
antichymotrypsin (ACT), interleukin-6 (IL6) and to a lesser extent C-
reactive protein (CRP) were associated with increased risk of dementia, 
Alzheimer's disease and particularly vascular dementia. No association was 
found for soluble intercellular adhesion molecule-1 and soluble vascular cell 
adhesion molecule-1. Increased plasma levels of inflammatory cells, such as 
leucocytes, were also 
(chapter 2.2). None 
atherosclerosis. 
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associated with higher risk of Alzheimer's disease 
of these associations could be explained by 
Elevated plasma levels of inflammatory factors in dementia may be 
derived from the brain or from the peripheral immune system. However, 
plasma levels of inflammatory proteins, such as ACT and CRP, are 
generally more than 100 times higher compared to brain levels'· 2 
Therefore, the observed plasma elevations of ACT and CRP are probably 
derived from the peripheral immune system rather than from the brain. In 
contrast, levels of cytokines, such as IL6, are similar in brain and plasma,z. 3 
thus plasma elevations of IL6 may either be derived from increased 
production in the brain or the periphery. 
Increased plasma levels of inflammatory factors before clinical dementia 
indicate that the peripheral immune system contributes to the pathogenetic 
process that leads to dementia. This view is supported by the observation 
that inflammatory proteins, such as ACT, are known to reinforce the 
formation of beta-amyloid.4 Because ACT is elevated in the periphery and 
because peripheral proteins may be able to cross the blood-brain barrier,s 
peripherally produced inflammatory proteins may also amplify formation of 
cerebral beta-amyloid deposits. In addition, inflammatory proteins in 
plasma, particularly CRP, may increase the amount of atherosclerosis.6 
Atherosclerosis in arteries that supply the brain may in turn lead to 
cerebral ischemia, which may result in oxidative stress7 and abnormal 
protein processing and thus increased beta-amyloid production and 
deposition.s However, the relation between inflammatory proteins and 
dementia may not entirely be explained by atherosclerosis, because 
adjustment for atherosclerotic measures did not change our results. 
Alternatively, elevated inflammatory proteins in plasma prior to clinical 
dementia onset may be the result of the beta-amyloid deposits within the 
brain. Beta-amyloid deposition may trigger the occurrence of local 
inflammation and the production of cytokines,9 which may subsequently 
stimulate the peripheral production of inflammatory proteins as shown in 
animal models.lO Furthermore, elevated inflammatory proteins may be a 
consequence of atherosclerosis that is both related to higher plasma levels of 
inflammatory proteinsll and to dementia.U However, this explanation is 
less likely, because our results were similar after adjustment for 
atherosclerosis. 
If inflammation is both a cause and a consequence of the pathogenetic 
process of dementia, a self-enhancing cascade will take place. This cascade 
includes beta-amyloid deposit formation that leads to local inflammation 
within the brain and inflammation in the periphery, which both result in 
increased beta-amyloid deposit formation. 
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Antioxidants and dementia 
Oxidative stress within the brain may lead to neuronal cell death, which is 
thought to result in clinical symptoms of Alzheimer's disease. Because 
oxidative stress is reduced by antioxidants, high levels of antioxidants may 
also be associated with lower risk of Alzheimer's disease. 
Previous hospital-based studies examined the relationship between 
plasma levels of antioxidants and prevalence of Alzheimer's disease. These 
studies showed inconsistent results, but did not adequately adjust for 
confounders. In our population-based study we showed that the cross-
sectional association between plasma levels of the antioxidant vitamins A 
and E and Alzheimer's disease was largely due to confounding factors, such 
as age, gender, total cholesterol and smoking (chapter 3.1.1). In addition, no 
relation was observed between vitamin A and vitamin E and cognitive 
decline (chapter 3.1.1). Because levels of antioxidants may have changed as 
a result of dementia or cognitive decline, prospective studies are needed to 
elucidate the longitudinal relation between antioxidants and risk of 
dementia. 
We performed a prospective study to examine the association between 
dietary intake of antioxidants from food and risk of Alzheimer's disease. We 
found that higher intake of vitamin C and vitamin E were associated with a 
lower risk of Alzheimer's disease (chapter 3.1.2). Within current smokers, 
this relationship seemed also present for intake of beta carotene and 
flavonoids. The associations could not be explained by the presence of 
atherosclerosis. 
The discrepancy in results of the study on antioxidant plasma levels and 
antioxidant intake may be explained by the difference in study design, i.e. 
cross-sectional versus longitudinal. Another explanation for the discrepancy 
may be the relatively low correlation between blood levels and intake of 
vitamin A and vitamin E.13 
Antioxidants from food may be associated with lower risk of dementia, 
because they may reduce the level of oxidative stress within the brain. This 
may occur if antioxidants pass the blood-brain barrier, which has been 
suggested by animal studies. These studies showed that higher antioxidant 
intake or antioxidant blood levels were associated with increased brain 
levels for vitamin A, vitamin C and vitamin E.14·16 In addition, high intake 
of antioxidants may decrease dementia risk by reducing the risk of 
atherosclerosis, because atherosclerosis has both been associated with 
oxidative stress17 and with dementiaJ2,lB However, because additional 
adjustment for carotid plaques as a measure of atherosclerosis did not 
change our results, I doubt that atherosclerosis is an important 
intermediary in the relationship between antioxidants and risk of 
Alzheimer's disease. 
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Inflanunatory factors, antioxidants and dementia 
Inflammation and oxidative stress may interact with each other in 
Alzheimer pathogenesis. On the one hand, inflammation may induce 
oxidative stress by the activation of microglia that generate free radicals 
within the brain.' On the other hand, inflammation within the brain may be 
amplified by oxidative stress, because the accompanying free radicals may 
activate pro-inflammatory genes in neurons.9 Because inflammation in the 
brain may result in activation of the peripheral immune systemiO and 
because peripheral antioxidants may be associated with antioxidant levels 
within the brain,l4-16 peripheral antioxidants may interact with 
inflammation as reflected in peripheral inflammation in Alzheimer 
pathogenesis. 
We examined whether the association between peripheral inflammation, 
as indicated by plasma leucocyte count, and risk of Alzheimer's disease was 
modified by dietary intake of the antioxidants beta carotene, flavonoids, 
vitamin C and vitamin E (chapter 2.2). We found this interaction and 
showed that risk of .Alzheimer's disease was higher with higher leucocyte 
count, particularly when dietary intake of antioxidants was low. 
The interaction between peripheral inflammation and antioxidants in 
Alzheimer's disease may also be explained by atherosclerosis. In 
atherogenesis, inflammation is also suggested to interact with oxidative 
stress and thus antioxidants, because oxidative stress leads to LDL-
oxidation, subsequent inflammation and atherosclerotic plaques19 and 
because inflammation is accompanied by increased count of leucocytes that 
produce free radicals and oxidative stress in itself. However, we think that 
the interaction between peripheral inflammation and antioxidants cannot 
entirely be explained by atherosclerosis, because additional adjustment for 
carotid plaques as a measure of atherosclerosis did not change our results. 
Lipids and dementia 
Risk of Alzheimer's disease may be increased with higher levels of 
cholesterol for 2 reasons. First, high levels of cholesterol have been 
associated with more beta-amyloid deposition in animal models.zo Second, 
high cholesterol levels are associated with more atherosclerosis. Other lipids 
including saturated fatty acids (saturated fat), trans fatty acids (trans fat), 
cis monounsaturated fatty acids (MUFA) and cis polyunsaturated fatty 
acids (PUFA) have also been associated with cholesterol levels and 
atherosclerosis21·23 and may thus also be related to dementia risk. The n-3 
PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may 
be associated with dementia risk because of their anti-inflammatory 
properties. 
Previously, 2 cross-sectional studies examined the relation between fatty 
acids in plasma phospholipids and dementia and showed that levels of 
saturated fat24 were higher and levels of EPA and DHA were lower24, 25 
within Alzheimer patients as compared to control subjects. Whether fatty 
acids are related to cognitive decline, which precedes dementia diagnosis, 
had not yet been studied. 
We examined the relation between fatty acids in plasma phospholipids 
and cognitive change in dementia-free subjects and observed that high levels 
of saturated fat, low levels of PUFA and n-6 PUFA and a low ratio of PUFA 
to saturated fat were significantly associated with increased cognitive 
decline (chapter 3.2.1). These relations could not be explained by 
atherosclerosis. Cognitive decline was not associated with levels of trans fat, 
MUFA, n-3 PUFA, EPA, DHA, linoleic acid, alpha-linolenic acid or 
arachidonic acid or with the ratio of n-6 PUFA to n-3 PUFA. However, 
because fatty acid levels were assessed after the occurrence of cognitive 
decline, we cannot exclude that the (absence of) associations are the 
consequence rather than the cause of change in cognitive function. 
Therefore, prospective studies are needed. 
We prospectively examined the relation between lipids and dementia 
using data on dietary intake (chapter 3.2.2), Our hypothesis was that high 
intake of total fat, saturated fat and trans fat, and low intake of MUFA, 
PUFA, n-6 PUFA and n-3 PUFA were associated with higher risk of 
dementia and its subtypes. However, we could not confirm this hypothesis 
for any of the lipids. 
The discrepancy in results for fatty acids in plasma and fatty acids from 
intake may be explained in several ways. First, the plasma study was cross-
sectional, whereas the intake study was longitudinaL Second, because 
correlations between plasma phospholipid levels and dietary intake of fatty 
acids are generally low, 26 results may not be comparable, Third, results of 
studies on cognitive decline may not necessarily be comparable with results 
of studies on dementia, as will be later discussed in this chapter. 
If saturated fat and n-6 PUFA are etiologically related to cognitive 
decline, it may be through atherosclerosis, although atherosclerosis was no 
intermediary factor in our analysis. Another possibh~ explanation for the 
association may be that peripheral levels of fatty acids may determine the 
fatty acid composition of brain cell membranes that is involved in optimal 
cell functioning. However, not much is known on thi:s topic and the latter 
mechanism would particularly hold for DHA for which no association was 
found. 
Based on the cholesterol-lowering properties of statin medications, it has 
been hypothesized that statin use may be associated with lower risk of 
dementia. Previously, 3 studies reported that use of statins was related to 
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an approximately 70% reduction in risk of Alzheimer's disease.27·29 However, 
these studies may have been biased because of confounding by indication 
and misclassification of drug use. In our study, we could not confirm that 
statin use was associated with a dementia risk reduction of 70% (chapter 
3.2.3). If anything, the risk reduction associated with statin use is less than 
50%. \Vhether an inverse association of modest strength is present remains 
to be elucidated, because the power to detect such a relationship was 
insufficient in our study. 
Inflammation, antioxidants and lipids and Alzheimer's disease 
In summary, inflammatory proteins from plasma, and antioxidants and 
lipids from plasma or diet may etiologically be related to Alzheimer's disease 
in several ways. Inflammatory proteins in plasma may increase the amount 
of beta-amyloid formation and deposition within the brain< and thereby 
increase neuronal cellloss30 either directly or through local inflammation9 
and subsequent oxidative stress. In addition, inflammatory proteins may 
increase the amount of atherosclerosis,6 which might result in more 
oxidative stress,? beta-amyloid formation,s and neuronal cell loss. 
Antioxidants in plasma or from food may be related to a lower risk of 
Alzheimer pathogenesis in 2 ways. First, antioxidants may reduce oxidative 
stress within the brain and thereby reduce inflammation, beta-amyloid 
formation and neuronal cell death. Second, antioxidants may be associated 
with lower risk of Alzheimer's disease through the inverse relationship with 
atherosclerosis. If atherosclerosis is reduced, oxidative stress, beta-amyloid 
formation and neuronal cell death will also be reduced. 
Cholesterol may be related to Alzheimer's disease through its possible 
association with beta-amyloid formation20 or atherosclerosis.22 However, our 
findings did not support a relation between cholesterol and Alzheimer's 
disease as we saw no association between Alzheimer's disease and high 
intake of fats that increase levels of cholesterol and low intake of fats that 
reduce cholesterol. Also, we could not confirm that use of cholesterol-
lowering medication, such as statins, is associated with risk of dementia or 
Alzheimer's disease. On the other hand, we did observe that high levels of 
saturated fat and low levels of n-6 PUFA in plasma phospholipids that are 
related to more atherosclerosis,21 were associated with increased cognitive 
decline. 
N-3 PUFA, particularly EPA and DHA, would be related to dementia 
because of their anti-inflammatory properties. However, even though 
inflammatory processes seem to play a role in Alzheimer pathogenesis, we 
did not find an association between plasma levels of n-3 PUFA and cognitive 
decline or between intake of n-3 PUFA and risk of dementia. 
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Methodological considerations 
Nutrient intake versus nutrient blood levels 
The relationship between nutrient and disease can be examined by 
assessment of dietary intake or by measurement of nutrient level in blood or 
tissue. For the purpose of etiologic research, nutrient blood levels may 
generally be more appropriate for 2 reasons. First, nutrient levels will 
generally reflect nutrient status better, because nutrient levels are not only 
affected by intake but also by nutrient absorption, usage and storage. 
Second, measurement of nutrient level may be less susceptible to random 
misclassification particularly because dietary assessment is prone to 
inaccuracies. These inaccuracies are the result of error in dietary reporting 
and use of composition tables that assume constant nutrient content of foods 
and are based on chemical analyses with their own measurement error.31 
However, if intake and blood levels of nutrients are highly correlated, 
both measures can be used as a proxy for nutrient status. If the nutrient 
level is extremely susceptible to short-term fluctuations in intake, 
assessment of dietary intake may be more appropriate than nutrient levels, 
because dietary assessment will then better reflect long-term nutrient 
status that is thought to influence disease risk rather than short-term 
status. 
The extent to which intake and levels of antioxidants reflect long-term 
status considerably differs for the various antioxidants.13 For beta carotene 
both intake and blood levels would represent long-term status reasonably 
well. Vitamin C intake would better reflect long-term vitamin C status than 
blood levels, because vitamin C levels are very susceptible to short-term 
fluctuations of dietary intake. With respect to vitamin E, blood levels would 
be more appropriate as a marker of long-term status, because the 
correlation between intake and blood levels is low. The reflection of long-
term vitamin A status by intake or blood levels is limited due to storage of 
large amounts of vitamin A in the liver that buffers blood levels to maintain 
constant levels.13 The correlation between intake and blood levels of 
flavonoids has not yet been studied. 
Long-term status of fatty acids and cholesterol may generally be hard to 
predict, because fat intake may have substantially changed over the last 
decade due to health campaigns. Nevertheless, blood levels of fatty acids 
may be a better marker of fatty acid status than intake because of the weak 
correlation between intake and (fasting) blood levels. 26 This also holds for 
cholesterol. 
Blood levels versus brain levels 
Because dementia pathology occurs within the brain, levels of inflammatory 
factors or nutrients within the brain are likely to be more closely related to 
~2c 
dementia pathogenesis than peripheral levels, such as plasma levels. 
However, obtaining a. sample of cerebrospinal fluid (CSF) to assess brain 
levels is a large burden for people and is thus not feasible for large 
population-based studies. Instead, blood samples were drawn, although 
blood levels may not necessarily reflect levels within the brain because of 
the blood-brain barrier. 
To date, correlations between inflammatory protein levels in plasma and 
CSF have hardly been reported. These correlations are also unknown for 
antioxidants, fatty acids and cholesterol. However, as previously discussed 
peripheral proteins, such as inflammatory proteins, as well as antioxidants 
may be able to cross the blood-brain barrier.5. lH6 Therefore, higher plasma 
levels of inflammatory proteins and antioxidants might also lead to higher 
levels within the brain. In addition, some PUFAs have been found to cross 
the blood-brain barrier by means of transporters.32 Saturated fat and 
cholesterol have not been found to pass the blood-brain barrier. 
Cognitive decline versus dementia 
In addition to dementia I examined risk factors for cognitive decline since 
dementia is preceded by decline in cognitive function.33 However, although 
previous studies showed at least a 3-fold increased risk of dementia for 
subjects with cognitive impairment compared with the general population,34 
many subjects with cognitive decline do not develop dementia. Therefore, 
the use of cognitive decline as a proxy for preclinical dementia is susceptible 
to misclassification. In our studies on cognitive decline, misclassification 
may also have occurred, because decline was calculated on the basis of 
actual performed Mini Mental State Examinations (MMSE). This may have 
led to bias, because subjects with serious cognitive decline will have been 
less inclined to participate in follow-up examinations and thus in the 
MMSE. As a result, the distribution of cognitive decline in our study 
population will have been too small and the power to detect associations will 
therefore have been ]less. However, research on cognitive decline may still 
help to elucidate early risk factors of dementia, because appropriate 
(biological) markers of preclinical stages of dementia are not yet available. 
In addition, research on cognitive decline is important on its own, because 
cognitive decline reduces quality oflife and should therefore be prevented. 
Clinical relevance 
Tbe finding of higher risk of dementia with higher plasma levels of 
inflammatory factors may be of clinical relevance in 2 ways. First, if the 
relation is etiological, our finding may indicate that anti-inflammatory 
medication that reduces these levels would also reduce dementia risk. 
Although observational studies showed this association for NSAIDs,-35~37 
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randomized controlled trials should first confirm this finding before 
recommendations can be given for clinical practice. Second, increased 
inflammatory proteins may help to identify subjects who are at high risk of 
dementia. However, because dementia is not the only condition in which 
inflammatory factors are elevated, assessment of inflammatory factors as a 
biomarker for dementia may only be useful in combination with 
determination of other risk factors. 
Our study on dietary intake of antioxidants and dementia suggests that 
subjects with high antioxidant intake are at lower risk of Alzheimer's 
disease compared with subjects with low intake. If antioxidants truly reduce 
dementia risk, recommendations to increase antioxidant intake should be 
given, particularly to elderly at high risk of dementia. However, randomized 
controlled trials should first be performed before our finding can be applied 
in clinical practice. 
Our observations with respect to fatty acids in phospholipids and change 
in cognitive function imply that low intake of saturated fatty acids and high 
intake of PUFA might limit decline in cognition. Even though this could not 
be confirmed in our prospective study of fat intake and dementia, such a 
diet might be worthwhile particularly in the light of reduction of 
cardiovascular disease. 
Future research 
We found that peripheral inflammatory factors are elevated prior to clinical 
onset of dementia. However, the impact of peripheral inflammation on 
dementia pathogenesis is yet unknown. To answer this question, studies are 
needed that examine the time-dependent relation between peripheral 
inflammatory factors and clinical symptoms as well as the association 
between peripheral inflammatory factors and the extent of cerebral 
pathology, such as beta-amyloid deposits, neuronal cell loss and 
neuroinflammation. To study the latter association, specific markers of 
cerebral pathology need to be developed. In this respect, the current 
possibility to depict activated microglia by PET -scans with labelling may be 
helpful, as although this technique is not suitable for large population-based 
studies. In addition, genetic research should examine the association 
between genes or genetic profiles that are involved in responses to 
inflammation, and risk of dementia. 
Our findings regarding the relation between diet and risk of dementia 
were based on a single dietary assessment. Although single dietary 
assessment reasonably reflects long-term intake, repeated measurements of 
dietary intake will be a more reliable marker. Therefore, and because long-
term intake rather than short-term intake will affect dementia risk, the 
association between diet and dementia should be further examined using 
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repeated measurements of dietary intake. In addition, it should be further 
explored what factors determine the bioavailability of nutrients from food 
within plasma as well as within the brain. These factors may include 
genetic influences, lifestyle and intake of other nutrients. 
Furthermore, because dementia is a multifactorial disease, effort should 
be put into research of mutual relationships between the different 
pathogenetic processes in Alzheimer's disease, such as beta-amyloid 
deposition, the formation of neurofibrillary tangles, inflammation, oxidative 
stress and atherosclerosis. 
In parallel with research on mechanisms, preventive strategies should be 
developed and examined. In particular, randomized controlled trials should 
be performed to investigate whether anti-inflammatory medication, such as 
NSAIDs, and antioxidant supplements can prevent or slow down dementia 
onset. Preferably, the ,,ffect of NSAIDs and antioxidant supplements should 
be examined in a 4-arm-trial in order to additionally examine whether 
NSAIDs and antioxidant supplements interact with each other in relation to 
dementia. However, it. should first be considered what the optimal timing 
and duration of use would be in order to obtain most benefit of treatment. 
If a preventive effect of NSAIDs or antioxidant supplements is 
demonstrated, these medications may be recommended for elderly. 
However, considering costs and possible side-effects of treatment, 
recommendations should be selectively given to persons who are at high risk 
of dementia. To identify those persons, predictive models should be made on 
the basis of the risk factors that are thus far recognized. 
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Chapter 5.1 
Summary 
T his thesis describes the relationship between inflammation, antioxidants and lipids and risk of dementia. The results were based on data from the Rotterdam Study, a large population-based cohort 
study among elderly inhabitants of the suburb Ommoord in Rotterdam, the 
Netherlands. In total, 7983 persons of 55 years and over (response rate 78%) 
participated in the study. Of these, 7525 participants underwent cognitive 
screening at baseline (1990-1993), of whom 482 persons were diagnosed 
with dementia. This resulted in 7043 dementia-free participants at baseline 
who were followed for incident dementia by means of follow-up 
examinations (1993-1994 and 1997-1999) and continuous monitoring of 
medical records from general practitioners and the Regional Institute for 
Outpatient Mental Health Care (RIAGG). After a mean follow-up of 5. 7 
years 395 incident dementia cases were identified. 
Chapter 2.1 described the relationship between inflammatory proteins in 
plasma and risk of dementia. I found that higher levels of alpha1-
antichymotrypsin, interleukin-6 and to a lesser extent C-reactive protein 
were elevated prior to clinical onset of dementia, Alzheimer's disease and 
particularly vascular dementia. Soluble intercellular adhesion molecule-1 
and soluble vascular cell adhesion molecule-1 were not associated with 
dementia or its subtypes. The associations between inflammatory proteins 
and dementia could not be explained by atherosclerosis and were similar for 
subjects with and subjects without an apolipoprotein E (APOE)*4 allele. 
In chapter 2.2 I examined whether leucocyte count in serum was 
associated with risk of Alzheimer's disease and whether this relationship 
was modified by dietary intake of antioxidants. I observed that higher 
leucocyte count was related to a higher risk of Alzheimer's disease, 
particularly within subjects with low antioxidant intake. The association 
was not confounded by smoking, atherosclerosis or supplement use. 
In chapter 3.1.1 I studied the cross-sectional relationship between plasma 
levels of the antioxidant vitamins A and E and Alzheimer's disease and 
cognitive decline. I showed that the inverse association between antioxidant 
levels and Alzheimer's disease was largely due to confounding factors 
including age, gender and total cholesterol level. Plasma levels of vitamin A 
and E were not related to cognitive decline. 
Chapter 3.1.2 presented the longitudinal association between dietary 
intake of antioxidants and risk of Alzheimer's disease. High antioxidant 
intake, particularly of vitamin C and vitamin E, was related to a reduced 
risk of Alzheimer's disease. Within current smokers, this relationship was 
most pronounced and was also present for beta carotene and flavonoids. The 
relationship was not confounded by education or atherosclerosis. In 
addition, APOE genotype did not modify the relationship between 
antioxidant intake and Alzheimer's disease. 
In chapter 3.2.1 I studied the relationship between fatty acid levels in 
plasma phospholipids and change in cognitive function that occurred in 
dementia-free subjects over a mean period of 6.5 years. I observed that 
higher percentage of saturated fatty acids in plasma phospholipids was 
associated with more decline in cognitive function. In addition, decline in 
cognitive function was increased with lower percentage of cis 
polyunsaturated fatty acids (PUFA) and n-6 PUFA and a lower ratio of 
PUFA to saturated fatty acids. I did not observe that the anti-inflammatory 
n-3 PUFA were associated with less cognitive decline. Also, I found no 
association between cognitive change and trans fatty acids, cis 
monounsaturated fatty acids (MUFA), the essential fatty acids linoleic acid 
and alpha-linolenic acid, arachidonic acid and the n-6 PUFA to n-3 PUFA 
ratio. 
In chapter 3.2.2 I reported findings about dietary intake of fat and risk of 
dementia and its subtypes. I could not confirm the a priori hypothesis that 
high intake of total fat, saturated fat, trans fat and cholesterol and low 
intake of MUFA, PUFA, n-6 PUFA and n-3 PUFA, were associated with 
increased risk of dementia, Alzheimer's disease or vascular dementia. The 
results did not change when lifestyle-associated factors, use oflipid-lowering 
medication or cardiovascular disease were taken into account. 
Chapter 3.2.3 showed the longitudinal relationship between use of lipid-
lowering medication, such as statins, and risk of dementia and Alzheimer's 
disease using time-varying exposure methods. I failed to show that statin 
use, either short-term or long-term or in low dose or high dose, was 
associated with reduced risk of dementia or Alzheimer's disease. Although 
the power of the study was low, I showed that, if anything, statin use is 
associated with a smaller reduction in dementia risk than the 70% 
previously reported in cross-sectional and GP register based case-control 
studies. 
Finally, in chapter 4 I discussed our findings in the light of other studies. 
I gave an overview of possible mechanisms in which I showed that 
inflammation and antioxidants may be related to dementia through their 
effect on beta-amyloid deposition, on loss of neuronal cells or on 
atherosclerosis. In addition, inflammation and antioxidants may interact 
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with each other in relation to beta-amyloid deposition or atherosclerosis. 
Although findings in this thesis indicate no clear relationship between lipids 
and dementia, I also discussed possible mechanisms by which fat might play 
a role in dementia. Furthermore, I considered methodological issues of the 
studies in this thesis. In particular, I considered the relationship between 
intake and blood levels of nutrients, the relationship between blood levels 
and brain levels, and the relationship between dementia and cognitive 
decline. I also discussed shortly the possible clinical rE,Jevance of our results. 
Finally, I gave some recommendations for future research that should focus 
on further elucidating the importance of inflammation, both cerebral and 
peripheral, on dementia pathology. In addition, future research should aim 
to elucidate factors that determine bioavailability in blood and brain of 
nutrients that have been associated with lower risk of dementia, such as 
antioxidants. This may help to translate the potential beneficial effects of 
these nutrients into preventive interventions. 

Chapter 5.2 
Samenvatting 
D it proefschrift beschrijft de relatie tussen ontsteking, antioxidanten en lipiden en het risico op dementie. De resultaten zijn gebaseerd op data van het Erasmus Rotterdam Gezondheid en Ouderen 
(ERGO) onderzoek. Dit is een groot cohort onderzoek onder oudere bewoners 
van de wijk Ommoord in Rotterdam. In totaal deden 7983 bewoners van 55 
jaar en ouder (78%) mee, waarvan 7525 personen getest zijn op cognitie bij 
de eerste onderzoeksronde (1990-1993). Daarbij werd bij 482 mensen de 
diagnose dementie gesteld. De overige 7043 mensen werden over de tijd 
gevolgd op het krijgen van incidente dementie. Dit werd gedaan door middel 
van meerdere onderzoeksronden (1993-1994 en 1997-1999) en door het 
continu controleren van medische dossiers van huisartsen en RlAGGs. Op 
deze marrier werden na een gemiddelde vervolg duur van 5, 7 jaar 395 
personen incident dement bevonden. 
Hoofdstuk 2.1 beschrijft de relatie tussen ontstekingseiwitten in plasma 
en het risico op dementie. Ik vond dat de concentraties van alphal-
antichymotrypsine, interleukine-6 en in mindere mate C-reactief protelne 
waren verhoogd voordat klinische symptomen van dementie, de ziekte van 
Alzheimer en vasculaire dementie aanwezig waren. Oplosbaar intercellulair 
adhesie molecuul¥1 en oplosbaar vasculaire eel adhesie molecuul¥1 waren 
niet geassocieerd met dementie of dementie subtypen. De associatie tussen 
ontstekingseiwitten en dementie kon niet worden verklaard door 
atherosclerose en was gelijk voor personen met en personen zonder een 
apolipoprotei'ne E (APOE) *4 aile!. 
In hoofdstuk 2.2 onderzocht ik of het aantal witte bloedcellen in serum 
geassocieerd is met het risico op de ziekte van Alzheimer en of deze relatie 
werd gemodificeerd door inname van de antioxidanten beta caroteen, 
flavonoiden, vitamine C en vitamine E uit de voeding. Ik zag dat een hoger 
aantal witte bloedcellen was gerelateerd aan een hoger risico op de ziekte 
van Alzheimer, met name in personen met lage antioxidant inname. Dit 
verband werd niet verklaard door roken, atherosclerose of het gebruik van 
voedingssupplementen. 
In hoofdstuk 3.1.1 onderzocht ik de relatie tussen de concentraties van de 
antioxidanten vitamine A en E in het bloed en de ziekte van Alzheimer en 
cognitieve achteruitgang. Dit dwarsdoorsnede onderzoek liet zien dat het 
omgekeerde verband tussen antioxidant concentraties en de ziekte van 
Alzheimer met name te verklaren was door de confounders leeftijd, geslacht, 
en cholesterol concentratie in het bloed. 
In hoofdstuk 3. L2 presenteerde ik de associatie tussen inname van 
antioxidanten uit de voeding en het risico op de ziekte van Alzheimer. 
Hogere inname van antioxidanten, met name van vitamine C en vitamine E, 
bleek gerelateerd te zijn aan een lager risico op de ziekte van Alzheimer. 
Binnen rokers was deze relatie het duidelijkst en was dan ook aanwezig 
voor beta caroteen en flavonoiden. Het verband werd niet verklaard door 
opleidingsniveau of atherosclerose. Tevens werd de relatie tussen 
antioxidant inname en de ziekte van Alzheimer niet gemodificeerd door het 
APOE genotype. 
In hoofdstuk 3.2.1 werd binnen dementie-vrije personen de relatie 
onderzocht tussen vetzuren in plasma fosfolipiden en verandering in 
cognitie over gemiddeld 6.5 jaar. Een hoger percentage van verzadigde 
vetzuren in plasma fosfolipiden bleek geassocieerd te zijn was met meer 
cognitieve achteruitgang. Ook nam de cognitieve achteruitgang toe met 
lagere percentages van meervoudig onverzadigde vetzuren (PUFA) en n-6 
PUFA en een lagere ratio van PUFA en verzadigde vetzuren. De 
ontstekingsremmende n-3 PUFA waren niet geassocieerd met minder 
cognitieve achteruitgang. Ook vond ik geen verband tussen cognitieve 
verandering en het percentage van trans vetzuren, enkelvoudig 
onverzadigde vetzuren (MUFA), de essentiele vetzuren linolzuur en alpha-
linoleenzuur, arachidonzuur en de n-6 PUFA/n-3 PUFA ratio. 
In hoofdstuk 3.2.2. rapporteer ik onze bevindingen over de inname van 
vetten en het risico op dementie en dementie subtypen. Mijn a priori 
hypothese kon niet hevestigd worden, want hogere inname van totaal vet, 
verzadigd vet, trans fat en cholesterol en een lagere inname van MUFA, 
PUFA, n-6 PUFA en n-3 PUFA waren niet geassocieerd met een hoger risico 
op dementie, de ziekte van Alzheimer of vasculaire dementie. Deze 
bevindingen veranderden niet als rekening gehouden werd met het gebruik 
van cholesterol-verlagende medica tie, de aanwezigheid van hart/vaatziekten 
of factoren die gerelat,eerd zijn a an levensstijl. 
Hoofdstuk 3.2.3 liet de longitudinale relatie zien tussen het gebruik van 
cholesterol-verlagende medicatie (statines) en het risico op dementie en de 
ziekte van Alzheimer. Dit verband werd geanalyseerd door middel van 
methoden die rekening houden met verandering in statine gebruik over de 
tijd (time-varying exposure methoden). Ik kon niet bevestigen dat 
kortdurend of langdurig gebruik van statines in lage of hoge dosering 
geassocieerd was met een lager risico op dementie of de ziekte van 
Alzheimer. Alhoewel de power van de studie laag was, liet ik zien dat iUs 
statines al geassocieerd zijn met een lager risico op dementie, de risico 
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reductie in ieder geval kleiner is dan de 70% dat gerapporteerd was in 
eerder dwarsdoorsnede en patient-controle onderzoek. 
Tot slot besprak ik in hoofdstuk 4 de bevindingen in het Iicht van andere 
studies. Ik gaf een overzicht van mogelijke mechanismen, waarbij ik laat 
zien dat ontsteking en antioxidanten aan dementie gerelateerd zouden 
kunnen zijn via hun effect op de neerslag van beta-amyloid, op het verlies 
van neuronen of op atherosclerose. Tevens besprak ik mogelijke 
mechanismen waarop lipiden een rol zouden kunnen spelen bij dementie, 
ook a! laat het onderzoek in dit proefschrift geen duidelijk verband zien 
tussen lipiden en dementie. Ook maakte ik methodologische kanttekeningen 
bij het proefschrift en besprak ik met name het verband tussen inname van 
nutrienten en hun concentraties in het bloed, het verband tussen 
concentraties in het bloed en in de hersenen en de relatie tussen dementie 
en cognitieve achteruitgang. Daarna besprak ik kort de mogelijke klinische 
relevantie van onze resultaten. Tot slot gaf ik wat aanbevelingen voor 
toekomstig onderzoek dat zich zou moeten richten op het verder ophelderen 
van de rol die ontsteking speelt in zowel de hersenen als daarbuiten bij het 
ontstaan van dementie pathologie. Daarnaast zou toekomstig onderzoek 
zich tot doe! moeten stellen factoren te achterhalen die de beschikbaarheid 
van nutriEmten in het bloed en de hersenen bepahm. Als deze factoren 
bekend zijn voor nutrienten die samen haugen met dementie, zoals mogelijk 
de antioxidanten, dan zou dit kunnen bijdragen aan het vertalen van de 
resultaten van ons onderzoek naar eventuele preventieve interventies. 
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